

Search Notes

Application No.

09/843,221

Examiner

Christopher Nichols, Ph.D.

Applicant(s)

KOSTENUK ET AL.

Art Unit

1647

SEARCHED


Class	Subclass	Date	Examiner

INTERFERENCE SEARCHED

Class	Subclass	Date	Examiner

**SEARCH NOTES
(INCLUDING SEARCH STRATEGY)**

	DATE	EXMR
NCBI (PUBMED) STN (BIOSCIENCE)	12/8/2003	CJN



Entrez PubMed Nucleotide Protein Genome Structure PMC Journals Book
 Search PubMed for parathyroid hormone AND Fc Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Caddy

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text
 Items 1-15 of 15 One page.

1: [Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ](#) Related Articles, Links



Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.

Bone. 2003 Jul;33(1):28-37.

PMID: 12919697 [PubMed - in process]

2: [Astrand J, Skripitz R, Skoglund B, Aspenberg P](#) Related Articles, Links



A rat model for testing pharmacologic treatments of pressure-related bone loss.

Clin Orthop. 2003 Apr;(409):296-305.

PMID: 12671515 [PubMed - indexed for MEDLINE]

3: [Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU](#) Related Articles, Links



Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.

Maturitas. 2002 Nov 20;43(3):207-14.

PMID: 12443837 [PubMed - indexed for MEDLINE]

4: [Zittermann A, Sabatschus O, Jantzen S, Platen P, Danz A, Stiehle P](#) Related Articles, Links



Evidence for an acute rise of intestinal calcium absorption in response to aerobic exercise.

Eur J Nutr. 2002 Oct;41(5):189-96.

PMID: 12395212 [PubMed - indexed for MEDLINE]

5: [Nosaka K, Miyamoto T, Sakai T, Mitsuva H, Suda T, Matsuoka M](#) Related Articles, Links



Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells.

Blood. 2002 Jan 15;99(2):634-40.

PMID: 11781248 [PubMed - indexed for MEDLINE]

6: [Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR](#) Related Articles, Links



Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.

Cancer Res. 2001 Mar 15;61(6):2572-8.

PMID: 11289133 [PubMed - indexed for MEDLINE]

7: [Massry S, Smogorzewski M](#) Related Articles, Links



Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone.

Kidney Int Suppl. 2001 Feb;78:S195-6. Review.

PMID: 11169010 [PubMed - indexed for MEDLINE]

8: [Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL](#) Related Articles, Links

Dunstan CR.



A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH) 2D3.

J Bone Miner Res. 1999 Sep;14(9):1478-85.

PMID: 10469275 [PubMed - indexed for MEDLINE]

☐ **9:** Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG.

[Related Articles, Links](#)



Impaired phagocytosis in dialysis patients: studies on mechanisms.

Am J Nephrol. 1991;11(2):102-11.

PMID: 1951470 [PubMed - indexed for MEDLINE]

☐ **10:** Athanasou NA, Wells CA, Quinn J, Ferguson DP, Heryet A, McGee JO.

[Related Articles, Links](#)



The origin and nature of stromal osteoclast-like multinucleated giant cells in breast carcinoma: implications for tumour osteolysis and macrophage biology.

Br J Cancer. 1989 Apr;59(4):491-8.

PMID: 2713238 [PubMed - indexed for MEDLINE]

☐ **11:** Boyde A, Jones SJ.

[Related Articles, Links](#)



Early scanning electron microscopic studies of hard tissue resorption: their relation to current concepts reviewed.

Scanning Microsc. 1987 Mar;1(1):369-81.

PMID: 3589611 [PubMed - indexed for MEDLINE]

☐ **12:** Goldring SR, Schiller AL, Mankin HJ, Dayer JM, Krane SM.

[Related Articles, Links](#)



Characterization of cells from human giant cell tumors of bone.

Clin Orthop. 1986 Mar;(204):59-75. Review.

PMID: 3006962 [PubMed - indexed for MEDLINE]

☐ **13:** Lang I, Feuer L, Nekam K, Torok K, Kalmar L, Gergely P.

[Related Articles, Links](#)



Effect of treatment with glutaurine on human antibody-dependent cell-mediated cytotoxicity (ADCC).

Immunol Commun. 1981;10(6):499-509.

PMID: 7319545 [PubMed - indexed for MEDLINE]

☐ **14:** Hogg N, Shapiro IM, Jones SJ, Slusarenko M, Boyde A.

[Related Articles, Links](#)



Lack of Fc receptors on osteoclasts.

Cell Tissue Res. 1980;212(3):509-16.

PMID: 7459990 [PubMed - indexed for MEDLINE]

☐ **15:** Goldring SR, Dayer JM, Russell RG, Mankin HJ, Krane SM.

[Related Articles, Links](#)



Response to hormones of cells cultured from human giant cell tumors of bone.

J Clin Endocrinol Metab. 1978 Mar;46(3):425-33.

PMID: 87400 [PubMed - indexed for MEDLINE]

Display Show: Sort Send to
Items 1-15 of 15 One page.


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Dec 1 2003 07:03:59



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Journals

Book

Search **PubMed**for **parathyroid AND Fc****Go****Clear**

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display**Summary**

Show:

500**Sort****Send to****Text**

Items 1-15 of 15

One page.

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

- ☐ **1:** [Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ.](#) [Related Articles, Links](#)



Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.

Bone. 2003 Jul;33(1):28-37.

PMID: 12919697 [PubMed - in process]

- ☐ **2:** [Astrand J, Skripitz R, Skoglund B, Aspenberg P.](#) [Related Articles, Links](#)



A rat model for testing pharmacologic treatments of pressure-related bone loss.

Clin Orthop. 2003 Apr;(409):296-305.

PMID: 12671515 [PubMed - indexed for MEDLINE]

- ☐ **3:** [Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU.](#) [Related Articles, Links](#)



Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.

Maturitas. 2002 Nov 20;43(3):207-14.

PMID: 12443837 [PubMed - indexed for MEDLINE]

- ☐ **4:** [Zittermann A, Sabatschus O, Jantzen S, Platen P, Danz A, Stehle P.](#) [Related Articles, Links](#)



Evidence for an acute rise of intestinal calcium absorption in response to aerobic exercise.

Eur J Nutr. 2002 Oct;41(5):189-96.

PMID: 12395212 [PubMed - indexed for MEDLINE]

- ☐ **5:** [Nosaka K, Miyamoto T, Sakai T, Mitsuva H, Suda T, Matsuoka M.](#) [Related Articles, Links](#)



Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells.

Blood. 2002 Jan 15;99(2):634-40.

PMID: 11781248 [PubMed - indexed for MEDLINE]

- ☐ **6:** [Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR.](#) [Related Articles, Links](#)



Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.

Cancer Res. 2001 Mar 15;61(6):2572-8.

PMID: 11289133 [PubMed - indexed for MEDLINE]

- ☐ **7:** [Massry S, Smogorzewski M.](#) [Related Articles, Links](#)




Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone.

Kidney Int Suppl. 2001 Feb;78:S195-6. Review.

PMID: 11169010 [PubMed - indexed for MEDLINE]

- ☐ **8:** [Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL.](#) [Related Articles, Links](#)

Dunstan CR.


-  A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH) 2D3.

J Bone Miner Res. 1999 Sep;14(9):1478-85.

PMID: 10469275 [PubMed - indexed for MEDLINE]

- ☐ **9:** Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG.

[Related Articles, Links](#)


-  Impaired phagocytosis in dialysis patients: studies on mechanisms.

Am J Nephrol. 1991;11(2):102-11.

PMID: 1951470 [PubMed - indexed for MEDLINE]

- ☐ **10:** Athanasou NA, Wells CA, Quinn J, Ferguson DP, Heryet A, McGee JO.

[Related Articles, Links](#)


-  The origin and nature of stromal osteoclast-like multinucleated giant cells in breast carcinoma: implications for tumour osteolysis and macrophage biology.

Br J Cancer. 1989 Apr;59(4):491-8.

PMID: 2713238 [PubMed - indexed for MEDLINE]

- ☐ **11:** Boyde A, Jones SJ.

[Related Articles, Links](#)


-  Early scanning electron microscopic studies of hard tissue resorption: their relation to current concepts reviewed.

Scanning Microsc. 1987 Mar;1(1):369-81.

PMID: 3589611 [PubMed - indexed for MEDLINE]

- ☐ **12:** Goldring SR, Schiller AL, Mankin HJ, Dayer JM, Krane SM.

[Related Articles, Links](#)


-  Characterization of cells from human giant cell tumors of bone.

Clin Orthop. 1986 Mar;(204):59-75. Review.

PMID: 3006962 [PubMed - indexed for MEDLINE]

- ☐ **13:** Lang I, Feuer L, Nekam K, Torok K, Kalmar L, Gergely P.

[Related Articles, Links](#)

-  Effect of treatment with glutaurine on human antibody-dependent cell-mediated cytotoxicity (ADCC).

Immunol Commun. 1981;10(6):499-509.

PMID: 7319545 [PubMed - indexed for MEDLINE]

- ☐ **14:** Hogg N, Shapiro IM, Jones SJ, Slusarenko M, Boyde A.

[Related Articles, Links](#)


-  Lack of Fc receptors on osteoclasts.

Cell Tissue Res. 1980;212(3):509-16.

PMID: 7459990 [PubMed - indexed for MEDLINE]

- ☐ **15:** Goldring SR, Dayer JM, Russell RG, Mankin HJ, Krane SM.

[Related Articles, Links](#)

-  Response to hormones of cells cultured from human giant cell tumors of bone.

J Clin Endocrinol Metab. 1978 Mar;46(3):425-33.

PMID: 87400 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** Sort **Text**
Items 1-15 of 15 One page.


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

Dec 1 2003 07:03:59



Entrez PubMed

Nucleotide

Protein

Genome

Structure

PMC

Journals

Book

Search PubMed

for PTH AND Fc

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Items 1-13 of 13

One page.

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: [Astrand J, Skripitz R, Skoglund B, Aspenberg P.](#)[Related Articles, Links](#)

A rat model for testing pharmacologic treatments of pressure-related bone loss.

Clin Orthop. 2003 Apr;(409):296-305.

PMID: 12671515 [PubMed - indexed for MEDLINE]

2: [Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU.](#)[Related Articles, Links](#)

Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.

Maturitas. 2002 Nov 20;43(3):207-14.

PMID: 12443837 [PubMed - indexed for MEDLINE]

3: [Zittermann A, Sabatschus O, Jantzen S, Platen P, Danz A, Siehle P.](#)[Related Articles, Links](#)

Evidence for an acute rise of intestinal calcium absorption in response to aerobic exercise.

Eur J Nutr. 2002 Oct;41(5):189-96.

PMID: 12395212 [PubMed - indexed for MEDLINE]

4: [Massry S, Smogorzewski M.](#)[Related Articles, Links](#)

Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone.

Kidney Int Suppl. 2001 Feb;78:S195-6. Review.

PMID: 11169010 [PubMed - indexed for MEDLINE]

5: [Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR.](#)[Related Articles, Links](#)

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.

J Bone Miner Res. 1999 Sep;14(9):1478-85.

PMID: 10469275 [PubMed - indexed for MEDLINE]

6: [Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG.](#)[Related Articles, Links](#)

Impaired phagocytosis in dialysis patients: studies on mechanisms.

Am J Nephrol. 1991;11(2):102-11.

PMID: 1951470 [PubMed - indexed for MEDLINE]












7: [Athanasou NA, Wells CA, Quinn J, Ferguson DP, Heryet A, McGee JO.](#)[Related Articles, Links](#)

The origin and nature of stromal osteoclast-like multinucleated giant cells in breast carcinoma: implications for tumour osteolysis and macrophage biology.

Br J Cancer. 1989 Apr;59(4):491-8.

PMID: 2713238 [PubMed - indexed for MEDLINE]

8: [Boyde A, Jones SJ.](#)[Related Articles, Links](#)

-  **Early scanning electron microscopic studies of hard tissue resorption: their relation to current concepts reviewed.**
Scanning Microsc. 1987 Mar;1(1):369-81.
PMID: 3589611 [PubMed - indexed for MEDLINE]
-  **9: Goldring SR, Schiller AL, Mankin HJ, Dayer JM, Krane SM.** [Related Articles, Links](#)
 **Characterization of cells from human giant cell tumors of bone.**
Clin Orthop. 1986 Mar;(204):59-75. Review.
PMID: 3006962 [PubMed - indexed for MEDLINE]
-  **10: Dayer JM.** [Related Articles, Links](#)
 **Aspects of resorption and formation of connective tissue during chronic inflammation in rheumatoid arthritis.**
Eur J Rheumatol Inflamm. 1982;5(4):457-68.
PMID: 6295770 [PubMed - indexed for MEDLINE]
-  **11: Lang I, Feuer L, Nekam K, Torok K, Kalmar L, Gergely P.** [Related Articles, Links](#)
 **Effect of treatment with glutaurine on human antibody-dependent cell-mediated cytotoxicity (ADCC).**
Immunol Commun. 1981;10(6):499-509.
PMID: 7319545 [PubMed - indexed for MEDLINE]
-  **12: Hogg N, Shapiro IM, Jones SJ, Slusarenko M, Boyde A.** [Related Articles, Links](#)
 **Lack of Fc receptors on osteoclasts.**
Cell Tissue Res. 1980;212(3):509-16.
PMID: 7459990 [PubMed - indexed for MEDLINE]
-  **13: Goldring SR, Dayer JM, Russell RG, Mankin HJ, Krane SM.** [Related Articles, Links](#)
 **Response to hormones of cells cultured from human giant cell tumors of bone.**
J Clin Endocrinol Metab. 1978 Mar;46(3):425-33.
PMID: 87400 [PubMed - indexed for MEDLINE]

Items 1-13 of 13 One page.

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

Dec 1 2003 07:03:59

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 1 of 1 returned.☐ 1. Document ID: US 20030039654 A1

L1: Entry 1 of 1

File: PGPB

Feb 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030039654

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030039654 A1

TITLE: Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein

PUBLICATION-DATE: February 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kostenuik, Paul	Newbury Park	CA	US	
Liu, Chuan-Fa	Longmont	CO	US	
Lacey, David Lee	Newbury Park	CA	US	

US-CL-CURRENT: 424/178.1; 514/102, 514/12

ABSTRACT:

The present invention concerns therapeutic agents that modulate the activity of PTH and PTHrP. In accordance with the present invention, modulators of PTH and PTHrP comprise:

(a) a PTH/PTHrP modulating domain; and

(b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the C-terminus of the PTH/PTHrP modulating domain. The vehicle and the PTH/PTHrP modulating domain may be linked through the N- or C-terminus of the PTH/PTHrP modulating domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred PTH/PTHrP modulating domains comprise the PTH and PTHrP-derived amino acid sequences described hereinafter. Other PTH/PTHrP modulating domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein. Such peptides typically will be modulators of both PTH activity and PTHrP activity, although such techniques can be used to generate peptide sequences that serve as selective modulators (e.g., agonists of PTH activity but not PTHrP activity).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw	Desc	Image									

Generate Collection

Print

connecting via winsock to STN
Welcome to STN International! Enter x:x
***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 16:57:15 ON 08 DEC 2003

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 16:57:25 ON 08 DEC 2003

FILE 'ANABSTR' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 16:57:25 ON 08 DEC 2003

FILE 'CAPLUS' ENTERED AT 16:57:25 ON 08 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 16:57:25 ON 08 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 16:57:25 ON 08 DEC 2003

COPYRIGHT (C) 2003 Proquest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGMONO2' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 16:57:25 ON 08 DEC 2003

FILE 'FOMAD' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 16:57:25 ON 08 DEC 2003

FILE 'HEALSAFE' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 16:57:25 ON 08 DEC 2003

FILE 'NIOSHTIC' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 16:57:25 ON 08 DEC 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.

All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 16:57:25 ON 08 DEC 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 16:57:25 ON 08 DEC 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 16:57:25 ON 08 DEC 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 ACS

FILE 'USPATFULL' ENTERED AT 16:57:25 ON 08 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 16:57:25 ON 08 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 16:57:25 ON 08 DEC 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s parathyroid AND Fc
24 FILES SEARCHED...
L1 1905 PARATHYROID AND FC

=> DUP REM L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY 62% COMPLETE FOR L1
PROCESSING COMPLETED FOR L1
L2 1723 DUP REM L1 (182 DUPLICATES REMOVED)

=> S L2 AND PY<=2000
'2000' NOT A VALID FIELD CODE

6 FILES SEARCHED...
9 FILES SEARCHED...
13 FILES SEARCHED...
17 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
29 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
40 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
44 FILES SEARCHED...
49 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
56 FILES SEARCHED...
59 FILES SEARCHED...
L3 362 L2 AND PY<=2000

=> D L3 1-362

L3 ANSWER 1 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:430737 BIOSIS
DN PREV200000430737
TI Encapsulation of ***parathyroid*** cells in hollow fibers: A
preliminary report.
AU Granicka, Ludomira H.; Migaj, Malgorzata; Wozniewicz, B.; Zawitkowska,
Teresa; Tolloczko, Tadeusz; Werynski, Andrzej; Kawiak, Jerzy [Reprint
author]
CS Institute of Biocybernetics and Biomedical Engineering, PAN, Ks. Trojdena
4, 02-109, Warsaw, Poland
SO Folia Histochemica et Cytobiologica, (2000) Vol. 38, No. 3, pp. 129-131.
print.
CODEN: FHCYEM. ISSN: 0239-8508.
DT Article
LA English
ED Entered STN: 11 Oct 2000
Last Updated on STN: 10 Jan 2002

L3 ANSWER 2 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:387765 BIOSIS
DN PREV200000387765
TI Alu-mediated phylogenetic novelties in gene regulation and development.
AU Hamdi, Hamdi K.; Nishio, Hitomi; Tavis, Jeffrey; Zielinski, Rita;
Dugaiczky, Achilles [Reprint author]
CS Department of Biochemistry, University of California, Riverside, CA,
92521, USA
SO Journal of Molecular Biology, (16 June, 2000) Vol. 299, No. 4, pp.
931-939. print.
CODEN: JMOBAK. ISSN: 0022-2836.
DT Article
LA English
OS Genbank-AF251315; Genbank-AF251316; Genbank-AF251317; Genbank-AF251318;
Genbank-AF251319; Genbank-AF251320
ED Entered STN: 13 Sep 2000
Last Updated on STN: 8 Jan 2002

L3 ANSWER 3 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:461988 BIOSIS
DN PREV199900461988
TI A chimeric form of osteoprotegerin inhibits hypercalcemia and bone
resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1,25(OH)2D3.
AU Morony, Sean; Capparelli, Casey; Lee, Richard; Shimamoto, Grant; Boone,
Thomas; Lacey, David L.; Dunstan, Colin R. [Reprint author]
CS Department of Pathology, Amgen, Inc., One Amgen Center Drive, Thousand
Oaks, CA, 91320-1789, USA
SO Journal of Bone and Mineral Research, (Sept., 1999) Vol. 14, No. 9, pp.
1478-1485. print.
CODEN: JBMREJ. ISSN: 0884-0431.
DT Article
LA English
ED Entered STN: 1 Nov 1999
Last Updated on STN: 3 May 2000

L3 ANSWER 4 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1998:12049 BIOSIS
DN PREV199800012049
TI Responses of human MG-63 osteosarcoma cell line and human osteoblast-like

cells to pulsed electromagnetic fields.

AU Sollazzo, Vincenzo [Reprint author]; Traina, Gian Carlo; Demattei, Monica;
 Pellati, Agnese; Pezzetti, Furio; Caruso, Angelo
 CS Dip. Sci. Biomed. Ter. Avanzate, Sez. Clin. Ortop., Univ. Ferrara, Corso
 Giovecca 203, 44100 Ferrara, Italy
 SO Bioelectromagnetics, (1997) Vol. 18, No. 8, pp. 541-547. print.
 CODEN: BLCTDO. ISSN: 0197-8462.

DT Article
 LA English
 ED Entered STN: 23 Dec 1997
 Last Updated on STN: 23 Dec 1997

L3 ANSWER 5 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1997:386879 BIOSIS
 DN PREV199799686082
 TI Isolation of cells from ovine fetal long bone and characterization of
 their osteoblastic activities during in vitro mineralization.

AU Collignon, H. [Reprint author]; Davicco, M. J.; Barlet, J. P.
 CS Metabolisme Mineral et Osteogenese, INRA Theix, 63122 Ceyrat, France
 SO Archives of Physiology and Biochemistry, (1997) Vol. 105, No. 2, pp.
 158-166.
 ISSN: 1381-3455.

DT Article
 LA English
 ED Entered STN: 10 Sep 1997
 Last Updated on STN: 10 Sep 1997

L3 ANSWER 6 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1997:343501 BIOSIS
 DN PREV199799642704
 TI ***Parathyroid*** hormone prevents 1,25(OH)-2D-3 induced
 down-regulation of the vitamin D receptor in growth plate chondrocytes in
 vitro.

AU Klaus, Guenter [Reprint author]; May, Tanja; Huegel, Ulrike; Von Eichel,
 Barbara; Rodriguez, Julian; Fernandez, Porfirio; Reichrath, Joerg; Ritz,
 Eberhard; Mehls, Otto
 CS Dep. Pediatrics, Univ. Marburg, Deutschhausstr. 12, 35033 Marburg, Germany
 SO Kidney International, (1997) Vol. 52, No. 1, pp. 45-51.
 CODEN: KDYIA5. ISSN: 0085-2538.

DT Article
 LA English
 ED Entered STN: 11 Aug 1997
 Last Updated on STN: 11 Aug 1997

L3 ANSWER 7 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1993:503850 BIOSIS
 DN PREV199396127857
 TI Intermittent and continuous exposure to 1,25-(OH-2D-3) have different
 effects on growth plate chondrocytes in vitro.

AU Klaus, Guenter; Koenig, Birgit; Huegel, Ulrike; Ritz, Eberhard; Mehls,
 Otto [Reprint author]
 CS Dep. Pediatrics, Div. Pediatric Nephrology, Im Neuenheimer Feld 150, 69120
 Heidelberg, Germany
 SO Kidney International, (1993) Vol. 44, No. 4, pp. 708-715.
 CODEN: KDYIA5. ISSN: 0085-2538.

DT Article
 LA English
 ED Entered STN: 5 Nov 1993
 Last Updated on STN: 6 Nov 1993

L3 ANSWER 8 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1993:272172 BIOSIS
 DN PREV199396002397
 TI ***Parathyroid*** hormone-induced changes in alkaline phosphatase
 expression in fetal calvarial osteoblast: Differences between rat and
 mouse.

AU Jongen, J. W. J. M.; Bos, M. P.; Van Der Meer, J. M.; Herrmann-Erlee, M.
 P. M.
 CS Lab. Cell Biol. Histology, University Leiden, Rijnsburgerweg 10, 2333 AA
 Leiden, The Netherlands, netherlands
 SO Journal of Cellular Physiology, (1993) Vol. 155, No. 1, pp. 36-43.
 CODEN: JCLLAX. ISSN: 0021-9541.

DT Article
 LA English
 ED Entered STN: 9 Jun 1993
 Last Updated on STN: 9 Jun 1993

L3 ANSWER 9 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1992:508547 BIOSIS
 DN PREV199294127072; BA94:127072
 TI TRANSFORMED CLONED CELLS FROM MICRODISSECTED TUBULES PROXIMAL TUBULES.
 AU SUZUKI M [Reprint author]; MORITA T; HASEGAWA H; WATABE K; MIYAZAKI K;
 IKEDA M; HANAOKA K; KAWAGUCHI Y; SAKAI O
 CS DEP INTERNAL MED II, JIKEI UNIV, SCH MED, 3-25-8 NISHI-SHINBASHI,
 MINATO-KU, TOKYO 105, JPN
 SO Jikeikai Medical Journal, (1992) Vol. 39, No. 2, pp. 119-126.
 CODEN: JMEJAS. ISSN: 0021-6968.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 9 Nov 1992
 Last Updated on STN: 10 Nov 1992

L3 ANSWER 10 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1991:478858 BIOSIS
 DN PREV199192112618; BA92:112618
 TI IMPAIRED PHAGOCYTOSIS IN DIALYSIS PATIENTS STUDIES ON MECHANISMS.
 AU ALEXIEWICZ J M [Reprint author]; SMOGORZEWSKI M; FADDA G Z; MASSRY S G
 CS DIV NEPHROLOGY, UNIVERSITY SOUTHERN CALIFORNIA SCH MED, 2025 ZONAL AVENUE,
 LOS ANGELES, CALIF 90033, USA
 SO American Journal of Nephrology, (1991) Vol. 11, No. 2, pp. 102-111.
 CODEN: AJNED9. ISSN: 0250-8095.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 26 Oct 1991
 Last Updated on STN: 26 Oct 1991

L3 ANSWER 11 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1991:341215 BIOSIS
 DN PREV199192040590; BA92:40590
 TI REGULATION OF COLLAGENASE GENE EXPRESSION IN HUMAN OSTEOSARCOMA-DERIVED
 OSTEOBLASTIC CELL LINES.
 AU TAMURA M [Reprint author]
 CS DEP BIOCHEM, FAC DENTISTRY, TOKYO MED AND DENTAL UNIV, JPN
 SO Journal of the Stomatological Society Japan, (1991) Vol. 58, No. 1, pp.
 284-299.
 CODEN: KOGZA9. ISSN: 0300-9149.
 DT Article
 FS BA
 LA JAPANESE
 ED Entered STN: 31 Jul 1991
 Last Updated on STN: 1 Aug 1991

L3 ANSWER 12 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1991:227061 BIOSIS
 DN PREV199191118521; BA91:118521
 TI EPIDERMAL GROWTH FACTOR GENE EXPRESSION IN AVIAN EPIPHYSEAL GROWTH-PLATE
 CARTILAGE CELLS EFFECT OF SERUM ***PARATHYROID*** HORMONE AND ATRIAL
 NATRIURETIC PEPTIDE.
 AU HALEVY O [Reprint author]; SCHINDLER D; HURWITZ S; PINES M
 CS INST ANIMAL SCI, VOLCANI CENT, ARO, BET DAGAN 50-250, ISRAEL
 SO Molecular and Cellular Endocrinology, (1991) Vol. 75, No. 3, pp. 229-236.
 CODEN: MCEND6. ISSN: 0303-7207.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 9 May 1991
 Last Updated on STN: 10 May 1991

L3 ANSWER 13 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
 AN 1989:388737 BIOSIS
 DN PREV198988069327; BA88:69327
 TI DOG AND RAT KIDNEY PROXIMAL TUBULE CELLS IN CULTURE RESPONSES TO
 PARATHYROID HORMONE.
 AU RAO L G [Reprint author]; YAU C H; KOVACS K
 CS CALCIUM RES LAB, ROOM 212, ST MICHAEL'S HOSP, 38 SHUTER ST, ANNEX TORONTO,
 ONTARIO M5B 1A6, CAN
 SO Journal of Bone and Mineral Research, (1989) Vol. 4, No. 3, pp. 293-304.
 CODEN: JBMREJ. ISSN: 0884-0431.
 DT Article
 FS BA

LA ENGLISH
ED Entered STN: 17 Aug 1989
Last Updated on STN: 23 Sep 1989

L3 ANSWER 14 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1989:291977 BIOSIS
DN PREV198988017321; BA88:17321
TI THE ORIGIN AND NATURE OF STROMAL OSTEOCLAST-LIKE MULTINUCLEATED GIANT
CELLS IN BREAST CARCINOMA IMPLICATIONS FOR TUMOR OSTEOLYSIS AND MACROPHAGE
BIOLOGY.
AU ATHANASOU N A [Reprint author]; WELLS C A; QUINN J; FERGUSON D P; HERYET
A; MCGEE J O
CS NUFFIELD DEP PATHOLOGY, UNIV OXFORD, LEVEL 1, JOHN RADCLIFFE HOSP,
HEADINGTON, OXFORD OX3 9DU, UK
SO British Journal of Cancer, (1989) Vol. 59, No. 4, pp. 491-498.
CODEN: BJCAAI. ISSN: 0007-0920.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 20 Jun 1989
Last Updated on STN: 20 Jun 1989

L3 ANSWER 15 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1988:395985 BIOSIS
DN PREV198886068624; BA86:68624
TI ESTABLISHMENT OF PRIMARY CELL CULTURES FROM HUMAN AND CANINE
PARATHYROID GLAND EXPLANTS.
AU HORNICEK F J [Reprint author]; REISS E; MALININ T I; MALININ G I
CS SURG RES LAB, DEP SURGERY, PO BOX 016960, UNIV MIAMI SCH MED, MIAMI, FL
33101, USA
SO Bone and Mineral, (1988) Vol. 4, No. 2, pp. 157-166.
CODEN: BOMIET. ISSN: 0169-6009.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 7 Sep 1988
Last Updated on STN: 7 Sep 1988

L3 ANSWER 16 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1984:207831 BIOSIS
DN PREV198477040815; BA77:40815
TI DIFFERENTIAL SERUM DEPENDENCE OF CULTURED OSTEOCLASTIC AND OSTEO BLASTIC
BONE CELLS.
AU WONG G L [Reprint author]; KOCOUR B A
CS DEP OF BIOL, UNIV OF COLORADO, COLORADO SPRINGS, CO 80933-7150, USA
SO Calcified Tissue International, (1983) Vol. 35, No. 6, pp. 778-782.
CODEN: CTINDZ. ISSN: 0171-967X.
DT Article
FS BA
LA ENGLISH

L3 ANSWER 17 OF 362 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1982:223177 BIOSIS
DN PREV198273083161; BA73:83161
TI LACK OF ***FC*** RECEPTORS ON OSTEOCLASTS.
AU HOGG N [Reprint author]; SHAPIRO I M; JONES S J; SLUSARENKO M; BOYDE A
CS DEP ANAT, UNIV COLL LOND, GOWER ST, LONDON WC1E 6BT, ENGL, UK
SO Cell and Tissue Research, (1980) Vol. 212, No. 3, pp. 509-516.
CODEN: CTSRCS. ISSN: 0302-766X.
DT Article
FS BA
LA ENGLISH

L3 ANSWER 18 OF 362 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
AN 1999:30650608 BIOTECHNO
TI Characterization of immortalized osteoclast precursors developed from
mice transgenic for both bcl-X(L) and simian virus 40 large T antigen
AU Hentunen T.A.; Jackson S.H.; Chung H.; Reddy S.V.; Lorenzo J.; Sun Jin
Choi; Roodman G.D.
CS Dr. G.D. Roodman, Research Service (151), Audie Murphy Veterans Admin.
Hosp., 7400 Merton Minter Boulevard, San Antonio, TX 78284, United
States.
E-mail: roodman@uthscsa.edu
SO Endocrinology, (***1999***), 140/7 (2954-2961), 19 reference(s)
CODEN: ENDOAO ISSN: 0013-7227
DT Journal; Article

CY United States
 LA English
 SL English

L3 ANSWER 19 OF 362 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
 AN 1992:23013225 BIOTECHNO
 TI Responsiveness to synthetic ***parathyroid*** hormone in the portal
 vein of portal hypertensive rats
 AU Chao T.-W.; Yu P.-C.; Kuo J.-S.; Pang P.K.T.; Yang M.C.M.
 CS Department of Medical Research, Taipei Veterans General Hospital, Taipei
 11217, Taiwan.
 SO Journal of Hepatology, (***1992***), 16/3 (326-331)
 CODEN: JOHEEC ISSN: 0168-8278
 DT Journal; Article
 CY Ireland
 LA English
 SL English

L3 ANSWER 20 OF 362 CANCERLIT on STN
 AN 97418998 CANCERLIT
 DN 97418998 PubMed ID: 9275074
 TI Multiple extracellular signals promote osteoblast survival and apoptosis.
 AU Hill P A; Tumber A; Meikle M C
 CS Department of Orthodontics and Pediatric Dentistry, United Medical and
 Dental Schools of Guy's and St. Thomas' Hospitals, University of London,
 United Kingdom.
 SO ENDOCRINOLOGY, *** (1997 Sep) *** 138 (9) 3849-58.
 Journal code: 0375040. ISSN: 0013-7227.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS MEDLINE; Abridged Index Medicus Journals; Priority Journals
 OS MEDLINE 97418998
 EM 199709
 ED Entered STN: 19971009
 Last Updated on STN: 19971009

L3 ANSWER 21 OF 362 CANCERLIT on STN
 AN 86162585 CANCERLIT
 DN 86162585 PubMed ID: 3006962
 TI Characterization of cells from human giant cell tumors of bone.
 AU Goldring S R; Schiller A L; Mankin H J; Dayer J M; Krane S M
 NC AM-03564 (NIADDK)
 SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, *** (1986 Mar) *** (204)
 59-75. Ref: 84
 Journal code: 0075674. ISSN: 0009-921X.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS MEDLINE; Abridged Index Medicus Journals; Priority Journals
 OS MEDLINE 86162585
 EM 198605
 ED Entered STN: 19941107
 Last Updated on STN: 19941107

L3 ANSWER 22 OF 362 CANCERLIT on STN
 AN 83605007 CANCERLIT
 DN 83605007
 TI RESPONSE TO ***PARATHYROID*** AND CALCITONIN OF HUMAN GIANT CELL TUMOR
 OF BONE CULTURED IN PATIENTS' SERUM.
 AU Wientroub S; Binderman I; Somjen D; Kletter Y; Salama R; Weissman S L
 CS (c/o Binderman) Hard Tissue Res. Unit, Ichilov Hosp., Tel Aviv, Israel.
 SO Clin Orthop, *** (1982) *** (167) 277-279.
 ISSN: 0009-921X.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Institute for Cell and Developmental Biology
 EM 198303
 ED Entered STN: 19941107
 Last Updated on STN: 19941107

L3 ANSWER 23 OF 362 CANCERLIT on STN
 AN 82097007 CANCERLIT
 DN 82097007 PubMed ID: 7319545
 TI Effect of treatment with glutaurine on human antibody-dependent

cell-mediated cytotoxicity (ADCC).
 AU Lang I; Feuer L; Nekam K; Torok K; Kalmar L; Gergely P
 SO IMMUNOLOGICAL COMMUNICATIONS, *** (1981) *** 10 (6) 499-509.
 Journal code: 0353016. ISSN: 0090-0877.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS MEDLINE; Priority Journals
 OS MEDLINE 82097007
 EM 198203
 ED Entered STN: 19990618
 Last Updated on STN: 19990618

L3 ANSWER 24 OF 362 CANCERLIT on STN
 AN 81694082 CANCERLIT
 DN 81694082
 TI SQUAMOUS CELL CARCINOMA OF THE THYROID GLAND.
 AU Lee J R; Vohman M D; Pendergrast W J
 CS Dept. Surgical Education, Piedmont Hosp., 1968 Peachtree Road, Atlanta, GA, 30309.
 SO J Med Assoc Ga, *** (1980) *** 69 (9) 755-758.
 ISSN: 0025-7028.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Institute for Cell and Developmental Biology
 EM 198103
 ED Entered STN: 19941107
 Last Updated on STN: 19960517

L3 ANSWER 25 OF 362 CANCERLIT on STN
 AN 79604487 CANCERLIT
 DN 79604487
 TI SARCOMATOUS VARIANT OF MALIGNANT HISTIOCYTOSIS: A CASE REPORT AND REVIEW OF THE LITERATURE.
 AU Watanabe S; Mikata A; Toyama K; Kitamura K; Minato K
 CS Pathology Div., Natl. Cancer Center Res. Inst., 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104, Japan.
 SO Acta Pathol Jpn, *** (1978) *** 28 (6) 963-978.
 ISSN: 0001-6632.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Institute for Cell and Developmental Biology
 EM 197903
 ED Entered STN: 19941107
 Last Updated on STN: 19941107

L3 ANSWER 26 OF 362 CANCERLIT on STN
 AN 78613718 CANCERLIT
 DN 78613718
 TI RESPONSE TO HORMONES OF CELLS CULTURED FROM HUMAN GIANT CELL TUMORS OF BONE.
 AU Goldring S R; Dayer J M; Russell R G; Mankin H J; Krane S M
 CS Arthritis Unit, Massachusetts General Hosp., Boston, MA, 02114.
 SO J Clin Endocrinol Metab, *** (1978) *** 46 (3) 425-433.
 ISSN: 0021-972X.
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Institute for Cell and Developmental Biology
 EM 197806
 ED Entered STN: 19941107
 Last Updated on STN: 19941107

L3 ANSWER 27 OF 362 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:829001 CAPLUS
 DN 135:367227
 TI Methods of use for osteoprotegerin-binding protein receptors
 IN Boyle, William J.
 PA Amgen Inc., USA
 SO U.S., 59 pp., Cont.-in-part of U.S. Ser. No. 880,855.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6316408	B1	20011113	US 1998-52521	19980330

US 5843678	A	19981201	US 1997-842842	19970416	<--
WO 9846751	A1	19981022	WO 1998-US7584	19980415	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9871205	A1	19981111	AU 1998-71205	19980415	<--
AU 743257	B2	20020124			
EP 975754	A1	20000202	EP 1998-918244	19980415	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 9808545	A	20000523	BR 1998-8545	19980415	<--
EE 9900611	A	20000815	EE 1999-611	19980415	<--
JP 2001526532	T2	20011218	JP 1998-544257	19980415	
NZ 500253	A	20020927	NZ 1998-500253	19980415	
ZA 9803189	A	19981016	ZA 1998-3189	19980416	<--
US 2003104485	A1	20030605	US 1998-79569	19980514	
US 2003100488	A1	20030529	US 1998-211297	19981214	
MX 9909387	A	20000630	MX 1999-9387	19991013	<--
NO 9905044	A	19991215	NO 1999-5044	19991015	<--
PRAI US 1997-842842	A2	19970416			
US 1997-880855	A2	19970623			
US 1998-52521	A	19980330			
WO 1998-US7584	W	19980415			

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 362 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:306141 CAPLUS
DN 122:71608
TI The effects of anti-inflammatory and anti-rheumatic drugs, immunomodulators on bone resorption
AU Itokazu, Yoshihiko; Segawa, Yoshihide; Omata, Takeshi; Tsuzuike, Naoki; Yoshida, Kenji; Oka, Hideki; Matsuda, Kazuo
CS Cent. Res. Lab., Zeria Pharm. Co., Ltd., Japan
SO Ensho (***1994***), 14(5), 391-9
CODEN: ENSHEE; ISSN: 0389-4290
PB Nippon Ensho Gakkai Jimukyoku
DT Journal
LA Japanese

L3 ANSWER 29 OF 362 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:648000 CAPLUS
DN 119:248000
TI Method for making universal donor cells
IN Weiss, Tania L.; Garovoy, Marvin R.; Hunt, Anthony; Huey, Bing; Tam, Schuman
PA University of California, USA
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9314769	A1	19930805	WO 1993-US797	19930129	<--
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, UA, US						
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG						
	AU 9335982	A1	19930901	AU 1993-35982	19930129	<--
	EP 626852	A1	19941207	EP 1993-904719	19930129	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE						
	JP 07503612	T2	19950420	JP 1993-513441	19930129	<--
	HU 67676	A2	19950428	HU 1994-2188	19930129	<--
	BR 9307844	A	19960109	BR 1993-7844	19930129	<--
	NO 9402680	A	19940824	NO 1994-2680	19940715	<--
PRAI	US 1992-830427		19920131			
	US 1992-944868		19920914			
	WO 1993-US797		19930129			

L3 ANSWER 30 OF 362 CROPV COPYRIGHT 2003 THOMSON DERWENT on STN

AN 1994-84743 CROPU H S
TI A two-generation reproduction-fertility study in rats with MON 1850
AU Schroeder R E; Farmer D R
CS Pharmaco; Monsanto
LO East Millstone, N.J.; St. Louis, Mo., USA
SO Teratology (49, No. 5, 389, 1994)
CODEN: TJADAB
AV Pharmaco LSR Inc., Toxicology Services North America, East Millstone, New
Jersey, U.S.A.
DT Conference
LA English
FA AB; LA; CT

L3 ANSWER 31 OF 362 DISSABS COPYRIGHT (C) 2003 ProQuest Information and
Learning Company; All Rights Reserved on STN
AN 2001:16731 DISSABS Order Number: AAIMQ47439
TI Regulation of ***parathyroid*** hormone-related peptide in a squamous
cervical carcinoma cell line, CaSki
AU Buckle, Joy Ann [M.Sc.]; Kaiser, Stephanie [adviser]
CS Memorial University of Newfoundland (Canada) (0306)
SO Masters Abstracts International, (***1999***) Vol. 38, No. 4, p. 991.
Order No.: AAIMQ47439. 139 pages.
ISBN: 0-612-47439-9.
DT Dissertation
FS MAI
LA English

L3 ANSWER 32 OF 362 DISSABS COPYRIGHT (C) 2003 ProQuest Information and
Learning Company; All Rights Reserved on STN
AN 1999:50345 DISSABS Order Number: AAI9925061
TI SPREAD OF REPETITIVE DNA ELEMENTS IN THE HUMAN AND PRIMATE GENOMES:
EVOLUTIONARY IMPLICATIONS FOR THE PAST AND FUTURE (PHYLOGENETIC, ALU)
AU HAMDI, HAMDI KHALIL [PH.D.]; DUGAICZYK, ACHILLES [adviser]
CS UNIVERSITY OF CALIFORNIA, RIVERSIDE (0032)
SO Dissertation Abstracts International, (***1999***) Vol. 60, No. 4B, p.
1413. Order No.: AAI9925061. 137 pages.
DT Dissertation
FS DAI
LA English

L3 ANSWER 33 OF 362 DRUGU COPYRIGHT 2003 THOMSON DERWENT on STN
AN 1995-15930 DRUGU T P S E
TI Inhaled glucocorticoids for asthma.
AU Barnes P J
CS Nat.Heart+Lung-Inst.London
LO London, U.K.
SO N.Engl.J.Med. (332, No. 13, 868-75, 1995) 1 Fig. 1 Tab. 99 Ref.
CODEN: NEJMAG ISSN: 0028-4793
AV Department of Thoracic Medicine, National Heart and Lung Institute,
Dovehouse St., London SW3 6LY, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L3 ANSWER 34 OF 362 DRUGU COPYRIGHT 2003 THOMSON DERWENT on STN
AN 1984-39652 DRUGU B E
TI Paracrine Interactions in Bone-secreted Products of Osteoblasts Permit
Osteoclasts to Respond to ***Parathyroid*** Hormone.
AU Wong G L
LO Colorado Springs, Colorado, United States
SO J.Biol.Chem. (259, No. 7, 4019-22, 1984) 4 Tab. 40 Ref.
CODEN: JBCHA3 ISSN: 0021-9258
AV Department of Biology, University of Colorado at Colorado Springs,
Colorado 80933-7150, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L3 ANSWER 35 OF 362 DRUGU COPYRIGHT 2003 THOMSON DERWENT on STN
AN 1983-43004 DRUGU P B E
TI Differential Response to Hormones of Defined Distal Nephron Epithelia in
Culture.
AU Wilson P D; Horster M F
LO Munich, Germany,West

SO Am.J.Physiol. (244, No. 3, C166-C174, 1983) 10 Fig. 32 Ref.
CODEN: AJPBAP ISSN: 0002-9513
AV Physiologisches Institut der Universitat Munchen, Pettenkoferstrasse 12,
D-8000 Munchen 2, Federal Republic of Germany.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L3 ANSWER 36 OF 362 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 2001032420 EMBASE
TI Microgravity inhibits intestinal calcium absorption as shown by a stable
strontium test.
AU Zittermann A.; Heer M.; Caillot-Augusso A.; Rettberg P.; Scheld K.;
Drummer C.; Alexandre C.; Horneck G.; Vorobiev D.; Stehle P.
CS Dr. A. Zittermann, Department of Nutrition Science, University of Bonn,
Endenicher Allee 11-13, 53115 Bonn, Germany. a.zittermann@uni-bonn.de
SO European Journal of Clinical Investigation, (2000) 30/12 (1036-1043).
Refs: 33
ISSN: 0014-2972 CODEN: EJCIB8
CY United Kingdom
DT Journal; Article
FS 002 Physiology
LA English
SL English

L3 ANSWER 37 OF 362 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 91008329 EMBASE
DN 1991008329
TI Polarized membrane expression of brush-border hydrolases in primary
cultures of kidney proximal tubular cells depends on cell differentiation,
and is induced by dexamethasone.
AU Ronco P.; Antoine M.; Baudouin B.; Geniteau-Legendre M.; Lelongt B.;
Chatelet F.; Verroust P.; Vandewalle A.
CS Unite INSERM U.64, Hopital Tenon, 75970 Paris Cedex, France
SO Journal of Cellular Physiology, (1990) 145/2 (222-237).
ISSN: 0021-9541 CODEN: JCLLAX
CY United States
DT Journal; Article
FS 021 Developmental Biology and Teratology
029 Clinical Biochemistry
037 Drug Literature Index
LA English
SL English

L3 ANSWER 38 OF 362 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 82007882 EMBASE
DN 1982007882
TI Aspects of the cell biology of the rheumatoid synovial lesion.
AU Krane S.M.
CS Dept. Med., Harvard Med. Sch., Boston, MA, United States
SO Annals of the Rheumatic Diseases, (1981) 40/5 (433-448).
CODEN: ARDIAO
CY United Kingdom
DT Journal
FS 037 Drug Literature Index
031 Arthritis and Rheumatism
005 General Pathology and Pathological Anatomy
LA English

L3 ANSWER 39 OF 362 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 79152426 EMBASE
DN 1979152426
TI The growth of mouse melanoma cells in hormone-supplemented, serum-free
medium.
AU Mather J.P.; Sato G.H.
CS Biol. Dept., Univ. California, San Diego, La Jolla, Calif. 92093, United
States
SO Experimental Cell Research, (1979) 120/1 (191-200).
CODEN: ECREAL
CY United States
DT Journal

FS 037 Drug Literature Index
016 Cancer
023 Nuclear Medicine
005 General Pathology and Pathological Anatomy
LA English

L3 ANSWER 40 OF 362 IFIPAT COPYRIGHT 2003 IFI on STN
AN 3351076 IFIPAT;IFIUDB;IFICDB
TI LUMINESCENT CHIMERIC PROTEINS; PHOTOPROTEIN LIKE AEQUORIN, OBELIN,
BEROVIN, OR MNEMIOPSIN LINKED TO ANTIGEN-SPECIFIC PROTEIN LIKE
LIGHT-CHAIN OR HEAVY-CHAIN IMMUNOGLOBULIN, AVIDIN, STREPAVIDIN, PROTEIN
A, OR AN ANTIGENIC PEPTIDE OR FRAGMENT; SENSITIVE IMMUNOASSAY
IN Casadei Jan; Kenten John H; Powell Michael J
PA IGEN International Inc (44114)
PI US 6087476 20000711
AI US 1997-906654 19970807
RLI US 1988-173231 19880324 CONTINUATION ABANDONED
US 1991-789279 19911107 CONTINUATION ABANDONED
US 1993-110326 19930823 CONTINUATION ABANDONED
US 1994-358577 19941214 CONTINUATION ABANDONED
FI US 6087476 20000711
DT UTILITY
FS CHEMICAL
GRANTED
MRN 009396 MFN: 0070
CLMN 5
GI 9 Drawing Sheet(s), 9 Figure(s).

L3 ANSWER 41 OF 362 IFIPAT COPYRIGHT 2003 IFI on STN
AN 3002066 IFIPAT;IFIUDB;IFICDB
TI HEMATOPOIETIC FACILITATORY CELLS AND THEIR USES
IN Ildstad Suzanne T; Kaufman Christina; Ricordi Camillo; Simmons Richard L;
Wren Sherry M
PA Pittsburgh, University of (66208)
PI US 5772994 19980630
AI US 1995-463908 19950605
RLI US 1993-69315 19930528 CONTINUATION ABANDONED
FI US 5772994 19980630
DT UTILITY
FS CHEMICAL
GRANTED
CLMN 72
GI 1 Drawing Sheet(s), 1 Figure(s).

L3 ANSWER 42 OF 362 IFIPAT COPYRIGHT 2003 IFI on STN
AN 1544900 IFIPAT;IFIUDB;IFICDB
TI IMMUNOASSAY INVOLVING SOLUBLE COMPLEX OF SECOND ANTIBODY AND LABELED
BINDING PROTEIN; DIRECT, TWO-SITE; MEDICAL DIAGNOSIS
IN CHAPMAN DANA A; ST DENIS JOHN N; WOODS JAMES W
PA MALLINCKRODT INC (51840)
PI US 4469787 19840904 (CITED IN 022 LATER PATENTS)
AI US 1982-378126 19820514
FI US 4469787 19840904
DT UTILITY; REASSIGNED; EXPIRED
FS CHEMICAL
GRANTED
OS CA 101:166720
MRN 004004 MFN: 0497
CLMN 16

L3 ANSWER 43 OF 362 JICST-EPlus COPYRIGHT 2003 JST on STN
AN 900275347 JICST-EPlus
TI Effects of MP-Parotin and epidermal growth factor on osteogenic cell line
MC3T3E1.
AU KINOSHITA TOKUYASU; KOSANO HIROSHI; KUGAI NOBUO; NAGATA NAOKAZU; TAKATANI
OSAMU
CS National Defence Medical College
SO Nippon Daekisen Gakkaishi (Journal of the Japan Salivary Gland Society),
(1989) vol. 30, pp. (JA)29-31,(EN)30. Journal Code: Y0702A (Fig. 2)
ISSN: 0916-1104
CY Japan
DT Conference; Short Communication
LA Japanese; English
STA New

L3 ANSWER 44 OF 362 JICST-EPlus COPYRIGHT 2003 JST on STN

AN 890582148 JICST-EPlus
TI Effects of hydrostatic pressure on proliferation and expression of the differentiated phenotype of cultured chondrocytes derived from rabbit craniofacial complex.
AU SOMA SHUNICHI
CS Osaka Univ., Dental School
SO Osaka Daigaku Shigaku Zasshi (Journal of Osaka University Dental Society), (1989) vol. 34, no. 1, pp. 8-25. Journal Code: G0883A (Fig. 12, Tbl. 3, Ref. 41)
CODEN: ODSZA2; ISSN: 0473-4629
CY Japan
DT Journal; Article
LA Japanese
STA New

L3 ANSWER 45 OF 362 JICST-EPlus COPYRIGHT 2003 JST on STN
AN 890178018 JICST-EPlus
TI Effects of MP-parotin and parotin subunit on osteogenic cell line MC3T3-E1.
AU KINOSHITA TOKUYASU; KOSANO HIROSHI; KUGAI NOBUO; NAGATA NAOKAZU; TAKATANI OSAMU
CS National Defence Medical College
SO Nippon Daekisen Gakkaishi (Journal of the Japan Salivary Gland Society), (1988) vol. 29, pp. 29-32. Journal Code: Y0702A (Fig. 1, Tbl. 1)
ISSN: 0916-1104
CY Japan
DT Conference; Short Communication
LA Japanese
STA New

L3 ANSWER 46 OF 362 MEDLINE on STN
AN 89286182 MEDLINE
DN 89286182 PubMed ID: 2544153
TI [Parathormone, cyclic AMP, 1,25 dihydroxyvitamin D and osteocalcin in hypercalciuric renal lithiasis]. Parathormona, AMP ciclico, 1,25 dihidroxivitamina D y osteocalcina en la litiasis renal hipercalciurica (LRH).
AU Diaz Perez de Madrid J; Munoz Torres M; Garcia de Vinuesa M J; Mijan J L; Escobar Jimenez F; Zuluaga A
SO ARCHIVOS ESPANOL DE UROLOGIA, *** (1989 Mar)*** 42 (2) 129-31.
Journal code: 0064757. ISSN: 0004-0614.
CY Spain
DT Journal; Article; (JOURNAL ARTICLE)
LA Spanish
FS Priority Journals
EM 198907
ED Entered STN: 19900309
Last Updated on STN: 19900309
Entered Medline: 19890714

L3 ANSWER 47 OF 362 MEDLINE on STN
AN 87234209 MEDLINE
DN 87234209 PubMed ID: 3589611
TI Early scanning electron microscopic studies of hard tissue resorption: their relation to current concepts reviewed.
AU Boyde A; Jones S J
SO SCANNING MICROSCOPY, *** (1987 Mar)*** 1 (1) 369-81.
Journal code: 8704616. ISSN: 0891-7035.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198706
ED Entered STN: 19900305
Last Updated on STN: 19900305
Entered Medline: 19870626

L3 ANSWER 48 OF 362 PHIN COPYRIGHT 2003 PJB on STN
AN 2000:17955 PHIN
DN B00683182
DED 1 Sep 2000
TI What's in the Pipeline? - Bioventure-View's Roundup of Biotech Products in Phase III - Part B
SO Bioventure-View (***2000***) No. 1509 p12
DT Newsletter

FS FULL

L3 ANSWER 49 OF 362 PHIN COPYRIGHT 2003 PJB on STN

AN 88:5848 PHIN
DN C00161748
DED 8 Jun 1988
TI Results, news and comments from US companies
SO Clinica (***1988***) No. 304 p5
DT Newsletter
FS FULL

L3 ANSWER 50 OF 362 PROMT COPYRIGHT 2003 Gale Group on STN

ACCESSION NUMBER: 2000:664297 PROMT
TITLE: EUROPEAN PATENT DISCLOSURES.
SOURCE: BIOWORLD Today, (***2 Aug 2000***) Vol. 11, No. 148.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2029
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L3 ANSWER 51 OF 362 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

AN 2000:637415 SCISEARCH
GA The Genuine Article (R) Number: 344WA
TI Exercise-trained young men have higher calcium absorption rates and plasma calcitriol levels compared with age-matched sedentary controls
AU Zittermann A (Reprint); Sabatschus O; Jantzen S; Platen P; Danz A; Dimitriou T; Scheld K; Klein K; Stehle P
CS UNIV BONN, DEPT NUTR SCI, ENDENICHER ALLEE 11-13, D-53115 BONN, GERMANY (Reprint); UNIV COLOGNE, HLTH EDUC RES UNIT, D-5000 COLOGNE 41, GERMANY; GERMAN SPORTS UNIV, INST CARDIOL & SPORTS MED, COLOGNE, GERMANY
CYA GERMANY
SO CALCIFIED TISSUE INTERNATIONAL, (***SEP 2000***) Vol. 67, No. 3, pp. 215-219.
Publisher: SPRINGER-VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010.
ISSN: 0171-967X.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 34
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 52 OF 362 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

AN 2000:566972 SCISEARCH
GA The Genuine Article (R) Number: 336QF
TI Appearance and distribution of dendritic cells and macrophages in dental pulp during early postnatal morphogenesis of mouse mandibular first molars
AU Tsuruga E; Sakakura Y (Reprint); Yajima T; Shide N
CS HLTH SCI UNIV HOKKAIDO, SCH DENT, DEPT ORAL ANAT, 1757 KANAZAWA, ISHIKARI, HOKKAIDO 061029, JAPAN (Reprint); HLTH SCI UNIV HOKKAIDO, SCH DENT, DEPT ORAL ANAT, ISHIKARI, HOKKAIDO 061029, JAPAN; HOKKAIDO UNIV, PHYS EDUC LAB, HAKODATE, HOKKAIDO 040856, JAPAN
CYA JAPAN
SO HISTOCHEMISTRY AND CELL BIOLOGY, (***SEP 1999***) Vol. 112, No. 3, pp. 193-204.
Publisher: SPRINGER VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010.
ISSN: 0948-6143.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 72
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 53 OF 362 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN

AN 1999:787291 SCISEARCH
GA The Genuine Article (R) Number: 244EW
TI Determinants of soluble CD23 antigen levels in hemodialysis patients: effect of 1.25 dihydroxyvitamin D-3 and recombinant human erythropoietin treatment
AU Altun B (Reprint); Erdem Y; Usalan C; Arici M; Haznedaroglu I C; Yasavul U; Turgan C; Caglar S; Kirazli S
CS HACETTEPE HASTANESI, NEFROL BOLUMU, TR-06100 ANKARA, TURKEY (Reprint); UNIV HACETTEPE, FAC MED, DEPT INTERNAL MED, DIV NEPHROL, TR-06100 ANKARA, TURKEY; UNIV HACETTEPE, FAC MED, DEPT INTERNAL MED, DIV HAEMATOL, TR-06100

ANKARA, TURKEY
CYA TURKEY
SO CLINICAL NEPHROLOGY, (***OCT 1999***) Vol. 52, No. 4, pp. 230-238.
Publisher: DUSTRI-VERLAG DR KARL FEISTLE, BAHNHOFSTRABE 9 POSTFACH 49,
W-8024 MUNCHEN-DEISENHOFEN, GERMANY.
ISSN: 0301-0430.
DT Article; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 44
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 54 OF 362 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
AN 95:779820 SCISEARCH
GA The Genuine Article (R) Number: TD002
TI HYPERTROPHIC EFFECTS OF CALCITONIN-GENE-RELATED PEPTIDE (CGRP) AND AMYLIN
ON ADULT MAMMALIAN VENTRICULAR CARDIOMYOCYTES
AU BELL D (Reprint); SCHLUTER K D; ZHOU X J; MCDERMOTT B J; PIPER H M
CS QUEENS UNIV BELFAST, DEPT THERAPEUT & PHARMACOL, WHITLA MED BLDG, 97
LISBURN RD, BELFAST BT9 7BL, ANTRIM, NORTH IRELAND (Reprint); UNIV
DUSSELDORF, INST PHYSIOL 1, D-40001 DUSSELDORF, GERMANY
CYA NORTHERN IRELAND; GERMANY
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, (***NOV 1995***) Vol.
27, No. 11, pp. 2433-2443.
ISSN: 0022-2828.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 43
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 55 OF 362 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
AN 93:721300 SCISEARCH
GA The Genuine Article (R) Number: MJ678
TI EFFECT OF 1,25-DIHYDROXYVITAMIN-D3 ON INTERLEUKIN-1-BETA ACTIONS AND
CELL-GROWTH IN HUMAN SYNOVIAL FIBROBLAST-CULTURES
AU YARON I (Reprint); MEYER F A; WEISMAN Y; YARON M
CS ICHILOV HOSP, DEPT RHEUMATOL, ARTHRITIS RES UNIT, 6 WEIZMANN ST, IL-64239
TEL AVIV, ISRAEL (Reprint); ICHILOV HOSP, TEL AVIV MED CTR, BONE DIS UNIT,
IL-64239 TEL AVIV, ISRAEL
CYA ISRAEL
SO JOURNAL OF RHEUMATOLOGY, (***SEP 1993***) Vol. 20, No. 9, pp.
1527-1532.
ISSN: 0315-162X.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 39
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 56 OF 362 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
AN 92:501347 SCISEARCH
GA The Genuine Article (R) Number: JJ236
TI UREMIC INHIBITORS OF ERYTHROPOIESIS - A STUDY DURING TREATMENT WITH
RECOMBINANT-HUMAN-ERYTHROPOIETIN
AU BRUNATI C (Reprint); CAPPELLINI M D; DEFEO T; GUASTONI C; BALLERINI L;
BUSNACH G; CIVATI G; FIORELLI G; MINETTI L
CS OSPED NIGUARDA CA GRANDA, DIV NEFROL & DIALISI, PIAZZA OSPED MAGGIORE 3,
I-20162 MILAN, ITALY (Reprint); IST MED INTERNA & FISIOPATOL, CATTEDRA
CLIN MED, MILAN, ITALY
CYA ITALY
SO AMERICAN JOURNAL OF NEPHROLOGY, (***JAN/APR 1992***) Vol. 12, No. 1-2,
pp. 9-13.
ISSN: 0250-8095.
DT Article; Journal
FS CLIN
LA ENGLISH
REC Reference Count: 25
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 57 OF 362 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
AN 91:551331 SCISEARCH
GA The Genuine Article (R) Number: GH333
TI GROWTH-HORMONE AND INSULIN-LIKE GROWTH FACTOR-I REGULATE COLLAGEN
GENE-EXPRESSION AND EXTRACELLULAR COLLAGEN IN CULTURES OF AVIAN SKIN
FIBROBLASTS

AU GRANOT I; HALEVY O; HURWITZ S; PINES M (Reprint)
 CS AGR RES ORG, VOLCANI CTR, INST ANIM SCI, IL-50250 BET DAGAN, ISRAEL;
 HEBREW UNIV JERUSALEM, FAC AGR, DEPT ANIM SCI, IL-76100 REHOVOT, ISRAEL
 CYA ISRAEL
 SO MOLECULAR AND CELLULAR ENDOCRINOLOGY, (***1991***) Vol. 80, No. 1-3,
 pp. 1-9.
 DT Article; Journal
 FS LIFE
 LA ENGLISH
 REC Reference Count: 36
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 58 OF 362 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
 AN 91:143775 SCISEARCH
 GA The Genuine Article (R) Number: FA686
 TI EPIDERMAL GROWTH-FACTOR RECEPTOR GENE-EXPRESSION IN AVIAN EPIPHYSEAL
 GROWTH-PLATE CARTILAGE CELLS - EFFECT OF SERUM, ***PARATHYROID***
 -HORMONE AND ATRIAL-NATRIURETIC-PEPTIDE
 AU HALEVY O; SCHINDLER D; HURWITZ S; PINES M (Reprint)
 CS AGR RES ORG, VOLCANI CTR, INST ANIM SCI, IL-50250 BET DAGAN, ISRAEL;
 HEBREW UNIV JERUSALEM, FAC AGR, DEPT ANIM SCI, IL-76100 REHOVOT, ISRAEL
 CYA ISRAEL
 SO MOLECULAR AND CELLULAR ENDOCRINOLOGY, (***1991***) Vol. 75, No. 3, pp.
 229-235.
 DT Article; Journal
 FS LIFE
 LA ENGLISH
 REC Reference Count: 33
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 59 OF 362 TOXCENTER COPYRIGHT 2003 ACS on STN
 AN 2002:568556 TOXCENTER
 DN DART-TER-94000715
 TI A two-generation reproduction-fertility study in rats with MON 18500.
 AU Schroeder R E; Farmer D R
 CS Pharmaco LSR Inc., Toxicology Services North America, East Millstone, NJ.
 SO Teratology, (***1994 May***) 49 (5) 389-90.
 ISSN: 0040-3709.
 DT Abstract; (MEETING ABSTRACT)
 FS DART
 LA English
 ED Entered STN: 20021200
 Last Updated on STN: 20021200

L3 ANSWER 60 OF 362 USPATFULL on STN
 AN 2003:302879 USPATFULL
 TI Compositions and methods for treating bone deficit conditions
 IN Orme, Mark W., Seattle, WA, United States
 Baidur, Nand, Edmonds, WA, United States
 Robbins, Kirk G., Rendon, WA, United States
 Harris, Scott M., Seattle, WA, United States
 Kontoyianni, Maria, Seattle, WA, United States
 Hurley, Laurence H., Austin, TX, United States
 Kerwin, Sean M., Round Rock, TX, United States
 Mundy, Gregory, San Antonio, TX, United States
 Petrie, Charles, Woodinville, WA, United States
 PA The Board of Regents of the University of Texas System, Austin, TX,
 United States (U.S. corporation)
 ZymoGenetics Corporation, Seattle, WA, United States (U.S. corporation)
 OsteoScreen, San Antonio, TX, United States (U.S. corporation)
 PI US 6649631 B1 20031118
 WO 9817267 19980430 <--
 AI US 1999-297188 19991119 (9)
 WO 1997-US18864 19971023
 DT Utility
 FS GRANTED
 LN.CNT 1701
 INCL INCLM: 514/332.000
 INCLS: 514/334.000; 514/255.000; 514/275.000; 514/256.000; 514/242.000;
 514/245.000
 NCL NCLM: 514/332.000
 NCLS: 514/334.000; 514/255.000; 514/275.000; 514/256.000; 514/242.000;
 514/245.000
 IC [7]
 ICM: A61K031-44
 EXF 514/332; 514/334; 514/255; 514/275; 514/256; 514/242; 514/245

L3 ANSWER 61 OF 362 USPATFULL on STN
 AN 2003:268067 USPATFULL
 TI Particulate delivery systems and methods of use
 IN Bot, Adrian I., San Diego, CA, United States
 Tarara, Thomas E., San Diego, CA, United States
 Weers, Jeffry G., San Diego, CA, United States
 Kabalnov, Alexev, Corvalis, OR, United States
 Schutt, Ernest G., San Diego, CA, United States
 Dellamary, Luis A., San Marcos, CA, United States
 PA Nektar Therapeutics, San Carlos, CA, United States (U.S. corporation)
 PI US 6630169 B1 20031007
 WO 2000000215 20000106 <--
 AI US 2000-720536 20001222 (9)
 WO 1999-US6855 19990331
 DT Utility
 FS GRANTED
 LN.CNT 3994
 INCL INCLM: 424/489.000
 INCLS: 424/426.000; 424/434.000; 424/450.000; 424/490.000
 NCL NCLM: 424/489.000
 NCLS: 424/426.000; 424/434.000; 424/450.000; 424/490.000
 IC [7]
 ICM: A61K009-14
 ICS: A61K009-16; A61K009-127; A61E002-00
 EXF 424/426; 424/434; 424/489; 424/490; 424/450; 424/484
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 62 OF 362 USPATFULL on STN
 AN 2003:203246 USPATFULL
 TI Infectious papillomavirus pseudoviral particles
 IN Lowy, Douglas R., Bethesda, MD, United States
 Schiller, John T., Silver Spring, MD, United States
 Roden, Richard B., Washington, DC, United States
 PA The United States of America as represented by the Department of Health
 & Human Services, Washington, DC, United States (U.S. government)
 PI US 6599739 B1 20030729
 WO 9802548 19980122 <--
 AI US 2000-509748 20000330 (9)
 WO 1997-US12115 19970714
 PRAI US 1996-22104P 19960717 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2308
 INCL INCLM: 435/325.000
 INCLS: 435/069.100; 435/091.400; 435/235.100; 435/320.100
 NCL NCLM: 435/325.000
 NCLS: 435/069.100; 435/091.400; 435/235.100; 435/320.100
 IC [7]
 ICM: C12N015-00
 ICS: C12N015-63
 EXF 435/235.1; 435/320.1; 435/456; 435/69.1; 435/325; 435/91.4; 424/204.1;
 514/44
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 63 OF 362 USPATFULL on STN
 AN 2003:137082 USPATFULL
 TI Thienyl substituted acylguanidines as inhibitors of bone resorption and
 vitronectin receptor antagonists
 IN Scheunemann, Karl-Heinz, Liederbach, GERMANY, FEDERAL REPUBLIC OF
 Knolle, Jochen, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF
 Peyman, Amuschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF
 Will, David William, Kriftel, GERMANY, FEDERAL REPUBLIC OF
 Carniato, Denis, Cagnes sur Mer, FRANCE
 Gourvest, Jean-Francois, Claye Souilly, FRANCE
 Gadek, Thomas, Oakland, CA, United States
 McDowell, Robert, San Francisco, CA, United States
 Bodary, Sarah Catherine, San Bruno, CA, United States
 Cuthbertson, Robert Andrew, Victoria, AUSTRALIA
 PA Aventis Pharma Deutschland GmbH, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
 corporation)
 Genentech, Inc., United States (U.S. corporation)
 PI US 6566366 B1 20030520
 WO 9959992 19991125 <--
 AI US 2001-700655 20010306 (9)
 WO 1999-EP3064 19990505

PRAI EP 1998-109077 19980519
DT Utility
FS GRANTED
LN.CNT 2479
INCL INCLM: 514/275.000
INCLS: 514/438.000; 514/448.000; 514/449.000; 514/218.000; 544/297.000;
544/330.000; 544/331.000; 544/332.000; 549/065.000; 549/066.000;
549/070.000; 549/072.000; 549/074.000; 549/075.000; 549/076.000;
549/079.000
NCL NCLM: 514/275.000
NCLS: 514/218.000; 514/438.000; 514/448.000; 514/449.000; 544/297.000;
544/330.000; 544/331.000; 544/332.000; 549/065.000; 549/066.000;
549/070.000; 549/072.000; 549/074.000; 549/075.000; 549/076.000;
549/079.000
IC [7]
ICM: A61K031-505
ICS: A61K031-381; C07D409-00; C07D333-34; C07D333-00
EXF 514/218; 514/275; 514/438; 514/448; 514/444; 544/297; 544/330; 544/331;
544/332; 549/65; 549/66; 549/70; 549/72; 549/74; 549/75; 549/76; 549/79
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 64 OF 362 USPATFULL on STN
AN 2003:6968 USPATFULL
TI GDNF receptor
IN Klein, Robert D., South San Francisco, CA, United States
Moore, Mark W., San Francisco, CA, United States
Rosenthal, Arnon, Burlingham, CA, United States
Ryan, Anne M., Millbrae, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6504007 B1 20030107
WO 9733912 19970918 <--
AI US 1997-860370 19970606 (8)
WO 1997-US4363 19970313
19970606 PCT 371 date
RLI Continuation-in-part of Ser. No. US 1996-618236, filed on 14 Mar 1996,
now abandoned Continuation-in-part of Ser. No. US 1996-615902, filed on
14 Mar 1996, now abandoned
DT Utility
FS GRANTED
LN.CNT 4881
INCL INCLM: 530/350.000
INCLS: 930/010.000
NCL NCLM: 530/350.000
NCLS: 930/010.000
IC [7]
ICM: C07K014-71
EXF 536/23.1; 536/23.4; 536/23.5; 435/69.1; 435/325; 435/320.1; 530/350;
930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 65 OF 362 USPATFULL on STN
AN 2002:340331 USPATFULL
TI Prostaglandin agonists and their use to treat bone disorders
IN Cameron, Kimberly O., East Lyme, CT, United States
Lefker, Bruce A., Gales Ferry, CT, United States
Rosati, Robert L., Mystic, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6498172 B1 20021224
WO 9919300 19990422 <--
AI US 1999-367970 19990820 (9)
WO 1998-IB1540 19981005
PRAI US 1997-61727P 19971010 (60)
DT Utility
FS GRANTED
LN.CNT 7931
INCL INCLM: 514/347.000
INCLS: 514/231.500; 514/242.000; 514/252.100; 514/255.050; 514/266.240;
514/269.000; 514/335.000; 514/336.000; 514/337.000; 514/338.000;
514/339.000; 514/341.000; 514/342.000; 514/343.000; 514/357.000;
514/362.000; 514/364.000; 514/365.000; 514/369.000; 514/380.000;
514/397.000; 514/398.000; 514/399.000; 514/406.000; 514/422.000;
514/445.000; 514/448.000; 514/452.000; 514/466.000; 514/469.000;
514/539.000; 514/562.000; 544/146.000; 544/182.000; 544/285.000;
544/383.000; 544/335.000; 544/336.000; 544/405.000; 546/261.000;
546/269.700; 546/275.100; 546/275.400; 546/276.100; 546/277.400;

546/278.400; 546/280.400; 546/282.400; 546/283.400; 546/283.700;
 546/284.100; 546/284.700; 546/293.000; 546/335.000; 548/126.000;
 548/185.000; 548/187.000; 548/204.000
 NCL NCLM: 514/347.000
 NCLS: 514/231.500; 514/242.000; 514/252.100; 514/255.050; 514/266.240;
 514/269.000; 514/335.000; 514/336.000; 514/337.000; 514/338.000;
 514/339.000; 514/341.000; 514/342.000; 514/343.000; 514/357.000;
 514/362.000; 514/364.000; 514/365.000; 514/369.000; 514/380.000;
 514/397.000; 514/398.000; 514/399.000; 514/406.000; 514/422.000;
 514/445.000; 514/448.000; 514/452.000; 514/466.000; 514/469.000;
 514/539.000; 514/562.000; 544/146.000; 544/182.000; 544/285.000;
 544/335.000; 544/336.000; 544/383.000; 544/405.000; 546/261.000;
 546/269.700; 546/275.100; 546/275.400; 546/276.100; 546/277.400;
 546/278.400; 546/280.400; 546/282.400; 546/283.400; 546/283.700;
 546/284.100; 546/284.700; 546/293.000; 546/335.000; 548/126.000;
 548/185.000; 548/187.000; 548/204.000

IC [7]

ICM: A61P019-08

ICS: A61K031-44; A61K031-495; A61K031-505; C07D213-70

EXF 514/255.05; 514/269; 514/335; 514/336; 514/337; 514/338; 514/339;
 514/341; 514/342; 514/343; 514/347; 544/333; 544/405; 546/261;
 546/269.7; 546/275.1; 546/275.4; 546/276.1; 546/277.4; 546/278.4;
 546/280.4; 546/282.4; 546/283.4; 546/283.7; 546/284.1; 546/284.7;
 546/293

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 66 OF 362 USPATFULL on STN

AN 2002:230807 USPATFULL

TI Human melanocyte stimulating hormone receptor polypeptide and DNA

IN Wikberg, Jarl, Trillvagen 13, S-905 92 Ume.ang., SWEDEN

PI Chhajlani, Vijay, stigbergsvagen 8 A, S-752 42 Uppsala, SWEDEN

PI US 6448032 B1 20020910

WO 9404674 19940303

<--

AI US 1995-387805 19950221 (8)

WO 1993-DK273 19930820

19950221 PCT 371 date

PRAI DK 1992-1046 19920821

DK 1992-1118 19920910

DK 1993-528 19930505

DT Utility

FS GRANTED

LN.CNT 3610

INCL INCLM: 435/069.100

INCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.100; 435/069.700;
 530/350.000; 530/306.000; 530/312.000; 530/300.000; 536/023.100;
 536/023.400; 536/023.500; 536/024.330

NCL NCLM: 435/069.100

NCLS: 435/069.700; 435/252.300; 435/254.100; 435/320.100; 435/325.000;
 530/300.000; 530/306.000; 530/312.000; 530/350.000; 536/023.100;
 536/023.400; 536/023.500; 536/024.330

IC [7]

ICM: C07K014-72

ICS: C12N015-10; C12N005-10; C12N015-12

EXF 435/69.1; 435/240.7; 435/243; 435/320.1; 435/325; 435/254.11; 435/69.7;
 435/252.3; 530/306; 530/312; 530/350; 536/23.1; 536/23.4; 536/23.5;
 536/24.33

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 67 OF 362 USPATFULL on STN

AN 2002:216860 USPATFULL

TI Use of crataegus formulations for prophylaxis and treatment of
 neoplastic diseases

IN Schumacher, Katrin U., Aachen, GERMANY, FEDERAL REPUBLIC OF

PA Nativia Health Products GmbH, Innsbruck, AUSTRIA (non-U.S. corporation)

PI US 6440451 B1 20020827

WO 9959605 19991125

<--

AI US 2000-700174 20001113 (9)

WO 1999-EP3302 19990514

20001113 PCT 371 date

PRAI DE 1998-19823679 19980520

DT Utility

FS GRANTED

LN.CNT 951

INCL INCLM: 424/439.000

INCLS: 424/725.000

NCL NCLM: 424/439.000

NCLS: 424/725.000
 IC [7]
 ICM: A61K047-00
 ICS: A61K035-78
 EXF 424/439; 424/725

 L3 ANSWER 68 OF 362 USPATFULL on STN
 AN 2002:152775 USPATFULL
 TI Nucleic acids encoding A-33 related antigen polypeptides
 IN Ashkenazi, Avi, San Mateo, CA, United States
 Fong, Sherman, Alameda, CA, United States
 Goddard, Audrey, San Francisco, CA, United States
 Gurney, Austin L., Belmont, CA, United States
 Napier, Mary A., Hillsborough, CA, United States
 Tumas, Daniel, Orinda, CA, United States
 Wood, William I., Hillsborough, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 6410708 B1 20020625
 WO 9927098 19990603 <--
 AI US 1999-254465 19990305 (9)
 WO 1998-US24855 19981120
 19990305 PCT 371 date
 PRAI US 1998-78936P 19980320 (60)
 US 1997-66364P 19971121 (60)
 DT Utility
 FS GRANTED
 LN.CNT 4361
 INCL INCLM: 536/023.500
 INCLS: 536/023.100; 435/069.100; 435/071.100; 435/071.200; 435/455.000;
 435/471.000; 435/252.300; 435/320.100; 435/252.330; 435/254.200;
 435/348.000; 435/358.000
 NCL NCLM: 536/023.500
 NCLS: 435/069.100; 435/071.100; 435/071.200; 435/252.300; 435/252.330;
 435/254.200; 435/320.100; 435/348.000; 435/358.000; 435/455.000;
 435/471.000; 536/023.100
 IC [7]
 ICM: C07H021-04
 ICS: C12N015-09; C12N015-12; C12N015-63; C12N015-85
 EXF 536/23.1; 536/23.5; 435/69.1; 435/71.1; 435/71.2; 435/455; 435/471;
 435/252.3; 435/320.1; 435/252.33; 435/254.2; 435/34; 435/358
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 69 OF 362 USPATFULL on STN
 AN 2002:115819 USPATFULL
 TI Fibrinogen-coated particles for therapeutic use
 IN Yen, Richard C. K., Yorba Linda, CA, United States
 PA Hemosphere, Inc., Anaheim, CA, United States (U.S. corporation)
 PI US 6391343 B1 20020521
 WO 9639128 19961212 <--
 AI US 1998-952765 19980410 (8)
 WO 1996-US9458 19960604
 19980410 PCT 371 date
 RLI Continuation-in-part of Ser. No. US 1995-554919, filed on 9 Nov 1995,
 now abandoned Continuation-in-part of Ser. No. US 1995-471650, filed on
 6 Jun 1995, now patented, Pat. No. US 5725804 Continuation-in-part of
 Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US
 5616311 Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun
 1993, now abandoned Continuation-in-part of Ser. No. US 1992-959560,
 filed on 13 Oct 1992, now patented, Pat. No. US 5308620
 Continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991,
 now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 2407
 INCL INCLM: 424/491.000
 INCLS: 424/078.060; 427/002.140; 514/002.000; 514/834.000; 514/937.000;
 514/951.000; 516/077.000
 NCL NCLM: 424/491.000
 NCLS: 424/078.060; 427/002.140; 514/002.000; 514/834.000; 514/937.000;
 514/951.000; 516/077.000
 IC [7]
 ICM: A61K009-16
 ICS: A61K038-36; A61K038-38
 EXF 264/4.3; 427/2.14; 427/2.21; 427/213.3; 427/213.33; 424/78.06; 424/491;
 424/493; 514/2; 514/834; 514/937; 514/951; 514/965; 516/77

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 70 OF 362 USPATFULL on STN
AN 2002:81275 USPATFULL
TI Bio-artificial organ containing a matrix having hollow fibers for
supplying gaseous oxygen
IN Flendrig, Leonardus Marcus, Amsterdam-Buitenveldert, NETHERLANDS
PA Seed Capital Investments-2 (SCI-2) B.V., Utrecht, NETHERLANDS (non-U.S.
corporation)
PI US 6372495 B1 20020416
WO 9712960 19970410 <--
AI US 1998-51273 19980602 (9)
WO 1996-NL389 19961004
19980602 PCT 371 date
DT Utility
FS GRANTED
LN.CNT 2278
INCL INCLM: 435/395.000
INCLS: 435/177.000; 435/325.000; 435/370.000; 435/289.100
NCL NCLM: 435/395.000
NCLS: 435/177.000; 435/289.100; 435/325.000; 435/370.000
IC [7]
ICM: C12N011-02
ICS: C12N005-00; C12N005-08; C12M001-00
EXF 435/395; 435/398; 435/399; 435/400; 435/289.1; 435/370; 435/177; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 71 OF 362 USPATFULL on STN
AN 2002:34330 USPATFULL
TI Tie receptor tyrosine kinase ligand homologues
IN Fong, Sherman, Alameda, CA, United States
Ferrara, Napoleone, San Francisco, CA, United States
Goddard, Audrey, San Francisco, CA, United States
Godowski, Paul J., Burlingame, CA, United States
Gurney, Austin L., Belmont, CA, United States
Hillan, Kenneth, San Francisco, CA, United States
Williams, P. Mickey, Half Moon Bay, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6348351 B1 20020219
WO 9915654 19990401 <--
AI US 1998-202089 19981208 (9)
WO 1998-US19094 19980914
19981208 PCT 371 date
RLI Continuation-in-part of Ser. No. US 1997-934494, filed on 19 Sep 1997,
now patented, Pat. No. US 6030831
DT Utility
FS GRANTED
LN.CNT 3551
INCL INCLM: 435/325.000
INCLS: 536/023.100; 536/023.500; 530/350.000; 435/069.100; 435/320.100;
435/252.300; 435/254.110
NCL NCLM: 435/325.000
NCLS: 435/069.100; 435/252.300; 435/254.110; 435/320.100; 530/350.000;
536/023.100; 536/023.500
IC [7]
ICM: C07K014-475
ICS: C12N005-10; C12N015-12
EXF 530/350; 530/300; 536/23.1; 536/23.5; 536/23.4; 435/69.1; 435/320.1;
435/252.3; 435/325; 435/254.11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 72 OF 362 USPATFULL on STN
AN 2001:221154 USPATFULL
TI SH2 domain-containing peptides
IN Stewart, Timothy A., San Francisco, CA, United States
Lu, Yanmei, Belmont, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6326482 B1 20011204
WO 9954467 19991028 <--
AI US 1999-367206 19990809 (9)
WO 1999-US8847 19990423
19990809 PCT 371 date
19990809 PCT 102(e) date
PRAI US 1998-82767P 19980423 (60)

US 1998-11329P 19981222 (60)
DT Utility
FS GRANTED
LN.CNT 4794
INCL INCLM: 536/023.500
NCL NCLM: 536/023.500
IC [7]
ICM: C12P021-06
ICS: C12N005-06; C12N005-10; C12N001-20
EXF 514/44; 536/23.1; 536/24.1; 536/23.5; 424/130.1; 435/325; 435/252.1;
435/254.2; 435/69.1; 435/320.1; 435/348; 435/358; 435/252.33; 530/350;
530/387.1; 530/388.1; 530/388.15; 530/388.2; 530/388.22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 73 OF 362 USPATFULL on STN
AN 2001:196989 USPATFULL
TI Pharmaceutical compositions containing TSG-6 for treating inflammatory
diseases and cancer-related pathologies and method
IN Wisniewski, Hans-Georg, New York, NY, United States
Vilcek, Jan, New York, NY, United States
Cronstein, Bruce, New York, NY, United States
PA New York University, New York, NY, United States (U.S. corporation)
PI US 6313091 B1 20011106
WO 9704075 19970206 <--
AI US 1998-179 19980520 (9)
WO 1996-US11995 19960719
19980505 PCT 371 date
19980505 PCT 102(e) date

DT Utility
FS GRANTED
LN.CNT 1764
INCL INCLM: 514/012.000
INCLS: 530/350.000; 530/351.000; 530/395.000; 514/002.000; 536/023.100;
435/069.100; 435/252.300; 435/320.100
NCL NCLM: 514/012.000
NCLS: 435/069.100; 435/252.300; 435/320.100; 514/002.000; 530/350.000;
530/351.000; 530/395.000; 536/023.100
IC [7]
ICM: A61K038-00
ICS: C07K014-00; C07H021-02; A01N037-18; C12P021-06
EXF 435/69.1; 435/252.3; 435/320.1; 536/23.1; 514/44; 514/2; 514/12;
530/350; 530/351; 530/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 74 OF 362 USPATFULL on STN
AN 2001:173134 USPATFULL
TI Human interferon-epsilon: a type I interferon
IN Chen, Jian, San Mateo, CA, United States
Godowski, Paul, Burlingame, CA, United States
Wood, William I., Hillsborough, CA, United States
Zhang, Dong-Xiao, Burlingame, CA, United States
PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)
PI US 6299869 B1 20011009
WO 9929863 19990617 <--
AI US 1999-202122 19990304 (9)
WO 1998-US25672 19981203
19990304 PCT 371 date
19990304 PCT 102(e) date
PRAI US 1998-106463P 19981030 (60)
US 1998-84045P 19980504 (60)
US 1997-67897P 19971208 (60)

DT Utility
FS GRANTED
LN.CNT 3713
INCL INCLM: 424/085.400
INCLS: 530/351.000; 530/350.000; 536/023.100; 536/023.520; 514/002.000;
514/012.000; 435/069.510; 435/023.500; 435/320.100; 435/325.000;
435/252.330; 435/259.200; 435/358.000; 435/069.100; 435/069.200
NCL NCLM: 424/085.400
NCLS: 435/069.100; 435/069.200; 435/069.510; 435/252.330; 435/320.100;
435/325.000; 435/358.000; 514/002.000; 514/012.000; 530/350.000;
530/351.000; 536/023.100; 536/023.520
IC [7]
ICM: A61K038-21
ICS: A61K038-00; C07K014-00; C07H021-04; C12P021-04
EXF 530/351; 530/350; 435/69.51; 435/23.5; 435/320.1; 435/323; 435/252.33;

435/259.2; 435/358; 435/69.1; 435/69.2; 424/85.7; 424/85.4; 536/23.1;
536/23.52; 514/2; 514/12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 75 OF 362 USPATFULL on STN
AN 2001:10929 USPATFULL
TI Use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl ester and its
derivatives in disease regression
IN Edmundson, Allen B., Edmond, OK, United States
Manion, Carl V., Oklahoma City, OK, United States
PA Oklahoma Medical Research Foundation, Oklahoma City, OK, United States
(U.S. corporation)
PI US 6177467 B1 20010123
WO 9813062 19980402 <--
AI US 1999-269420 19990326 (9)
WO 1997-US17357 19970926
19990326 PCT 371 date
19990326 PCT 102(e) date
PRAI US 1996-26720P 19960926 (60)
US 1997-44831P 19970425 (60)
DT Utility
FS Granted
LN.CNT 794
INCL INCLM: 514/538.000
INCLS: 514/531.000; 514/575.000; 514/534.000
NCL NCLM: 514/538.000
NCLS: 514/531.000; 514/534.000; 514/575.000
IC [7]
ICM: A61K031-24
ICS: A61K031-215; A61K031-19
EXF 514/534; 514/531; 514/575; 514/538
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 76 OF 362 USPATFULL on STN
AN 2001:1757 USPATFULL
TI Mer receptor activation by gas6
IN Chen, Jian, Burlingame, CA, United States
Hammonds, R. Glenn, Berkeley, CA, United States
Godowski, Paul J., Burlingame, CA, United States
Mark, Melanie R., Burlingame, CA, United States
Mather, Jennie P., Millbrae, CA, United States
Li, Ronghao, Millbrae, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6169070 B1 20010102
WO 9628548 19960919 <--
AI US 1996-628747 19960417 (8)
WO 1996-US3031 19960305
19960417 PCT 371 date
19960417 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-438861, filed on 10 May 1995,
now abandoned Continuation-in-part of Ser. No. US 1995-412253, filed on
28 Mar 1995, now patented, Pat. No. US 5580984
DT Utility
FS Granted
LN.CNT 2940
INCL INCLM: 514/002.000
INCLS: 424/085.100
NCL NCLM: 514/002.000
NCLS: 424/085.100
IC [7]
ICM: A61K038-18
ICS: A61K038-36
EXF 514/2; 530/350; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 77 OF 362 USPATFULL on STN
AN 2000:174129 USPATFULL
TI Preparation for the application of agents in mini-droplets
IN Cevc, Gregor, Heimstetten, Germany, Federal Republic of
PA Idea AG, Munich, Germany, Federal Republic of (non-U.S. corporation)
PI US 6165500 20001226 <--
AI US 1992-844664 19920408 (7)
PRAI DE 1990-4026834 19900824
DE 1990-4026833 19900824
DE 1991-4107153 19910306

WO 1991-EP1596 19910822
DT Utility
FS Granted
LN.CNT 4336
INCL INCLM: 424/450.000
INCLS: 428/402.200; 424/094.300
NCL NCLM: 424/450.000
NCLS: 424/094.300; 428/402.200
IC [7]
ICM: A61K009-127
EXF 424/450; 424/1.21; 424/9.321; 424/9.51; 424/417; 424/96.3; 428/402.2;
436/829; 935/54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 78 OF 362 USPATFULL on STN
AN 2000:167753 USPATFULL
TI Recombinant yeast cells for identifying receptor effectors
IN Trueheart, Joshua, Concord, MA, United States
Paul, Jeremy I., Nyack, NY, United States
Fuernkranz, Hans A., San Jose, CA, United States
Nathan, Debra, Mt. Kisco, NY, United States
Holmes, Scott, Middlebury, CT, United States
PA Cadus Pharmaceutical Corporation, New York, NY, United States (U.S.
corporation)
PI US 6159705 20001212 <--
AI US 1997-936632 19970924 (8)
RLI Continuation-in-part of Ser. No. US 1996-718910, filed on 24 Sep 1996,
now abandoned And a continuation-in-part of Ser. No. US 1997-851469,
filed on 5 May 1997, now abandoned
DT Utility
FS Granted
LN.CNT 5260
INCL INCLM: 435/029.000
INCLS: 435/254.110
NCL NCLM: 435/029.000
NCLS: 435/254.110
IC [7]
ICM: C12N001-19
ICS: C12Q001-02
EXF 435/6; 435/7.1; 435/7.2; 435/69.1; 435/69.7; 435/29; 435/254.11;
436/501; 576/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 79 OF 362 USPATFULL on STN
AN 2000:167510 USPATFULL
TI Uses of wnt polypeptides
IN Matthews, William, Woodside, CA, United States
Austin, Timothy W., Morgan Hill, CA, United States
PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)
PI US 6159462 20001212 <--
AI US 1997-911860 19970815 (8)
PRAI US 1996-24068P 19960816 (60)
DT Utility
FS Granted
LN.CNT 3907
INCL INCLM: 424/085.100
INCLS: 424/085.200; 435/383.000; 435/395.000; 435/404.000; 435/405.000;
435/406.000; 514/002.000; 514/814.000; 530/350.000; 530/351.000;
530/868.000
NCL NCLM: 424/085.100
NCLS: 424/085.200; 435/383.000; 435/395.000; 435/404.000; 435/405.000;
435/406.000; 514/002.000; 514/814.000; 530/350.000; 530/351.000;
530/868.000
IC [7]
ICM: A61K045-05
ICS: C12N005-02; A01N037-18; C07K001-00
EXF 530/350; 530/351; 530/868; 514/2; 514/814; 424/85.1; 424/85.2; 435/383;
435/395; 435/404; 435/405; 435/406
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 80 OF 362 USPATFULL on STN
AN 2000:164064 USPATFULL
TI Gene transfer for studying and treating a connective tissue of a
mammalian host
IN Glorioso, Joseph C., Cheswick, PA, United States
Evans, Christopher H., Pittsburgh, PA, United States

PA Robbins, Paul D., Pittsburgh, PA, United States
University of Pittsburgh of the Commonwealth System of Higher Education,
Pittsburgh, PA, United States (U.S. corporation)
PI US 6156304 20001205 <--
AI US 1997-924777 19970905 (8)
RLI Continuation-in-part of Ser. No. US 1995-381603, filed on 27 Jan 1995,
now patented, Pat. No. US 5858355 And a continuation-in-part of Ser. No.
US 1996-685212, filed on 23 Jul 1996 which is a continuation of Ser. No.
US 1993-27750, filed on 8 Mar 1993, now abandoned And a
continuation-in-part of Ser. No. US 1995-567710, filed on 5 Dec 1995,
now abandoned which is a continuation of Ser. No. US 1994-183563, filed
on 18 Jan 1994, now abandoned which is a continuation of Ser. No. US
1992-963928, filed on 20 Oct 1992, now abandoned which is a continuation
of Ser. No. US 1990-630981, filed on 20 Dec 1990, now abandoned
DT Utility
FS Granted
LN.CNT 3218
INCL INCLM: 424/093.200
NCL NCLM: 424/093.200
IC [7]
ICM: A01N063-00
EXF 435/320.1; 435/325; 514/44; 424/450; 424/93.2; 935/52; 935/55; 935/56;
935/57
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 81 OF 362 USPATFULL on STN
AN 2000:161028 USPATFULL
TI Compositions and methods for treating bone deficit conditions
IN Petrie, Charles, Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
Baindur, Nand, Edmonds, WA, United States
Robbins, Kirk G., Renton, WA, United States
Mundy, Gregory R., San Antonio, TX, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6153631 20001128 <--
AI US 1997-806768 19970226 (8)
RLI Continuation of Ser. No. US 1996-736221, filed on 23 Oct 1996, now
abandoned
DT Utility
FS Granted
LN.CNT 997
INCL INCLM: 514/367.000
NCL NCLM: 514/367.000
IC [7]
ICM: A61K031-425
EXF 514/367
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 82 OF 362 USPATFULL on STN
AN 2000:160980 USPATFULL
TI OP-3 induced morphogenesis
IN Oppermann, Hermann, Medway, MA, United States
Ozkaynak, Engin, Milford, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
Rueger, David C., Hopkinton, MA, United States
Pang, Roy H. L., Etna, NH, United States
Cohen, Charles M., Medway, MA, United States
PA Stryker Corporation, Hopkinton, MA, United States (U.S. corporation)
PI US 6153583 20001128 <--
AI US 1998-219391 19981223 (9)
RLI Division of Ser. No. US 1997-901200, filed on 28 Jul 1997, now patented,
Pat. No. US 5854071 which is a division of Ser. No. US 1995-479666,
filed on 7 Jun 1995, now patented, Pat. No. US 5652337 which is a
division of Ser. No. US 1992-971009, filed on 3 Nov 1992, now abandoned
which is a continuation-in-part of Ser. No. US 1992-922813, filed on 31
Jul 1992, now abandoned Ser. No. Ser. No. US 1992-923780, filed on 31
Jul 1992, now abandoned Ser. No. Ser. No. US 1992-938336, filed on 28
Aug 1992, now abandoned Ser. No. Ser. No. US 1992-938337, filed on 28
Aug 1992, now abandoned Ser. No. Ser. No. US 1992-938021, filed on 28
Aug 1992, now abandoned Ser. No. Ser. No. US 1992-945285, filed on 15
Sep 1992, now abandoned Ser. No. Ser. No. US 1992-945286, filed on 15
Sep 1992, now abandoned Ser. No. Ser. No. US 1992-946235, filed on 16
Sep 1992, now abandoned And Ser. No. US 1992-946238, filed on 16 Sep
1992, now abandoned, said Ser. No. US 922813 which is a
continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991,
now abandoned And Ser. No. US 1991-752857, filed on 30 Aug 1991, now

abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned, said Ser. No. US 938336, said Ser. No. US 938337 which is a continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 667274, said Ser. No. US 938021 which is a continuation-in-part of Ser. No. US 1991-752861, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 667274, said Ser. No. US 945285, said Ser. No. US 945286 which is a continuation-in-part of Ser. No. US 752764 which is a continuation-in-part of Ser. No. US 667274, said Ser. No. US 946235, said Ser. No. US 946238 which is a continuation-in-part of Ser. No. US 752764 which is a continuation-in-part of Ser. No. US 667274

DT Utility
FS Granted
LN.CNT 3363
INCL INCLM: 514/012.000
INCLS: 530/324.000; 530/350.000; 530/399.000
NCL NCLM: 514/012.000
NCLS: 530/324.000; 530/350.000; 530/399.000
IC [7]
ICM: A61K038-18
ICS: C07K014-51
EXF 514/2; 514/12; 530/300; 530/324; 530/350; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 83 OF 362 USPATFULL on STN
AN 2000:160777 USPATFULL
TI Methods for screening for transdominant intracellular effector peptides and RNA molecules
IN Nolan, Garry P., Palo Alto, CA, United States
Rothenberg, S. Michael, Palo Alto, CA, United States
PA Rigel Pharmaceuticals, Inc., Sunnyvale, CA, United States (U.S. corporation)
The Board of Trustees for the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
PI US 6153380 20001128 <--
AI US 1997-789333 19970123 (8)
RLI Continuation of Ser. No. US 1996-589108, filed on 23 Jan 1996, now abandoned And a continuation of Ser. No. US 1996-589911, filed on 23 Jan 1996, now abandoned
DT Utility
FS Granted
LN.CNT 4104
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/070.100; 435/091.100; 435/325.000; 536/023.100; 536/024.300; 536/024.310; 536/024.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/070.100; 435/091.100; 435/325.000; 536/023.100; 536/024.300; 536/024.310; 536/024.500
IC [7]
ICM: C12Q001-68
ICS: C12P019-34; C12N005-00; C07H021-04
EXF 435/6; 435/70.1; 435/325; 435/69.1; 435/91.1; 536/23.1; 536/24.3; 536/24.31; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 84 OF 362 USPATFULL on STN
AN 2000:156962 USPATFULL
TI Treatments using sertoli cells
IN Selawry, Helena P., Rileyville, VA, United States
PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)
PI US 6149907 20001121 <--
AI US 1999-298015 19990423 (9)
RLI Division of Ser. No. US 1996-660258, filed on 7 Jun 1996, now patented, Pat. No. US 5958404 And a continuation-in-part of Ser. No. US 1995-485340, filed on 7 Jun 1995, now patented, Pat. No. US 5849285 And a continuation-in-part of Ser. No. US 1995-421641, filed on 13 Apr 1995, now patented, Pat. No. US 5725854 And a continuation-in-part of Ser. No. US 1994-211695, filed on 13 Apr 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2007
INCL INCLM: 424/093.700
INCLS: 435/325.000; 435/326.000; 435/347.000; 435/366.000; 435/363.000; 435/373.000; 435/374.000

NCL NCLM: 424/093.700
NCLS: 435/325.000; 435/326.000; 435/347.000; 435/363.000; 435/366.000;
435/373.000; 435/374.000
IC [7]
ICM: A01N063-00
ICS: A01N065-00; C12N005-00; C12N005-02; C12N005-06
EXF 435/326; 435/347; 435/366; 435/363; 435/373; 435/374; 435/325; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 85 OF 362 USPATFULL on STN
AN 2000:146174 USPATFULL
TI Preparation of calcium phosphate transfectacons
IN Cohen, Darien L., Oakland, CA, United States
Kahn, David W., Foster City, CA, United States
Winkler, Marjorie E., Burlingame, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6140128 20001031 <--
AI US 1999-467723 19991220 (9)
PRAI US 1998-113614P 19981223 (60)
DT Utility
FS Granted
LN.CNT 1792
INCL INCLM: 435/455.000
INCLS: 435/320.100; 536/023.100
NCL NCLM: 435/455.000
NCLS: 435/320.100; 536/023.100
IC [7]
ICM: C12N015-64
EXF 435/320.1; 435/455; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 86 OF 362 USPATFULL on STN
AN 2000:138097 USPATFULL
TI Phosphodiesterase 8A
IN Loughney, Kate, Seattle, WA, United States
PA ICOS Corporation, Bothell, WA, United States (U.S. corporation)
PI US 6133007 20001017 <--
AI US 1998-174437 19981016 (9)
RLI Continuation-in-part of Ser. No. US 1997-951648, filed on 16 Oct 1997,
now patented, Pat. No. US 5932465
DT Utility
FS Granted
LN.CNT 2559
INCL INCLM: 435/196.000
INCLS: 435/183.000; 435/196.000
NCL NCLM: 435/196.000
NCLS: 435/183.000
IC [7]
ICM: C12N009-16
EXF 435/196; 435/199; 435/325; 435/252.3; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 87 OF 362 USPATFULL on STN
AN 2000:138079 USPATFULL
TI Methods and compositions for enhanced stability of non-adenoviral DNA
IN Kay, Mark A., Seattle, WA, United States
Lieber, Andre, Seattle, WA, United States
PA University of Washington, Seattle, WA, United States (U.S. corporation)
PI US 6132989 20001017 <--
AI US 1997-972657 19971118 (8)
RLI Continuation-in-part of Ser. No. US 1997-867012, filed on 2 Jun 1997,
now abandoned
PRAI US 1996-18928P 19960603 (60)
DT Utility
FS Granted
LN.CNT 1601
INCL INCLM: 435/069.100
INCLS: 435/448.000; 435/455.000; 435/456.000; 435/320.100
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/448.000; 435/455.000; 435/456.000
IC [7]
ICM: C12N015-00
EXF 435/172.3; 435/69.1; 435/320.1; 435/370; 435/458; 435/235.1; 514/44;
536/23.1; 536/23.72; 536/29.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 88 OF 362 USPATFULL on STN
AN 2000:131998 USPATFULL
TI Protein purification by Protein A chromatography
IN Blank, Gregory S., Menlo Park, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6127526 20001003 <--
AI US 1997-995048 19971120 (8)
PRAI US 1996-31500P 19961127 (60)
DT Utility
FS Granted
LN.CNT 1009
INCL INCLM: 530/413.000
NCL NCLM: 530/413.000
IC [7]
ICM: C07K001-22
EXF 530/413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 89 OF 362 USPATFULL on STN
AN 2000:128467 USPATFULL
TI Carbohydrate-directed cross-linking reagents
IN Ashkenazi, Avi J., San Mateo, CA, United States
Chamow, Steven M., San Mateo, CA, United States
Kogan, Timothy P., Sugar Land, TX, United States
PA Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6124435 20000926 <--
AI US 1998-218408 19981222 (9)
RLI Continuation of Ser. No. US 1997-923590, filed on 4 Sep 1997, now patented, Pat. No. US 5929211 which is a continuation of Ser. No. US 1995-415018, filed on 31 Mar 1995, now patented, Pat. No. US 5889155 which is a continuation of Ser. No. US 1993-115404, filed on 1 Sep 1993, now abandoned which is a division of Ser. No. US 1992-926077, filed on 5 Aug 1992, now patented, Pat. No. US 5329028, issued on 12 Jul 1994
DT Utility
FS Granted
LN.CNT 1097
INCL INCLM: 530/351.000
INCLS: 530/352.000; 530/359.000; 530/380.000; 530/387.100; 530/389.100; 530/389.200; 530/391.100; 530/391.300; 530/391.500; 530/391.700; 530/391.900; 548/544.000; 548/546.000; 548/547.000; 548/548.000; 548/549.000; 424/085.100; 424/178.100; 424/179.100; 424/194.100; 424/195.110
NCL NCLM: 530/351.000
NCLS: 424/085.100; 424/178.100; 424/179.100; 424/194.100; 424/195.110; 530/352.000; 530/359.000; 530/380.000; 530/387.100; 530/389.100; 530/389.200; 530/391.100; 530/391.300; 530/391.500; 530/391.700; 530/391.900; 548/544.000; 548/546.000; 548/547.000; 548/548.000; 548/549.000
IC [7]
ICM: C07K015-14
ICS: C07D207-452
EXF 530/351; 530/352; 530/359; 530/380; 530/387.1; 530/389.1; 530/389.2; 530/391.1; 530/391.3; 530/391.5; 530/391.7; 530/391.9; 548/544; 548/546; 548/547; 548/548; 548/549; 424/85.1; 424/178.1; 424/179.1; 424/194.1; 424/195.11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 90 OF 362 USPATFULL on STN
AN 2000:128331 USPATFULL
TI Calcitonin mimetics
IN Baindur, Nand, Edmonds, WA, United States
Labroo, Virender, Bangalore, India
Stroop, Steven, Seattle, WA, United States
Beigel, Stephanie, Seattle, WA, United States
Martinez, Theresa, Greenbank, WA, United States
Petrie, Charles R., Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
McKernan, Patricia A., Woodinville, WA, United States
Moore, Emma E., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6124299 20000926 <--
AI US 1998-28085 19980223 (9)
PRAI US 1997-38971P 19970224 (60)

US 1997-67037P 19971201 (60)
DT Utility
FS Granted
LN.CNT 1332
INCL INCLM: 514/255.060
INCLS: 514/250.000; 514/396.000; 514/211.080; 514/218.000
NCL NCLM: 514/255.060
NCLS: 514/211.080; 514/218.000; 514/250.000; 514/396.000
IC [7]
ICM: A61K031-495
ICS: A61K031-55; A61K031-415
EXF 514/255.06; 514/250; 514/227.8; 514/235.8; 514/252; 514/357; 514/360;
514/396; 514/211.08; 514/218
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 91 OF 362 USPATFULL on STN
AN 2000:125204 USPATFULL
TI Protein recovery
IN Blank, Gregory S., Menlo Park, CA, United States
Narindray, Daljit S., Pleasanton, CA, United States
Zapata, Gerardo A., Foster City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6121428 20000919 <--
AI US 1998-97309 19980612 (9)
PRAI US 1997-50951P 19970613 (60)
DT Utility
FS Granted
LN.CNT 1682
INCL INCLM: 530/413.000
INCLS: 435/269.000; 435/272.000; 530/344.000; 530/412.000; 530/414.000;
530/417.000
NCL NCLM: 530/413.000
NCLS: 435/269.000; 435/272.000; 530/344.000; 530/412.000; 530/414.000;
530/417.000
IC [7]
ICM: C07K001-22
ICS: C07K001-34
EXF 435/68.1; 435/803; 435/269; 435/272; 530/387.1; 530/413; 530/412;
530/344; 530/390.5; 530/414; 530/417; 436/518; 436/824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 92 OF 362 USPATFULL on STN
AN 2000:124800 USPATFULL
TI Altered polypeptides with increased half-life
IN Presta, Leonard G., San Francisco, CA, United States
Snedecor, Bradley R., Portola Valley, CA, United States
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 6121022 20000919 <--
AI US 1995-422112 19950414 (8)
DT Utility
FS Granted
LN.CNT 3411
INCL INCLM: 435/069.700
INCLS: 435/069.600; 435/320.100; 435/328.000; 435/334.000; 530/350.000;
530/387.300; 530/388.220; 536/023.400; 536/023.530
NCL NCLM: 435/069.700
NCLS: 435/069.600; 435/320.100; 435/328.000; 435/334.000; 530/350.000;
530/387.300; 530/388.220; 536/023.400; 536/023.530
IC [7]
ICM: C07K016-00
ICS: C12N015-13; C12N015-62
EXF 536/23.53; 536/23.4; 530/389.1; 530/387.3; 530/388.22; 530/350;
435/69.7; 435/240.1; 435/240.27; 435/320.1; 435/328; 435/334;
435/240.18; 435/69.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 93 OF 362 USPATFULL on STN
AN 2000:124531 USPATFULL
TI Charged lipids and uses for the same
IN Unger, Evan C., Tucson, AZ, United States
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6120751 20000919 <--
AI US 1997-925353 19970908 (8)
RLI Continuation-in-part of Ser. No. US 1997-823791, filed on 21 Mar 1997
And a continuation-in-part of Ser. No. US 1997-851780, filed on 6 May

1997 And a continuation-in-part of Ser. No. US 1997-877826, filed on 18 Jun 1997 And a continuation-in-part of Ser. No. US 1997-887215, filed on 2 Jul 1997

DT Utility
FS Granted
LN.CNT 6059
INCL INCLM: 424/009.510
INCLS: 424/009.520; 424/450.000; 424/502.000; 264/004.100; 264/004.000;
428/402.200
NCL NCLM: 424/009.510
NCLS: 264/004.000; 264/004.100; 424/009.520; 424/450.000; 424/502.000;
428/402.200
IC [7]
ICM: A61K049-04
ICS: A61K009-50; A61K009-127; B01J013-02
EXF 424/450; 424/9.52; 424/9.51; 424/489; 424/498; 424/502; 424/1.21;
424/9.321; 424/812; 514/937; 264/4; 264/4.1; 264/4.32; 264/4.33;
427/2.14; 427/213.3; 427/213.31; 428/402; 428/402.24; 428/402.2; 436/829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 94 OF 362 USPATFULL on STN
AN 2000:113772 USPATFULL
TI Diminishing viral gene expression by promoter replacement
IN Fang, Bingliang, Houston, TX, United States
Roth, Jack A., Houston, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6110744 20000829 <--
AI US 1997-968014 19971112 (8)
PRAI US 1996-30675P 19961113 (60)
DT Utility
FS Granted
LN.CNT 3104
INCL INCLM: 435/456.000
INCLS: 435/320.100; 536/023.100; 536/023.500; 536/023.700; 536/023.720;
536/024.100
NCL NCLM: 435/456.000
NCLS: 435/320.100; 536/023.100; 536/023.500; 536/023.700; 536/023.720;
536/024.100
IC [7]
ICM: C12N015-64
ICS: C12N015-34; C12N015-12
EXF 435/69.1; 435/325; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 95 OF 362 USPATFULL on STN
AN 2000:105892 USPATFULL
TI Therapeutically effective 1.alpha.,25-dihydroxyvitamin D.sub.3 analogs and methods for treatment of vitamin D diseases
IN Norman, Anthony W., Riverside, CA, United States
Okamura, William H., Riverside, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6103709 20000815 <--
AI US 1998-73723 19980507 (9)
RLI Continuation-in-part of Ser. No. US 1995-558717, filed on 16 Nov 1995, now abandoned which is a continuation-in-part of Ser. No. US 1996-706356, filed on 30 Aug 1996, now abandoned which is a continuation-in-part of Ser. No. US 1994-249385, filed on 25 May 1994, now abandoned which is a continuation of Ser. No. US 1993-173561, filed on 23 Dec 1993, now abandoned
PRAI US 1997-60173P 19970926 (60)
DT Utility
FS Granted
LN.CNT 2580
INCL INCLM: 514/167.000
INCLS: 552/653.000
NCL NCLM: 514/167.000
NCLS: 552/653.000
IC [7]
ICM: C07C401-00
ICS: A61K031-59
EXF 514/167; 552/653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 96 OF 362 USPATFULL on STN

AN 2000:105418 USPATFULL
TI Cellular and serum protein anchors and conjugates
IN Pouletty, Philippe, Atherton, CA, United States
Pouletty, Christine, Atherton, CA, United States
PA Conjuchem, Inc., Montreal, Canada (non-U.S. corporation)
PI US 6103233 20000815 <--
AI US 1995-477900 19950607 (8)
RLI Continuation of Ser. No. US 1994-237346, filed on 3 May 1994, now
patented, Pat. No. US 5612034 which is a continuation-in-part of Ser.
No. US 1993-137821, filed on 15 Oct 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1993-70092, filed on 27 May 1993,
now abandoned which is a continuation-in-part of Ser. No. US
1990-592214, filed on 3 Oct 1990, now abandoned
DT Utility
FS Granted
LN.CNT 677
INCL INCLM: 424/133.100
INCLS: 424/136.100; 424/153.100; 424/173.100; 424/175.100; 530/387.300;
530/388.700; 530/388.850; 530/388.900; 530/389.600; 530/389.100;
530/389.800
NCL NCLM: 424/133.100
NCLS: 424/136.100; 424/153.100; 424/173.100; 424/175.100; 530/387.300;
530/388.700; 530/388.850; 530/388.900; 530/389.100; 530/389.600;
530/389.800
IC [7]
ICM: A61K039-395
ICS: C07K016-18; C07K016-28; C07K016-44
EXF 530/387.1; 530/402; 530/387.3; 530/388.7; 530/388.85; 530/388.9;
530/389.6; 530/389.1; 530/389.8; 424/133.1; 424/136.1; 424/153.1;
424/173.1; 424/175.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 97 OF 362 USPATFULL on STN
AN 2000:98553 USPATFULL
TI Polypeptides altered to contain an epitope from the ***Fc*** region
of an IgG molecule for increased half-life
IN Presta, Leonard G., San Francisco, CA, United States
Snedecor, Bradley R., Portola Valley, CA, United States
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 6096871 20000801 <--
AI US 1995-422093 19950414 (8)
DT Utility
FS Granted
LN.CNT 3391
INCL INCLM: 530/387.300
INCLS: 530/388.230; 424/133.100; 424/145.100; 435/069.600; 435/069.700;
435/328.000
NCL NCLM: 530/387.300
NCLS: 424/133.100; 424/145.100; 435/069.600; 435/069.700; 435/328.000;
530/388.230
IC [7]
ICM: A61K039-395
ICS: C07K016-00
EXF 424/130.1; 424/133.1; 424/135.1; 424/144.1; 424/173.1; 424/145.1;
435/69.7; 435/172.1; 435/69.6; 435/328; 530/387.3; 530/391.1;
530/388.23; 935/15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 98 OF 362 USPATFULL on STN
AN 2000:98221 USPATFULL
TI In vitro cell culture in media containing beta-alanyl-taurine or
carbobenzoxy beta-alanyl-taurine
IN Knight, Galen D., Albuquerque, NM, United States
Scallen, Terence J., Albuquerque, NM, United States
PA University of New Mexico, Albuquerque, NM, United States (U.S.
corporation)
PI US 6096536 20000801 <--
AI US 1995-463732 19950605 (8)
RLI Division of Ser. No. US 1994-321010, filed on 6 Oct 1994 which is a
division of Ser. No. US 1992-941926, filed on 8 Sep 1992 which is a
continuation-in-part of Ser. No. US 1990-549438, filed on 6 Jul 1990,
now abandoned
DT Utility
FS Granted
LN.CNT 1843
INCL INCLM: 435/325.000

INCLS: 435/384.000; 435/404.000; 435/405.000; 435/410.000; 435/420.000;
435/430.100; 435/245.000
NCL NCLM: 435/325.000
NCLS: 435/245.000; 435/384.000; 435/404.000; 435/405.000; 435/410.000;
435/420.000; 435/430.100
IC [7]
ICM: C12N005-00
ICS: C12N005-02; C12N005-04; C12N005-06
EXF 435/41; 435/240.2; 435/240.45; 435/244; 435/245; 435/325; 435/384;
435/404; 435/405; 435/410; 435/420; 435/430.1; 514/563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 99 OF 362 USPATFULL on STN
AN 2000:95105 USPATFULL
TI DNA encoding proteins of Kaposi's sarcoma associated herpesvirus
IN Cesarman, Ethel, Hoboken, NJ, United States
Knowles, Daniel M., Forest Hills, NY, United States
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S.
corporation)
PI US 6093806 20000725 <--
AI US 1996-728603 19961010 (8)
DT Utility
FS Granted
LN.CNT 1681
INCL INCLM: 536/023.100
NCL NCLM: 536/023.100
IC [7]
ICM: C07H021-04
EXF 536/23.1; 536/24.5; 514/44; 435/240.2; 435/252.3; 435/320.1; 435/325;
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 100 OF 362 USPATFULL on STN
AN 2000:94846 USPATFULL
TI Morphogen cell surface receptor and screening for morphogen analogs
IN Jin, Donald F., Shrewsbury, MA, United States
Oppermann, Hermann, Medway, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
Smart, John E., Weston, MA, United States
PA Creative Biomolecules, Inc., Boston, MA, United States (U.S.
corporation)
PI US 6093547 20000725 <--
AI US 1995-459951 19950602 (8)
RLI Division of Ser. No. US 1994-357533, filed on 16 Dec 1994, now patented,
Pat. No. US 5831050 which is a continuation of Ser. No. US 1993-73199,
filed on 7 Jun 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2330
INCL INCLM: 435/007.100
INCLS: 435/007.200; 435/810.000; 435/975.000
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/810.000; 435/975.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567
EXF 435/810; 435/975; 435/7.1; 435/7.2; 435/7.21; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 101 OF 362 USPATFULL on STN
AN 2000:94835 USPATFULL
TI Wood's anomaly assay technique and kit
IN Drake, Rosemary Ann Lucy, Royston, United Kingdom
Sawyer, Craig George, St. Neots, United Kingdom
Robinson, Grenville Arthur, London, United Kingdom
PA Ares-Serono Research & Development Limited Partnership, Boston, MA,
United States (U.S. corporation)
PI US 6093536 20000725 <--
AI US 1988-146246 19880120 (7)
PRAI GB 1987-1293 19870121
GB 1987-25797 19871104
DT Utility
FS Granted
LN.CNT 700
INCL INCLM: 435/006.000
INCLS: 356/354.000; 435/007.100; 435/007.200; 435/007.920; 435/007.940;

436/501.000; 436/518.000; 436/524.000; 436/532.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/007.200; 435/007.920; 435/007.940; 436/501.000;
436/518.000; 436/524.000; 436/532.000
IC [7]
ICM: C12Q001-68
EXF 356/128; 356/354; 436/518; 436/501; 436/524; 436/535; 436/532; 436/805;
436/808; 435/7; 435/287; 435/810; 435/7.1; 435/7.2; 435/7.6; 435/7.9;
435/7.92; 435/7.93; 435/7.94; 435/7.95; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 102 OF 362 USPATFULL on STN
AN 2000:84031 USPATFULL
TI Methods and compositions for identifying osteogenic agents
IN Harris, Stephen E., San Antonio, TX, United States
Mundy, Gregory R., San Antonio, TX, United States
Ghosh-Choudhury, Nandini, San Antonio, TX, United States
Feng, Jian Q., San Antonio, TX, United States
PA Osteoscreen, Inc., San Antonio, TX, United States (U.S. corporation)
PI US 6083690 20000704 <--
AI US 1995-458434 19950602 (8)
DT Utility
FS Granted
LN.CNT 1925
INCL INCLM: 435/006.000
INCLS: 435/004.000; 435/029.000; 435/320.100; 435/325.000; 435/375.000;
435/455.000; 536/023.100; 536/024.100
NCL NCLM: 435/006.000
NCLS: 435/004.000; 435/029.000; 435/320.100; 435/325.000; 435/375.000;
435/455.000; 536/023.100; 536/024.100
IC [7]
ICM: C12Q001-68
ICS: C12Q001-02; C07H021-04; C12N015-85
EXF 435/4; 435/6; 435/29; 435/172.3; 435/320.1; 435/325; 435/375; 435/440;
435/455; 536/23.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 103 OF 362 USPATFULL on STN
AN 2000:80787 USPATFULL
TI Compositions and methods for stimulating bone growth
IN Gasper, Shirley R., Seattle, WA, United States
West, Robert R., Seattle, WA, United States
Martinez, Theresa, Greenbank, WA, United States
Robbins, Kirk G., Renton, WA, United States
McKernan, Patricia A., Woodinville, WA, United States
Baindur, Nand, Edmonds, WA, United States
Labroo, Virender M., Bangalore, India
Mundy, Gregory R., San Antonio, TX, United States
PA OsteoScreen, Inc., San Antonio, TX, United States (U.S. corporation)
ZymoGenetics Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6080779 20000627 <--
AI US 1998-96957 19980612 (9)
RLI Continuation-in-part of Ser. No. US 1997-989862, filed on 12 Dec 1997
PRAI US 1996-32893P 19961213 (60)
DT Utility
FS Granted
LN.CNT 1473
INCL INCLM: 514/451.000
INCLS: 514/141.000; 514/185.000; 514/700.000
NCL NCLM: 514/451.000
NCLS: 514/141.000; 514/185.000; 514/700.000
IC [7]
ICM: A61K031-335
ICS: A61K031-33; A61K031-66
EXF 514/451; 514/185; 514/141; 514/700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 104 OF 362 USPATFULL on STN
AN 2000:80566 USPATFULL
TI Polynucleotide encoding human growth regulator protein
IN Bandman, Olga, Mountain View, CA, United States
Lal, Preeti, Sunnyvale, CA, United States
Shah, Purvi, Sunnyvale, CA, United States
Corley, Neil C., Mountain View, CA, United States
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

PI US 6080558 20000627 <--
AI US 1997-893852 19970711 (8)
DT Utility
FS Granted
LN.CNT 2303
INCL INCLM: 435/069.100
INCLS: 536/023.500; 435/252.300; 435/254.110; 435/320.100; 435/325.000
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C12N015-12
EXF 536/23.5; 536/24.31; 435/69.1; 435/325; 435/252.3; 435/254.11; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 105 OF 362 USPATFULL on STN
AN 2000:80414 USPATFULL
TI Hematopoietic cytokine receptor
IN Baumgartner, James W., Seattle, WA, United States
Foster, Donald C., Seattle, WA, United States
Grant, Frank J., Seattle, WA, United States
Sprecher, Cindy A., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6080406 20000627 <--
AI US 1999-275925 19990324 (9)
RLI Continuation of Ser. No. US 1998-73594, filed on 6 May 1998, now
patented, Pat. No. US 5925735 which is a division of Ser. No. US
1996-653740, filed on 23 May 1996, now patented, Pat. No. US 5792850
DT Utility
FS Granted
LN.CNT 2380
INCL INCLM: 424/143.100
INCLS: 424/139.100; 530/387.900; 530/388.220
NCL NCLM: 424/143.100
NCLS: 424/139.100; 530/387.900; 530/388.220
IC [7]
ICM: A61K039-395
EXF 424/143.1; 424/139.1; 530/388.22; 530/387.9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 106 OF 362 USPATFULL on STN
AN 2000:77350 USPATFULL
TI Delivery of compacted nucleic acid to cells
IN Hanson, Richard W., Cleveland Heights, OH, United States
Perales, Jose C., Cleveland Heights, OH, United States
Ferkol, Jr., Thomas W., Euclid, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S.
corporation)
Ohio University, Athens, OH, United States (U.S. corporation)
PI US 6077835 20000620 <--
AI US 1998-114475 19980713 (9)
RLI Division of Ser. No. US 1996-721094, filed on 27 Sep 1996, now patented,
Pat. No. US 5844107 which is a continuation-in-part of Ser. No. US
716415
DT Utility
FS Granted
LN.CNT 3800
INCL INCLM: 514/044.000
INCLS: 435/456.000; 435/458.000
NCL NCLM: 514/044.000
NCLS: 435/456.000; 435/458.000
IC [7]
ICM: A61K031-70
EXF 514/44; 435/122.3; 435/456; 435/458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 107 OF 362 USPATFULL on STN
AN 2000:74139 USPATFULL
TI Nucleic acids encoding NL-3
IN Fong, Sherman, Alameda, CA, United States
Ferrara, Napoleone, San Francisco, CA, United States
Goddard, Audrey, San Francisco, CA, United States
Godowski, Paul J., Burlingame, CA, United States
Gurney, Austin L., Belmont, CA, United States
Hillan, Kenneth, San Francisco, CA, United States
Williams, P. Mickey, Half Moon Bay, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.

corporation)
PI US 6074873 20000613 <--
AI US 1998-143068 19980828 (9)
RLI Continuation-in-part of Ser. No. US 1997-934494, filed on 19 Sep 1997
DT Utility
FS Granted
LN.CNT 3487
INCL INCLM: 435/325.000
INCLS: 536/023.100; 536/023.500; 435/069.100; 435/320.100; 435/252.300;
435/254.110; 530/350.000
NCL NCLM: 435/325.000
NCLS: 435/069.100; 435/252.300; 435/254.110; 435/320.100; 530/350.000;
536/023.100; 536/023.500
IC [7]
ICM: C12N015-12
ICS: C12N015-11; C12N005-10
EXF 536/23.1; 536/23.5; 435/69.1; 435/320.1; 435/325; 435/252.3; 435/254.11;
530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 108 OF 362 USPATFULL on STN
AN 2000:70638 USPATFULL
TI Morphogenic protein compositions of matter
IN Jones, William K., Brookline, MA, United States
Tucker, Ronald F., Holliston, MA, United States
Rueger, David C., Hopkinton, MA, United States
Oppermann, Hermann, Medway, MA, United States
Ozkaynak, Engin, Milford, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
PA Stryker Biotech, Natick, MA, United States (U.S. corporation)
PI US 6071708 20000606 <--
AI US 1997-889419 19970708 (8)
RLI Continuation of Ser. No. US 1995-459346, filed on 2 Jun 1995, now
patented, Pat. No. US 5834179 which is a division of Ser. No. US
1995-402542, filed on 13 Mar 1995 which is a continuation of Ser. No. US
1993-40510, filed on 31 Mar 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1993-29335, filed on 4 Mar 1993, now
abandoned And a continuation-in-part of Ser. No. US 1994-27070, filed on
4 Mar 1994, now abandoned And a continuation-in-part of Ser. No. US
1992-971091, filed on 3 Nov 1992, now abandoned And a
continuation-in-part of Ser. No. US 1992-946235, filed on 16 Sep 1992,
now abandoned And a continuation-in-part of Ser. No. US 1992-938336,
filed on 28 Aug 1992, now abandoned And a continuation-in-part of Ser.
No. US 1992-923780, filed on 31 Jul 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991,
now abandoned And a continuation-in-part of Ser. No. US 1991-752764,
filed on 30 Aug 1991, now abandoned which is a continuation-in-part of
Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned
DT Utility
FS Granted
LN.CNT 2654
INCL INCLM: 435/007.100
INCLS: 435/536.000
NCL NCLM: 435/007.100
NCLS: 436/536.000
IC [7]
ICM: G01N033-53
EXF 435/7.1; 436/536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 109 OF 362 USPATFULL on STN
AN 2000:53880 USPATFULL
TI Photocleavable agents and conjugates for the detection and isolation of
biomolecules
IN Rothschild, Kenneth J., Newton, MA, United States
Sonar, Sanjay M., Boston, MA, United States
Olejnik, Jerzy, Allston, MA, United States
PA The Trustees of Boston University, Boston, MA, United States (U.S.
corporation)
PI US 6057096 20000502 <--
AI US 1995-479389 19950607 (8)
RLI Continuation of Ser. No. US 1995-479389, filed on 7 Jun 1995 which is a
continuation of Ser. No. US 1994-345807, filed on 22 Nov 1994 which is a
continuation-in-part of Ser. No. US 1994-240511, filed on 11 May 1994,
now patented, Pat. No. US 5643722
DT Utility

FS Granted
LN.CNT 4007
INCL INCLM: 435/006.000
INCLS: 435/091.100; 435/091.200; 536/022.100; 536/024.300; 536/024.330;
536/025.320
NCL NCLM: 435/006.000
NCLS: 435/091.100; 435/091.200; 536/022.100; 536/024.300; 536/024.330;
536/025.320
IC [7]
ICM: C12Q001-68
ICS: C12Q019-34; C07H019-00; C07H021-04
EXF 435/6; 435/91.1; 435/91.2; 536/22.1; 536/24.3; 536/24.33; 536/25.32
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 110 OF 362 USPATFULL on STN
AN 2000:50523 USPATFULL
TI Inhibitors of alternative alleles of genes as a basis for cancer
therapeutic agents
IN Housman, David E., Newton, MA, United States
PA Variagenics Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6054273 20000425 <--
AI US 1997-967454 19971111 (8)
RLI Continuation of Ser. No. US 1995-379680, filed on 4 Apr 1995, now
patented, Pat. No. US 5702890 which is a continuation-in-part of Ser.
No. WO 1994-US8473, filed on 26 Jul 1994 which is a continuation-in-part
of Ser. No. US 1993-95597, filed on 26 Jul 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1260
INCL INCLM: 435/006.000
INCLS: 435/366.000
NCL NCLM: 435/006.000
NCLS: 435/366.000
IC [7]
ICM: C12Q001-68
ICS: C12N005-08
EXF 424/130.1; 514/2; 514/44; 435/6; 435/366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 111 OF 362 USPATFULL on STN
AN 2000:46887 USPATFULL
TI Compositions for targeting the vasculature of solid tumors
IN Thorpe, Philip E., Dallas, TX, United States
Burrows, Francis J., San Diego, CA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United
States (U.S. corporation)
PI US 6051230 20000418 <--
AI US 1995-457869 19950601 (8)
RLI Division of Ser. No. US 1994-350212, filed on 5 Dec 1994 which is a
continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994,
now patented, Pat. No. US 5855866 which is a continuation-in-part of
Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 6124
INCL INCLM: 424/178.100
INCLS: 424/179.100; 424/180.100; 424/181.100; 424/182.100; 424/183.100;
530/387.100; 530/387.700; 530/388.100; 530/388.200
NCL NCLM: 424/178.100
NCLS: 424/179.100; 424/180.100; 424/181.100; 424/182.100; 424/183.100;
530/387.100; 530/387.700; 530/388.100; 530/388.200
IC [7]
ICM: A61K039-395
ICS: C07K016-00
EXF 424/183.1; 424/178.1; 424/179.1; 424/180.1; 424/181.1; 424/182.1;
530/387.1; 530/387.7; 530/388.1; 530/388.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 112 OF 362 USPATFULL on STN
AN 2000:44203 USPATFULL
TI Compositions and therapeutic methods using morphogenic proteins and
stimulatory factors
IN Lee, John C., San Antonio, TX, United States
Yeh, Lee-Chuan C., San Antonio, TX, United States
PA Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)
PI US 6048964 20000411 <--

AI US 1995-570752 19951212 (8)
 DT Utility
 FS Granted
 LN.CNT 3062
 INCL INCLM: 530/350.000
 INCLS: 530/300.000; 514/002.000; 435/069.100; 435/235.100; 435/240.200;
 435/252.300; 435/320.100; 536/023.100
 NCL NCLM: 530/350.000
 NCLS: 435/069.100; 435/235.100; 435/252.300; 435/320.100; 435/325.000;
 435/375.000; 530/300.000; 536/023.100
 IC [7]
 ICM: A61K038-18
 ICS: A61L027-00; C12P021-02; C12N007-00
 EXF 435/69.1; 435/320.1; 435/235.1; 435/252.3; 435/240.2; 530/300; 530/350;
 514/2; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 113 OF 362 USPATFULL on STN
 AN 2000:41003 USPATFULL
 TI Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2;
 compositions and uses thereof
 IN Ariizumi, Kiyoshi, Dallas, TX, United States
 Takashima, Akira, Irving, TX, United States
 PA Board of Regents The University of Texas Systems, Austin, TX, United
 States (U.S. corporation)
 PI US 6046158 20000404 <--
 AI US 1996-772440 19961220 (8)
 DT Utility
 FS Granted
 LN.CNT 6533
 INCL INCLM: 514/002.000
 INCLS: 514/012.000; 514/013.000; 514/014.000; 424/185.100; 435/069.100;
 435/069.700; 530/350.000; 530/300.000; 530/324.000; 530/326.000;
 530/327.000
 NCL NCLM: 514/002.000
 NCLS: 424/185.100; 435/069.100; 435/069.700; 514/012.000; 514/013.000;
 514/014.000; 530/300.000; 530/324.000; 530/326.000; 530/327.000;
 530/350.000
 IC [7]
 ICM: A61K038-04
 ICS: C07K007-08; C07K014-705; C07K019-00
 EXF 530/300; 530/326-330; 530/350; 530/396; 530/324; 435/69.1; 435/69.7;
 424/185.1; 514/2; 514/12; 514/13; 514/14
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 114 OF 362 USPATFULL on STN
 AN 2000:40878 USPATFULL
 TI Basic osteoblast growth factor II (bOGF-II)
 IN Goto, Masaaki, Tochigi, Japan
 Tsuda, Eisuke, Tochigi, Japan
 Yano, Kazuki, Tochigi, Japan
 Kobayashi, Fumie, Tochigi, Japan
 Yamaguchi, Kyoji, Saitama, Japan
 Washida, Naohiro, Tochigi, Japan
 Ueda, Masatsugu, Saitama, Japan
 Morinaga, Tomonori, Tochigi, Japan
 Satake, Toshiko, Tochigi, Japan
 Higashio, Kanji, Saitama, Japan
 PA Snow Brand Milk Products Co., Ltd., Sapporo, Japan (non-U.S.
 corporation)
 PI US 6046033 20000404 <--
 WO 9600240 19960104 <--
 AI US 1996-604965 19960226 (8)
 WO 1995-JP1270 19950626
 19960226 PCT 371 date
 19960226 PCT 102(e) date
 PRAI JP 1994-168984 19940627
 DT Utility
 FS Granted
 LN.CNT 809
 INCL INCLM: 435/069.400
 INCLS: 435/069.100; 435/252.300; 435/325.000; 530/300.000; 530/324.000;
 530/350.000; 530/397.000; 530/399.000; 536/023.100; 536/023.500;
 436/501.000
 NCL NCLM: 435/069.400
 NCLS: 435/069.100; 435/252.300; 435/325.000; 436/501.000; 530/300.000;

530/324.000; 530/350.000; 530/397.000; 530/399.000; 536/023.100;
536/023.500

IC [7]
ICM: C07K014-51
ICS: C07K014-475
EXF 530/300; 530/324; 530/350; 530/399; 530/397; 536/23.1; 536/23.5;
435/240.2; 435/252.3; 435/69.1; 435/69.4; 435/325; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 115 OF 362 USPATFULL on STN
AN 2000:40844 USPATFULL
TI Transcription factor E2F-4
IN Bernards, Rene, Amsterdam, Netherlands
Beijersbergen, Roderick L., Amsterdam, Netherlands
PA Prolifix Limited, Oxon, United Kingdom (non-U.S. corporation)
PI US 6045999 20000404 <--
WO 9615243 19960523 <--
AI US 1997-836582 19970514 (8)
WO 1995-GB868 19950418
19970514 PCT 371 date
19970514 PCT 102(e) date

PRAI GB 1994-23049 19941115
DT Utility
FS Granted
LN.CNT 2461
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/069.100; 530/300.000; 530/350.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 530/300.000; 530/350.000
IC [7]
ICM: C07K014-47
ICS: C12P021-00; C12Q001-68; G01N033-53
EXF 435/6; 435/7.1; 435/69.1; 514/2; 530/350; 530/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 116 OF 362 USPATFULL on STN
AN 2000:34403 USPATFULL
TI Vascular endothelial growth factor 2
IN Hu, Jing-Shan, Sunnyvale, CA, United States
Rosen, Craig A., Laytonsville, MD, United States
Cao, Liang, South Horizons, Hong Kong
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6040157 20000321 <--
AI US 1998-42105 19980313 (9)
RLI Continuation-in-part of Ser. No. US 1997-999811, filed on 24 Dec 1997,
now patented, Pat. No. US 5932540 which is a continuation-in-part of
Ser. No. US 1997-824996, filed on 27 Mar 1997 And a continuation-in-part
of Ser. No. US 1995-465968, filed on 6 Jun 1995 which is a
continuation-in-part of Ser. No. US 1994-207550, filed on 8 Mar 1994
DT Utility
FS Granted
LN.CNT 5292
INCL INCLM: 435/069.400
INCLS: 435/007.100; 435/325.000; 435/243.000; 435/320.100; 536/023.510;
530/399.000
NCL NCLM: 435/069.400
NCLS: 435/007.100; 435/243.000; 435/320.100; 435/325.000; 530/399.000;
536/023.510
IC [7]
ICM: C12N015-18
ICS: C12N015-63; C12N001-21; C12N005-00
EXF 435/69.4; 435/320.1; 435/325; 435/243; 536/23.51; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 117 OF 362 USPATFULL on STN
AN 2000:27958 USPATFULL
TI Bone morphogenetic protein (BMP)-9 compositions and their uses
IN Thies, R. Scott, Andover, MA, United States
Song, Jeffrey J., Brighton, MA, United States
PA Genetics Institute, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 6034062 20000307 <--
AI US 1997-815652 19970313 (8)
DT Utility
FS Granted

LN.CNT 2197
INCL INCLM: 514/012.000
INCLS: 530/350.000; 530/399.000; 930/120.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 530/399.000; 930/120.000
IC [7]
ICM: A61K038-18
ICS: C07K014-51
EXF 530/350; 530/399; 930/120; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 118 OF 362 USPATFULL on STN
AN 2000:27562 USPATFULL
TI Compositions and methods for modulating leukocyte adhesion to brain
endothelial cells
IN Yednock, Theodore A., Fairfax, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6033665 20000307 <--
AI US 1995-457847 19950601 (8)
RLI Continuation of Ser. No. US 1995-402962, filed on 10 Mar 1995 which is a
continuation of Ser. No. US 1992-871223, filed on 17 Apr 1992, now
abandoned which is a continuation-in-part of Ser. No. US 1990-577650,
filed on 4 Sep 1990, now patented, Pat. No. US 5260210 which is a
continuation-in-part of Ser. No. US 1989-413274, filed on 27 Sep 1989,
now abandoned
DT Utility
FS Granted
LN.CNT 1635
INCL INCLM: 424/130.100
INCLS: 424/141.100; 424/143.100; 424/144.100; 514/002.000; 530/300.000;
530/350.000; 530/387.100; 530/388.220; 530/389.100; 530/395.000
NCL NCLM: 424/130.100
NCLS: 424/141.100; 424/143.100; 424/144.100; 514/002.000; 530/300.000;
530/350.000; 530/387.100; 530/388.220; 530/389.100; 530/395.000
IC [7]
ICM: A61K038-00
ICS: A61K039-395
EXF 424/145.1; 424/158.1; 424/141.1; 424/143.1; 424/144.1; 424/130.1;
530/387.1; 530/388.82; 530/395; 530/300; 530/350; 530/388.22; 530/389.1;
935/107; 935/110; 514/2

L3 ANSWER 119 OF 362 USPATFULL on STN
AN 2000:24287 USPATFULL
TI Receptor specific transepithelial transport of therapeutics
IN Blumberg, Richard S., Chestnut Hill, MA, United States
Simister, Neil E., Wellesley, MA, United States
Lencer, Wayne I., Jamaica Plain, MA, United States
PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S.
corporation)
Brandeis University, Waltham, MA, United States (U.S. corporation)
PI US 6030613 20000229 <--
AI US 1997-899856 19970724 (8)
RLI Continuation-in-part of Ser. No. US 1995-578171, filed on 29 Dec 1995
which is a continuation-in-part of Ser. No. US 1995-374159, filed on 17
Jan 1995, now patented, Pat. No. US 5671273
DT Utility
FS Granted
LN.CNT 1591
INCL INCLM: 424/134.100
INCLS: 424/178.100; 530/387.100; 530/388.220
NCL NCLM: 424/134.100
NCLS: 424/178.100; 530/387.100; 530/388.220
IC [7]
ICM: A61K039-385
ICS: A61K039-44
EXF 424/178.1; 424/179.1; 424/134.1; 530/387.1; 530/388.22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 120 OF 362 USPATFULL on STN
AN 2000:21215 USPATFULL
TI Device and method for encapsulated gene therapy
IN Hammang, Joseph P., Barrington, RI, United States
Aebischer, Patrick, Lutry, Switzerland
PA Cytotherapeutics, Inc., Lincoln, RI, United States (U.S. corporation)
PI US 6027721 20000222 <--

AI US 1996-650726 19960520 (8)
DT Utility
FS Granted
LN.CNT 1429
INCL INCLM: 424/093.200
INCLS: 424/452.000; 435/325.000; 435/465.000; 514/044.000
NCL NCLM: 424/093.200
NCLS: 424/452.000; 435/325.000; 435/465.000; 514/044.000
IC [7]
ICM: C12N015-85
ICS: C12N015-00; A61K048-00; A61K009-48
EXF 514/44; 424/93.1; 424/93.21; 424/93.2; 424/452; 435/325; 435/465
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 121 OF 362 USPATFULL on STN
AN 2000:18243 USPATFULL
TI Neurturin receptor
IN Klein, Robert D., Palo Alto, CA, United States
Rosenthal, Arnon, Burlingame, CA, United States
Hynes, Mary A., San Mateo, CA, United States
PA Genentech, Inc., United States (U.S. corporation)
PI US 6025157 20000215 <--
AI US 1997-957063 19971024 (8)
PRAI US 1997-38839P 19970218 (60)
US 1997-49818P 19970609 (60)
DT Utility
FS Granted
LN.CNT 5116
INCL INCLM: 435/069.100
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 536/023.100; 536/023.500
IC [7]
ICM: C12P021-06
ICS: C12N015-00; C07H021-02; C07H021-04
EXF 536/23.5; 536/23.1; 435/325; 435/320.1; 435/69.1; 800/8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 122 OF 362 USPATFULL on STN
AN 2000:15663 USPATFULL
TI Compositions and methods for stimulating bone growth
IN Gasper, Shirley R., Seattle, WA, United States
West, Robert R., Seattle, WA, United States
Martinez, Theresa, Greenbank, WA, United States
Robbins, Kirk G., Renton, WA, United States
McKernan, Patricia A., Woodinville, WA, United States
Baindur, Nand, Edmonds, WA, United States
Labroo, Virender M., Mill Creek, WA, United States
PA OsteoScreen, Inc., Seattle, WA, United States (U.S. corporation)
ZymoGenetics Corporation, San Antonio, TX, United States (U.S. corporation)
PI US 6022887 20000208 <--
AI US 1997-989862 19971212 (8)
PRAI US 1996-32893P 19961231 (60)
DT Utility
FS Granted
LN.CNT 1453
INCL INCLM: 514/451.000
INCLS: 514/451.000; 514/460.000; 549/273.000
NCL NCLM: 514/451.000
NCLS: 514/460.000; 549/273.000
IC [6]
ICM: A01N043-16
ICS: C07D309-00
EXF 514/451; 514/460; 549/273
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 123 OF 362 USPATFULL on STN
AN 2000:15506 USPATFULL
TI Methods for the isolation of bacteria containing eukaryotic genes
IN Robinson, Douglas H., 2301 N St., NW., Apt. 507, Washington, DC, United States 20037
PI US 6022730 20000208 <--
AI US 1996-719367 19960925 (8)
RLI Continuation-in-part of Ser. No. US 1994-261977, filed on 17 Jun 1994
DT Utility

FS Granted
LN.CNT 947
INCL INCLM: 435/252.300
INCLS: 435/034.000; 435/071.100; 435/240.200; 435/252.100
NCL NCLM: 435/252.300
NCLS: 435/034.000; 435/071.100; 435/252.100
IC [6]
ICM: C12Q001-04
ICS: C12N005-16; C12N005-08
EXF 435/240.2; 435/34; 435/252.1; 435/252.3; 435/71.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 124 OF 362 USPATFULL on STN
AN 2000:9929 USPATFULL
TI Compositions and methods for treating bone deficit conditions
IN Petrie, Charles, Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
Baindur, Nand, Edmonds, WA, United States
Robbins, Kirk G., Renton, WA, United States
Mundy, Gregory R., San Antonio, TX, United States
PA Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation)
Osteoscreen, Inc., San Antonio, TX, United States (U.S. corporation)
PI US 6017940 20000125 <--
AI US 1997-806770 19970226 (8)
RLI Continuation-in-part of Ser. No. US 1996-736222, filed on 23 Oct 1996,
now abandoned
DT Utility
FS Granted
LN.CNT 978
INCL INCLM: 514/367.000
INCLS: 514/371.000
NCL NCLM: 514/367.000
NCLS: 514/371.000
IC [6]
ICM: A61K031-425
EXF 514/367; 514/371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 125 OF 362 USPATFULL on STN
AN 2000:9896 USPATFULL
TI Structural analogues of vitamin D
IN Bouillon, Roger, Herent, Belgium
Vandewalle, Maurits, Ghent, Belgium
de Clercq, Pierre Jean, Ghent, Belgium
PA Laboratoire Theramex S.A., Monaco (non-U.S. corporation)
PI US 6017907 20000125 <--
WO 9501960 19950119 <--
AI US 1996-571887 19960628 (8)
WO 1994-EP2294 19940707
19960628 PCT 371 date
19960628 PCT 102(e) date
PRAI EP 1993-202037 19930709
DT Utility
FS Granted
LN.CNT 4601
INCL INCLM: 514/167.000
INCLS: 552/653.000
NCL NCLM: 514/167.000
NCLS: 552/653.000
IC [6]
ICM: A61K031-59
EXF 552/653; 514/167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 126 OF 362 USPATFULL on STN
AN 2000:7439 USPATFULL
TI Osteoprotegerin
IN Boyle, William J., Moorpark, CA, United States
Lacey, David L., Thousand Oaks, CA, United States
Calzone, Frank J., Westlake Village, CA, United States
Chang, Ming-Shi, Newbury Park, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 6015938 20000118 <--
AI US 1997-974022 19971118 (8)
RLI Division of Ser. No. US 1995-577788, filed on 22 Dec 1995
DT Utility

FS Granted
LN.CNT 2061
INCL INCLM: 800/018.000
INCLS: 800/014.000
NCL NCLM: 800/018.000
NCLS: 800/014.000
IC [6]
ICM: C12N005-00
EXF 800/2; 800/DIG.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 127 OF 362 USPATFULL on STN
AN 2000:7394 USPATFULL
TI Oligonucleoside compounds and methods for inhibiting tumor growth,
invasion and metastasis
IN Cance, William G., Chapel Hill, NC, United States
Liu, Edison T., Chapel Hill, NC, United States
Owens, Lewis V., Chapel Hill, NC, United States
PA The University of North Carolina at Chapel Hill, Chapel Hill, NC, United
States (U.S. corporation)
PI US 6015893 20000118 <--
AI US 1997-863118 19970527 (8)
RLI Continuation of Ser. No. US 1994-276843, filed on 18 Jul 1994, now
abandoned
DT Utility
FS Granted
LN.CNT 1556
INCL INCLM: 536/024.500
NCL NCLM: 536/024.500
IC [6]
ICM: C07H021-00
EXF 536/24.1; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 128 OF 362 USPATFULL on STN
AN 2000:7058 USPATFULL
TI Cytotoxic drug therapy
IN Bagshawe, Kenneth Dawson, London, United Kingdom
PA Enzacta R & D Limited, United Kingdom (non-U.S. corporation)
PI US 6015556 20000118 <--
AI US 1997-885281 19970630 (8)
RLI Continuation of Ser. No. US 256475
PRAI GB 1992-417 19920109
DT Utility
FS Granted
LN.CNT 1165
INCL INCLM: 424/134.100
INCLS: 514/002.000
NCL NCLM: 424/134.100
NCLS: 514/002.000
IC [6]
ICM: A61K039-395
ICS: A61K038-43; C07K016-28; C07K017-00
EXF 514/2; 424/134.1; 424/94.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 129 OF 362 USPATFULL on STN
AN 2000:4924 USPATFULL
TI Peptide variants of protein A
IN Braisted, Andrew C., San Francisco, CA, United States
Starovasnik, Melissa A., Burlingame, CA, United States
Wells, James A., Burlingame, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6013763 20000111 <--
AI US 1996-657983 19960604 (8)
DT Utility
FS Granted
LN.CNT 4172
INCL INCLM: 530/317.000
INCLS: 530/321.000; 530/324.000; 514/011.000; 514/012.000; 436/828.000
NCL NCLM: 530/317.000
NCLS: 436/828.000; 530/321.000; 530/324.000
IC [6]
ICM: C07K014-00
EXF 514/12; 514/11; 530/324; 530/317; 530/321; 436/828

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 130 OF 362 USPATFULL on STN
AN 2000:1692 USPATFULL
TI Sequence-directed DNA binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood, CA, United States (U.S.
corporation)
PI US 6010849 20000104 <--
AI US 1995-482080 19950607 (8)
RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented,
Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US
1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014
which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23
Dec 1992, now patented, Pat. No. US 5693463 which is a
continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
now abandoned
DT Utility
FS Granted
LN.CNT 10022
INCL INCLM: 435/006.000
INCLS: 435/007.100
NCL NCLM: 435/006.000
NCLS: 435/007.100
IC [6]
ICM: C12Q001-68
ICS: G01N033-53
EXF 435/6; 435/7.1; 436/501; 536/23.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 131 OF 362 USPATFULL on STN
AN 1999:170728 USPATFULL
TI Compacted nucleic acids and their delivery to cells
IN Hanson, Richard W., Cleveland Heights, OH, United States
Perales, Jose C., Cleveland Heights, OH, United States
Ferkol, Thomas W., Euclid, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S.
corporation)
Ohio University, Athens, OH, United States (U.S. corporation)
PI US 6008336 19991228 <--
AI US 1998-54453 19980403 (9)
RLI Continuation-in-part of Ser. No. US 1994-216534, filed on 23 Mar 1994,
now abandoned And a continuation of Ser. No. US 716415
DT Utility
FS Granted
LN.CNT 3531
INCL INCLM: 536/023.100
INCLS: 424/493.000; 424/093.210; 514/044.000
NCL NCLM: 536/023.100
NCLS: 424/093.210; 424/493.000
IC [6]
ICM: C12N015-11
EXF 536/23.1; 424/493; 424/93.21; 514/44; 435/440; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 132 OF 362 USPATFULL on STN
AN 1999:170600 USPATFULL
TI Compositions and methods for treating bone deficit conditions
IN Petrie, Charles, Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
Baindur, Nand, Edmonds, WA, United States
Robbins, Kirk G., Renton, WA, United States
Harris, Scott M., Seattle, WA, United States
Kontoyianni, Maria, Seattle, WA, United States
Mundy, Gregory R., San Antonio, TX, United States
PA OsteoScreen, Inc., San Antonio, TX, United States (U.S. corporation)
ZymoGenetics Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6008208 19991228 <--
AI US 1997-878868 19970619 (8)
RLI Continuation of Ser. No. US 1996-735875, filed on 23 Oct 1996, now
abandoned
DT Utility

FS Granted
LN.CNT 1364
INCL INCLM: 514/150.000
INCLS: 514/224.200; 514/456.000
NCL NCLM: 514/150.000
NCLS: 514/224.200; 514/456.000
IC [6]
ICM: A61K031-655
ICS: A61K031-47; A61K031-495; A61K031-35
EXF 514/150; 514/224.2; 514/456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 133 OF 362 USPATFULL on STN
AN 1999:170440 USPATFULL
TI Cell culturing method and medium
IN Curcio, Francesco, Pagnacco, Italy
Coon, Hayden G., East Sebago, ME, United States
Ambesi-Impimbato, F. Saverio, Udine, Italy
PA Livercell L.L.C., East Sebago, ME, United States (U.S. corporation)
PI US 6008047 19991228 <--
AI US 1998-66897 19980428 (9)
RLI Continuation-in-part of Ser. No. US 1993-480022, filed on 7 Jun 1993,
now patented, Pat. No. US 5888816 which is a continuation of Ser. No. US
1993-83772, filed on 30 Jun 1993, now abandoned which is a
continuation-in-part of Ser. No. US 1993-44010, filed on 8 Apr 1993, now
abandoned
DT Utility
FS Granted
LN.CNT 2290
INCL INCLM: 435/370.000
INCLS: 435/001.100; 435/370.000; 435/378.000; 435/383.000; 435/391.000;
435/392.000; 435/397.000; 424/093.700
NCL NCLM: 435/370.000
NCLS: 424/093.700; 435/001.100; 435/378.000; 435/383.000; 435/391.000;
435/392.000; 435/397.000
IC [6]
ICM: C12N005-00
ICS: A01N001-02
EXF 435/1.1; 435/370; 435/378; 435/383; 435/391; 435/392; 435/397; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 134 OF 362 USPATFULL on STN
AN 1999:159482 USPATFULL
TI Agonist antibodies against the flk2/flt3 receptor and uses thereof
IN Bennett, Brian D., 460 Point San Bruno Boulevard, South San Francisco,
CA, United States 94080
Broz, Susan D., 460 Point San Bruno Boulevard, South San Francisco, CA,
United States 94080
Matthews, William, 460 Point San Bruno Boulevard, South San Francisco,
CA, United States 94080
Zeigler, Francis C., 460 Point San Bruno Boulevard, South San Francisco,
CA, United States 94080
PI US 5997865 19991207 <--
AI US 1995-434878 19950504 (8)
RLI Division of Ser. No. US 1994-222299, filed on 4 Apr 1994, now patented,
Pat. No. US 5635388
DT Utility
FS Granted
LN.CNT 2155
INCL INCLM: 424/130.100
INCLS: 424/143.100; 530/388.220; 530/389.100; 530/387.300
NCL NCLM: 424/130.100
NCLS: 424/143.100; 530/387.300; 530/388.220; 530/389.100
IC [6]
ICM: A61K039-395
ICS: C07K016-00
EXF 424/130.1; 424/143.1; 530/388.22; 530/389.1; 530/387.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 135 OF 362 USPATFULL on STN
AN 1999:155894 USPATFULL
TI Anti-IgE antibodies and methods of improving polypeptides
IN Lowman, Henry B., El Granada, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Jardieu, Paula M., San Mateo, CA, United States
Lowe, John, Daly City, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5994511 19991130 <--
AI US 1997-887352 19970702 (8)
DT Utility
FS Granted
LN.CNT 5816
INCL INCL: 530/387.300
INCLS: 424/133.100; 424/135.100; 424/145.100; 424/810.000; 436/548.000;
530/388.250; 530/868.000
NCL NCLM: 530/387.300
NCLS: 424/133.100; 424/135.100; 424/145.100; 424/810.000; 436/548.000;
530/388.250; 530/868.000
IC [6]
ICM: A61K039-395
ICS: C07K016-42
EXF 530/387.3; 530/388.25; 530/868; 424/133.1; 424/135.1; 424/145.1;
424/810; 436/548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 136 OF 362 USPATFULL on STN
AN 1999:155741 USPATFULL
TI Compositions and methods for treating bone deficit conditions
IN Petrie, Charles, Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
Baindur, Nand, Edmonds, WA, United States
Robbins, Kirk G., Renton, WA, United States
Kontoyianni, Maria, Seattle, WA, United States
Mundy, Gregory R., San Antonio, TX, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
Osteoscreen, Inc., San Antonio, TX, United States (U.S. corporation)
PI US 5994358 19991130 <--
AI US 1997-808744 19970228 (8)
RLI Continuation of Ser. No. US 1996-736319, filed on 23 Oct 1996, now
abandoned
DT Utility
FS Granted
LN.CNT 973
INCL INCL: 514/255.000
INCLS: 514/311.000; 514/312.000; 514/313.000; 514/314.000; 514/432.000;
514/451.000; 514/452.000
NCL NCLM: 514/250.000
NCLS: 514/311.000; 514/312.000; 514/313.000; 514/314.000; 514/432.000;
514/451.000; 514/452.000
IC [6]
ICM: A61K031-495
ICS: A61K031-47; A61K031-38; A61K031-35
EXF 514/255; 514/311; 514/312; 514/313; 514/314; 514/432; 514/451; 514/452
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 137 OF 362 USPATFULL on STN
AN 1999:155724 USPATFULL
TI Anti-angiogenic Compositions and methods for the treatment of arthritis
IN Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
Arsenault, A. Larry, Paris, Canada
PA Angiogenesis Technologies, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5994341 19991130 <--
AI US 1995-478914 19950607 (8)
RLI Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned
which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19
Jul 1993, now abandoned
PRAI WO 1994-CA373 19940719
DT Utility
FS Granted
LN.CNT 5044
INCL INCL: 514/210.000
INCLS: 514/210.000; 514/250.000; 514/825.000; 514/886.000
NCL NCLM: 514/449.000
NCLS: 514/250.000; 514/825.000; 514/886.000
IC [6]
ICM: A01N043-00
EXF 514/210; 514/250; 514/825; 514/886; 514/449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 138 OF 362 USPATFULL on STN
 AN 1999:151272 USPATFULL
 TI Compositions and methods for treating bone deficit conditions
 IN Petrie, Charles, Woodinville, WA, United States
 Orme, Mark W., Seattle, WA, United States
 Baidur, Nand, Edmonds, WA, United States
 Robbins, Kirk G., Renton, WA, United States
 Harris, Scott M., Seattle, WA, United States
 Mundy, Gregory R., San Antonio, TX, United States
 PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
 Osteoscreen, Inc., San Antonio, TX, United States (U.S. corporation)
 PI US 5990169 19991123 <--
 AI US 1997-806771 19970226 (8)
 RLI Continuation of Ser. No. US 1996-736228, filed on 23 Oct 1996, now
 abandoned
 DT Utility
 FS Granted
 LN.CNT 1040
 INCL INCLM: 514/613.000
 INCLS: 514/322.000; 514/614.000; 514/616.000; 514/167.000; 514/706.000
 NCL NCLM: 514/613.000
 NCLS: 514/167.000; 514/322.000; 514/614.000; 514/616.000; 514/706.000
 IC [6]
 ICM: A61K031-445
 ICS: A61K031-16; A61K031-18
 EXF 514/322; 514/613; 514/614; 514/616; 514/617; 514/706
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 139 OF 362 USPATFULL on STN
 AN 1999:146775 USPATFULL
 TI Photocleavable agents and conjugates for the detection and isolation of
 biomolecules
 IN Rothschild, Kenneth J., Newton, MA, United States
 Sonar, Sanjay M., Boston, MA, United States
 Olejnik, Jerzy, Allston, MA, United States
 PA Trustees of Boston University, Boston, MA, United States (U.S.
 corporation)
 PI US 5986076 19991116 <--
 AI US 1994-345807 19941122 (8)
 RLI Continuation of Ser. No. US 1994-345807, filed on 22 Nov 1994 which is a
 continuation-in-part of Ser. No. US 1994-240511, filed on 11 May 1994
 DT Utility
 FS Granted
 LN.CNT 3996
 INCL INCLM: 536/022.100
 INCLS: 435/006.000; 424/130.100; 424/184.100; 514/002.000; 514/044.000;
 536/023.100; 536/025.320; 530/300.000; 530/350.000
 NCL NCLM: 536/022.100
 NCLS: 424/130.100; 424/184.100; 435/006.000; 530/300.000; 530/350.000;
 536/023.100; 536/025.320
 IC [6]
 ICM: C07H019-00
 ICS: C12Q001-68; A01N037-18; A61K039-245
 EXF 435/6; 536/22.1; 536/23.1; 536/25.32; 424/130.1; 424/184.1; 514/2;
 514/44; 530/300; 530/350
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 140 OF 362 USPATFULL on STN
 AN 1999:141602 USPATFULL
 TI Chimeric receptors and methods for identifying compounds active at
 metabotropic glutamate receptors
 IN Fuller, Forrest H., La Jolla, CA, United States
 Krapcho, Karen J., Salt Lake City, UT, United States
 Hammerland, Lance G., Bountiful, UT, United States
 PA NPS Pharmaceuticals, Inc., Salt Lake City, UT, United States (U.S.
 corporation)
 PI US 5981195 19991109 <--
 AI US 1996-687289 19960725 (8)
 PRAI US 1995-1526P 19950726 (60)
 DT Utility
 FS Granted
 LN.CNT 4472
 INCL INCLM: 435/007.100
 INCLS: 435/007.200; 435/069.700; 435/252.300; 435/320.100; 530/350.000;
 536/023.400
 NCL NCLM: 435/007.100

NCLS: 435/007.200; 435/069.700; 435/252.300; 435/320.100; 530/350.000;
536/023.400

IC [6]
ICM: C07K019-00
ICS: C12N015-62

EXF 435/69.7; 435/6; 435/7.1; 435/7.2; 435/252.3; 435/32.7; 530/350;
536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 141 OF 362 USPATFULL on STN
AN 1999:136986 USPATFULL
TI Secreted proteins and polynucleotides encoding them
IN Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaVallie, Edward R., Harvard, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Spaulding, Vikki, Billerica, MA, United States
Agostino, Michael J., Andover, MA, United States
PA Genetics Institute, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 5976837 19991102 <--
AI US 1997-960022 19971029 (8)
RLI Continuation-in-part of Ser. No. US 1997-815047, filed on 14 Mar 1997,
now abandoned
DT Utility
FS Granted
LN.CNT 3683
INCL INCLM: 435/069.100
INCLS: 435/091.400; 435/252.300; 435/320.100; 536/023.100; 536/023.500;
536/024.100; 536/024.310; 530/350.000
NCL NCLM: 435/069.100
NCLS: 435/091.400; 435/252.300; 435/320.100; 530/350.000; 536/023.100;
536/023.500; 536/024.100; 536/024.310

IC [6]
ICM: C12N015-00

EXF 435/69.1; 435/91.4; 435/252.3; 435/320.1; 536/23.1; 536/23.5; 536/24.1;
536/24.31; 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 142 OF 362 USPATFULL on STN
AN 1999:132786 USPATFULL
TI Serpin enzyme complex receptor--mediated gene transfer
IN Ferkol, Jr., Thomas W., Euclid, OH, United States
Davis, Pamela B., Cleveland Heights, OH, United States
Ziady, Assem-Galal, Cleveland Heights, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S.
corporation)
PI US 5972901 19991026 <--
AI US 1996-656906 19960603 (8)
RLI Continuation-in-part of Ser. No. US 1996-655705, filed on 3 Jun 1996
which is a continuation of Ser. No. WO 1995-US3677, filed on 23 Mar 1995
which is a continuation-in-part of Ser. No. US 1994-216534, filed on 23
Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 5111
INCL INCLM: 514/044.000
INCLS: 424/093.210; 435/007.800; 435/091.400; 435/320.100; 435/325.000;
435/455.000; 530/388.220; 530/887.300; 530/324.000; 536/023.100
NCL NCLM: 514/044.000
NCLS: 424/093.210; 435/007.800; 435/091.400; 435/320.100; 435/325.000;
435/455.000; 530/324.000; 530/388.220; 530/388.730; 536/023.100

IC [6]
ICM: A01N043-04

EXF 514/44; 424/93.21; 435/7.8; 435/91.4; 435/320.1; 435/325; 435/172.3;
435/45; 435/375; 435/455; 530/388.22; 530/887.3; 530/324; 536/23.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 143 OF 362 USPATFULL on STN
AN 1999:132785 USPATFULL
TI Delivery of nucleic acid to cells
IN Ferkol, Jr., Thomas W., Concord, OH, United States
Davis, Pamela B., Cleveland Heights, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S.

corporation)
PI US 5972900 19991026 <--
AI US 1996-655705 19960603 (8)
RLI Continuation of Ser. No. WO 1995-US3677, filed on 23 Mar 1995 which is a
continuation-in-part of Ser. No. US 1994-216534, filed on 23 Mar 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 3321
INCL INCLM: 514/044.000
INCLS: 435/375.000; 435/320.100; 424/093.200; 424/093.210; 514/002.000;
536/023.100; 536/024.500
NCL NCLM: 514/044.000
NCLS: 424/093.200; 424/093.210; 435/320.100; 435/375.000; 514/002.000;
536/023.100; 536/024.500
IC [6]
ICM: A61K048-00
ICS: C12N015-09; C12N015-63; C07H021-04
EXF 514/44; 514/2; 435/172.3; 435/240.1; 435/240.2; 435/320.1; 435/45;
435/375; 424/93.2; 424/93.21; 536/23.1; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 144 OF 362 USPATFULL on STN
AN 1999:128396 USPATFULL
TI Dendritic cell-derived growth factor
IN Fan, Ping, Gaithersburg, MD, United States
Soppet, Daniel R., Centreville, VA, United States
Li, Yi, Sunnyvale, CA, United States
Dillon, Patrick J., Carlsbad, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 5968780 19991019 <--
AI US 1998-19201 19980205 (9)
PRAI US 1997-38829P 19970206 (60)
DT Utility
FS Granted
LN.CNT 3473
INCL INCLM: 435/069.400
INCLS: 435/455.000; 435/325.000; 435/252.300; 435/254.110; 435/320.100;
536/023.100; 536/023.500; 536/023.510; 536/024.100; 536/024.300;
536/024.310; 536/024.330
NCL NCLM: 435/069.400
NCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 435/455.000;
536/023.100; 536/023.500; 536/023.510; 536/024.100; 536/024.300;
536/024.310; 536/024.330
IC [6]
ICM: C12N015-16
ICS: C12N001-21; C12N005-10; C12N015-63
EXF 536/23.1; 536/23.5; 536/23.51; 536/24.1; 536/24.3; 536/24.31; 536/24.33;
435/69.1; 435/69.4; 435/455; 435/325; 435/252.3; 435/254.11; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 145 OF 362 USPATFULL on STN
AN 1999:128368 USPATFULL
TI Method for identifying an OP-1 analog which binds an ALK-1 receptor
IN Ichijo, Hidenori, Tokyo, Japan
Nishitoh, Hideki, Kanagawa-ken, Japan
Sampath, Kuber T., Medway, MA, United States
PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S.
corporation)
The Ludwig Institute for Cancer Research, New York, NY, United States
(U.S. corporation)
PI US 5968752 19991019 <--
AI US 1996-696268 19960813 (8)
PRAI US 1995-2313P 19950814 (60)
DT Utility
FS Granted
LN.CNT 2503
INCL INCLM: 435/007.200
INCLS: 435/007.100; 530/350.000
NCL NCLM: 435/007.200
NCLS: 435/007.100; 530/350.000
IC [6]
ICM: G01N033-566
ICS: C07K014-71; C07K014-705
EXF 435/7.1; 435/7.2; 435/69.1; 436/501; 530/300; 530/350

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 146 OF 362 USPATFULL on STN
AN 1999:128130 USPATFULL
TI ErbB3 antibodies
IN Akita, Robert, Hayward, CA, United States
Sliwkowski, Mark, San Carlos, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5968511 19991019 <--
AI US 1997-827009 19970325 (8)
PRAI US 1996-46850P 19960327 (60)
DT Utility
FS Granted
LN.CNT 2264
INCL INCLM: 424/141.100
INCLS: 424/142.100; 424/143.100; 424/152.100; 424/155.100; 435/330.000; 435/334.000; 435/344.000; 435/007.100; 435/007.230; 530/387.700; 530/388.150; 530/388.100; 530/388.220
NCL NCLM: 424/141.100
NCLS: 424/142.100; 424/143.100; 424/152.100; 424/155.100; 435/007.100; 435/007.230; 435/330.000; 435/334.000; 435/344.000; 530/387.700; 530/388.100; 530/388.150; 530/388.220
IC [6]
ICM: A61K039-395
ICS: G01N033-574; C12N005-20; C07K016-00
EXF 530/388.22; 530/388.1; 530/388.15; 530/387.7; 435/330; 435/334; 435/344; 435/7.23; 435/7.1; 424/141.1; 424/142.1; 424/143.1; 424/152.1; 424/155.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 147 OF 362 USPATFULL on STN
AN 1999:124909 USPATFULL
TI Compositions and methods for treating bone deficit conditions
IN Petrie, Charles, Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
Baindur, Nand, Edmonds, WA, United States
Robbins, Kirk G., Renton, WA, United States
Kontoyianni, Maria, Seattle, WA, United States
Mundy, Gregory R., San Antonio, TX, United States
PA Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation)
Osteoscreen, Inc., San Antonio, TX, United States (U.S. corporation)
PI US 5965573 19991012 <--
AI US 1997-812141 19970306 (8)
RLI Continuation of Ser. No. US 1996-735874, filed on 23 Oct 1996, now abandoned
DT Utility
FS Granted
LN.CNT 1038
INCL INCLM: 514/316.000
INCLS: 514/183.000; 514/247.000; 514/255.000; 514/256.000; 514/272.000; 514/351.000; 514/187.000; 514/275.000; 514/277.000; 514/299.000; 514/329.000; 514/330.000; 514/349.000; 514/350.000; 514/317.000; 514/357.000; 514/422.000
NCL NCLM: 514/316.000
NCLS: 514/183.000; 514/187.000; 514/247.000; 514/252.030; 514/252.050; 514/256.000; 514/272.000; 514/275.000; 514/277.000; 514/299.000; 514/317.000; 514/329.000; 514/330.000; 514/349.000; 514/350.000; 514/351.000; 514/357.000; 514/422.000
IC [6]
ICM: A61K031-33
ICS: A61K031-445; A61K031-495; A61K031-40
EXF 514/183; 514/247; 514/255; 514/256; 514/272; 514/316; 514/351; 514/187; 514/275; 514/277; 514/299; 514/329; 514/330; 514/349; 514/350; 514/317; 514/357; 514/422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 148 OF 362 USPATFULL on STN
AN 1999:124469 USPATFULL
TI Methods and compositions for targeting the vasculature of solid tumors
IN Thorpe, Philip E., Dallas, TX, United States
Burrows, Francis J., San Diego, CA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5965132 19991012 <--
AI US 1994-350212 19941205 (8)
RLI Continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994

which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5
Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 5943
INCL INCLM: 424/149.000
INCLS: 424/088.000; 424/001.450; 424/139.100; 424/156.100; 424/183.100;
530/391.700; 530/391.900; 530/387.200; 530/807.000; 530/828.000;
435/070.100; 435/070.200; 435/182.200; 435/240.200
NCL NCLM: 424/001.490
NCLS: 424/001.450; 424/139.100; 424/156.100; 424/183.100; 435/070.100;
435/070.200; 530/387.200; 530/391.700; 530/391.900; 530/807.000;
530/828.000
IC [6]
ICM: A61K051-00
EXF 424/1.49; 424/88; 424/1.45; 424/139.1; 424/156.1; 424/183.1; 424/145.1;
424/158.1; 424/195.1; 424/195.11; 424/198.1; 530/391.7; 530/391.9;
530/387.2; 530/807; 530/828; 530/388.23; 530/388.24; 530/389.2;
435/70.1; 435/70.2; 435/172.2; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 149 OF 362 USPATFULL on STN
AN 1999:121379 USPATFULL
TI Screening methods for cytokine inhibitors
IN Mak, Vivian, Menlo Park, CA, United States
PA Adolor Corporation, Malvern, PA, United States (U.S. corporation)
PI US 5962477 19991005 <--
AI US 1998-97441 19980615 (9)
RLI Continuation-in-part of Ser. No. WO 1995-US4677, filed on 11 Apr 1995
which is a continuation-in-part of Ser. No. US 1995-400234, filed on 3
Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US
1994-271287, filed on 6 Jul 1994, now abandoned which is a
continuation-in-part of Ser. No. US 1994-225991, filed on 12 Apr 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 5138
INCL INCLM: 514/327.000
INCLS: 424/078.050
NCL NCLM: 514/327.000
NCLS: 424/078.050
IC [6]
ICM: A61K031-445
EXF 514/327; 424/78.05
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 150 OF 362 USPATFULL on STN
AN 1999:116976 USPATFULL
TI Treatment methods for disease using co-localized cells and Sertoli cells
obtained from a cell line
IN Selawry, Helena P., Rileyville, VA, United States
PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
corporation)
PI US 5958404 19990928 <--
AI US 1996-660258 19960607 (8)
RLI Continuation-in-part of Ser. No. US 1995-485340, filed on 7 Jun 1995,
now patented, Pat. No. US 5849285 which is a continuation-in-part of
Ser. No. US 1995-421641, filed on 13 Apr 1995, now patented, Pat. No. US
5725854 which is a continuation-in-part of Ser. No. US 1994-211695,
filed on 13 Apr 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2027
INCL INCLM: 424/093.700
INCLS: 435/325.000; 435/373.000; 435/404.000
NCL NCLM: 424/093.700
NCLS: 435/325.000; 435/373.000; 435/404.000
IC [6]
ICM: A01N063-00
ICS: C12N005-00; C12N005-02
EXF 424/93.7; 435/325; 435/373; 435/404; 435/284.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 151 OF 362 USPATFULL on STN
AN 1999:113930 USPATFULL
TI Thrombin receptor deficient transgenic mice

IN Leung, Wai-Ping, San Diego, CA, United States
 Andrade-Gordon, Patricia, Doylestown, PA, United States
 Zhou, Lubing, East Brunswick, NJ, United States
 PA Ortho Pharmaceutical Corporation, Raritan, NJ, United States (U.S. corporation)
 PI US 5955645 19990921 <--
 AI US 1997-847953 19970422 (8)
 PRAI US 1996-16070P 19960423 (60)
 US 1996-20544P 19960625 (60)
 DT Utility
 FS Granted
 LN.CNT 1458
 INCL INCLM: 800/018.000
 INCLS: 800/021.000; 800/022.000; 435/325.000; 435/455.000; 435/463.000
 NCL NCLM: 800/018.000
 NCLS: 435/325.000; 435/455.000; 435/463.000; 800/021.000; 800/022.000
 IC [6]
 ICM: C12N005-00
 ICS: C12N015-85; C12N015-00; C12N005-06
 EXF 800/2; 800/18; 800/21; 800/22; 435/325; 435/354; 435/320.1; 435/172.3;
 435/455; 435/463; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 152 OF 362 USPATFULL on STN
 AN 1999:109966 USPATFULL
 TI Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
 IN Segal, Andrew H., Boston, MA, United States
 PA Whitenead Institute for Biomedical Research, Cambridge, MA, United States (U.S. corporation)
 PI US 5951976 19990914 <--
 AI US 1997-826259 19970327 (8)
 DT Utility
 FS Granted
 LN.CNT 2180
 INCL INCLM: 424/093.210
 INCLS: 424/093.700; 435/325.000; 514/012.000; 514/021.000
 NCL NCLM: 424/093.210
 NCLS: 424/093.700; 435/325.000; 514/012.000; 514/021.000
 IC [6]
 ICM: A61K038-00
 ICS: C12N009-00; C12N005-06; A01N063-00
 EXF 424/93.21; 424/93.7; 435/325; 514/12; 514/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 153 OF 362 USPATFULL on STN
 AN 1999:106452 USPATFULL
 TI Compositions and methods for treating bone deficit conditions
 IN Petrie, Charles, Woodinville, WA, United States
 Orme, Mark W., Seattle, WA, United States
 Baidur, Nand, Edmonds, WA, United States
 Robbins, Kirk G., Renton, WA, United States
 Mundy, Gregory R., San Antonio, TX, United States
 PA Zymogenetic, Inc., Seattle, WA, United States (U.S. corporation)
 Osteoscreen, Inc., San Antonio, TX, United States (U.S. corporation)
 PI US 5948776 19990907 <--
 AI US 1997-808739 19970228 (8)
 RLI Continuation of Ser. No. US 1996-736318, filed on 23 Oct 1996, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1056
 INCL INCLM: 514/222.500
 INCLS: 514/223.200; 514/223.800; 514/224.200; 514/226.500; 514/229.200;
 514/230.500; 514/255.000; 514/258.000; 514/259.000; 514/296.000;
 514/307.000; 514/311.000; 514/336.000; 514/345.000; 514/352.000;
 514/354.000; 514/365.000; 514/457.000; 514/367.000; 514/374.000;
 514/375.000; 514/385.000; 514/394.000; 514/396.000; 514/397.000;
 514/415.000; 514/443.000; 514/535.000
 NCL NCLM: 514/222.500
 NCLS: 514/140.000; 514/223.200; 514/223.800; 514/224.200; 514/226.500;
 514/229.200; 514/230.500; 514/252.060; 514/255.050; 514/296.000;
 514/307.000; 514/311.000; 514/336.000; 514/345.000; 514/352.000;
 514/354.000; 514/365.000; 514/367.000; 514/374.000; 514/375.000;
 514/385.000; 514/394.000; 514/396.000; 514/397.000; 514/415.000;
 514/443.000; 514/457.000; 514/535.000

IC [6]
ICM: A61K031-165
ICS: A61K031-215; A61K031-33
EXF 574/222.5; 574/223.2; 574/223.8; 574/224.2; 574/226.5; 574/229.2;
574/230.5; 574/255; 574/258; 574/259; 574/296; 574/307; 574/311;
574/336; 574/345; 574/352; 574/354; 574/457; 574/365; 574/367; 574/374;
574/375; 574/385; 574/394; 574/396; 574/397; 574/415; 574/443; 574/535;
574/646

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 154 OF 362 USPATFULL on STN
AN 1999:106302 USPATFULL
TI Methods for the detection and isolation of biomolecules
IN Rothschild, Kenneth J., 97 Dorcar Rd., Newton, MA, United States 02159
Sonar, Sanjay M., 1575 Tremont St., Apt. 306, Boston, MA, United States
02120
Olejnik, Jerzy, 1307 Commonwealth Ave., Allston, MA, United States
02134
PI US 5948624 19990907 <--
AI US 1997-978897 19971126 (8)
RLI Continuation of Ser. No. US 1995-487909, filed on 7 Jun 1995, now
abandoned which is a continuation of Ser. No. US 1994-345807, filed on
22 Nov 1994 which is a continuation-in-part of Ser. No. US 1994-240511,
filed on 11 May 1994, now patented, Pat. No. US 5643722
DT Utility
FS Granted
LN.CNT 3916
INCL INCLM: 435/006.000
INCLS: 435/004.000; 435/005.000; 435/091.100; 435/091.210; 424/130.100;
536/022.100; 536/023.100
NCL NCLM: 435/006.000
NCLS: 424/130.100; 435/004.000; 435/005.000; 435/091.100; 435/091.210;
536/022.100; 536/023.100

IC [6]
ICM: C12Q001-68
ICS: C12P019-34; A61K039-395; C07H019-00
EXF 435/4; 435/5; 435/6; 435/91.1; 435/91.2; 424/130.1; 536/22.1; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 155 OF 362 USPATFULL on STN
AN 1999:106108 USPATFULL
TI Compositions and therapeutic methods using morphogenic proteins and
stimulatory factors
IN Lee, John C., San Antonio, TX, United States
Yeh, Lee-Chuan C., San Antonio, TX, United States
PA Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)
PI US 5948428 19990907 <--
AI US 1996-761468 19961206 (8)
RLI Continuation-in-part of Ser. No. US 1995-570752, filed on 12 Dec 1995
DT Utility
FS Granted
LN.CNT 3767
INCL INCLM: 424/426.000
INCLS: 523/114.000; 523/115.000; 623/016.000; 530/353.000
NCL NCLM: 424/426.000
NCLS: 523/114.000; 523/115.000; 530/353.000
IC [6]
ICM: A61F002-28
ICS: A61K038-17
EXF 424/426; 623/16; 523/114; 523/115; 530/356; 530/353
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 156 OF 362 USPATFULL on STN
AN 1999:102423 USPATFULL
TI Method for making non-crosslinked protein particles for therapeutic and
diagnostic use
IN Yen, Richard C. K., Glendora, CA, United States
PA Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)
PI US 5945033 19990831 <--
AI US 1996-747137 19961112 (8)
RLI Continuation of Ser. No. US 1994-212546, filed on 14 Mar 1994, now
patented, Pat. No. US 5616311 which is a continuation-in-part of Ser.
No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US
1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620
which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15
Jan 1991, now abandoned

DT Utility
FS Granted
LN.CNT 3655
INCL INCLM: 252/314.000
INCLS: 424/001.290; 424/499.000; 252/302.000; 428/402.000; 428/402.240;
427/213.300; 427/213.330; 427/213.310
NCL NCLM: 516/077.000
NCLS: 424/001.290; 424/499.000; 427/213.300; 427/213.310; 427/213.330;
428/402.000; 428/402.240
IC [6]
ICM: B01J013-00
ICS: A61K009-50; B32B005-16
EXF 424/499; 424/1.29; 424/1.37; 424/489; 424/491; 264/4.3; 264/4; 264/4.1;
264/5; 427/213.33; 427/213; 427/213.31; 428/402.2; 428/402.24; 428/402;
514/832; 514/965; 435/177; 252/302; 252/314
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 157 OF 362 USPATFULL on STN
AN 1999:96395 USPATFULL
TI Compositions and methods for treating bone deficit conditions
IN Petrie, Charles, Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
Baindur, Nand, Edmonds, WA, United States
Robbins, Kirk G., Renton, WA, United States
Mundy, Gregory R., San Antonio, TX, United States
PA Zymogenetic, Inc., Seattle, WA, United States (U.S. corporation)
Osteoscreen, Inc., San Antonio, TX, United States (U.S. corporation)
PI US 5939444 19990817 <--
AI US 1997-808740 19970228 (8)
RLI Continuation of Ser. No. US 1996-735873, filed on 23 Oct 1996, now
abandoned
DT Utility
FS Granted
LN.CNT 1003
INCL INCLM: 514/367.000
INCLS: 514/369.000; 514/370.000; 514/371.000
NCL NCLM: 514/367.000
NCLS: 514/369.000; 514/370.000; 514/371.000
IC [6]
ICM: A61K031-421
EXF 514/369; 514/370; 514/371; 514/367

L3 ANSWER 158 OF 362 USPATFULL on STN
AN 1999:92566 USPATFULL
TI Methods and compositions of growth control for cells encapsulated within
bioartificial organs
IN Schinstine, Malcolm, Bristol, RI, United States
Shoichet, Molly S., Canton, MA, United States
Gentile, Frank T., Warwick, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Holland, Laura M., Providence, RI, United States
Cain, Brian M., Everett, MA, United States
Doherty, Edward J., Mansfield, MA, United States
Winn, Shelley R., Smithfield, RI, United States
Aebischer, Patrick, Lutry, Switzerland
PA CytoTherapeutics, Inc., United States (U.S. corporation)
PI US 5935849 19990810 <--
AI US 1994-279773 19940720 (8)
DT Utility
FS Granted
LN.CNT 2234
INCL INCLM: 435/325.000
INCLS: 435/375.000; 435/377.000; 435/400.000
NCL NCLM: 435/325.000
NCLS: 435/375.000; 435/377.000; 435/400.000
IC [6]
ICM: C12N005-00
EXF 435/240.2; 435/240.22; 435/240.23; 435/240.242; 435/240.243; 435/325;
435/375; 435/377; 435/400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 159 OF 362 USPATFULL on STN
AN 1999:85562 USPATFULL
TI Carbohydrate-directed cross-linking reagents
IN Ashkenazi, Avi J., San Mateo, CA, United States
Chamow, Steven M., San Mateo, CA, United States

Kogan, Timothy P., Sugar Land, TX, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5929211 19990727 <--
 AI US 1997-923590 19970904 (8)
 RLI Continuation of Ser. No. US 1995-415018, filed on 31 Mar 1995 which is a continuation of Ser. No. US 1993-115404, filed on 1 Sep 1993, now abandoned which is a division of Ser. No. US 1992-926077, filed on 5 Aug 1992, now patented, Pat. No. US 5329028, issued on 12 Jul 1994
 DT Utility
 FS Granted
 LN.CNT 1082
 INCL INCLM: 530/351.000
 INCLS: 530/359.000; 530/380.000; 530/387.100; 530/389.100; 530/389.200; 530/391.100; 530/391.300; 530/391.500; 530/391.700; 530/391.900; 530/395.000; 530/396.000; 530/397.000; 530/398.000; 530/399.000; 424/085.100; 424/178.100; 424/179.100; 424/194.100; 424/195.110; 548/544.000; 548/546.000
 NCL NCLM: 530/351.000
 NCLS: 424/085.100; 424/178.100; 424/179.100; 424/194.100; 424/195.110; 530/359.000; 530/380.000; 530/387.100; 530/389.100; 530/389.200; 530/391.100; 530/391.300; 530/391.500; 530/391.700; 530/391.900; 530/395.000; 530/396.000; 530/397.000; 530/398.000; 530/399.000; 548/544.000; 548/546.000
 IC [6]
 ICM: C07K015-14
 ICS: C07D207-452
 EXF 548/546; 548/544; 548/547; 548/548; 548/549; 530/351; 530/359; 530/387.1; 530/395; 530/396; 530/397; 530/398; 530/399; 530/380; 530/389.1; 530/389.2; 530/391.1; 530/391.3; 530/391.5; 530/391.7; 530/391.9; 514/8; 514/12; 514/21; 424/85.1; 424/178.1; 424/179.1; 424/194.1; 424/195.11
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 160 OF 362 USPATFULL on STN
 AN 1999:85291 USPATFULL
 TI Morphogen-responsive signal transducer and methods of use thereof
 IN Sampath, Kuber T., Holliston, MA, United States
 Takeda, Kohsuke, Ichikawa, Japan
 Ichijo, Hidenori, Tokyo, Japan
 PA Creative BioMolecules, Inc., Boston, MA, United States (U.S. corporation)
 PI US 5928940 19990727 <--
 AI US 1996-727118 19961008 (8)
 PRAI US 1996-25311P 19960924 (60)
 DT Utility
 FS Granted
 LN.CNT 2733
 INCL INCLM: 435/325.000
 INCLS: 435/006.000; 435/007.100; 435/320.100; 536/023.500; 536/024.310; 935/009.000; 935/066.000
 NCL NCLM: 435/325.000
 NCLS: 435/006.000; 435/007.100; 435/320.100; 536/023.500; 536/024.310
 IC [6]
 ICM: C12N005-00
 ICS: C12N015-00; C07H021-04
 EXF 536/23.1; 536/23.5; 536/24.1; 536/24.5; 435/6; 435/7.1; 435/320.1; 435/325; 935/9; 935/66
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 161 OF 362 USPATFULL on STN
 AN 1999:81535 USPATFULL
 TI Canine granulocyte macrophage colony stimulating factor
 IN Nash, Richard A., Seattle, WA, United States
 Storb, Rainer, Seattle, WA, United States
 PA Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S. corporation)
 PI US 5925343 19990720 <--
 AI US 1997-902513 19970729 (8)
 RLI Division of Ser. No. US 1994-259696, filed on 14 Jun 1994, now patented, Pat. No. US 5702919 which is a continuation of Ser. No. US 1990-616678, filed on 21 Nov 1990, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1239
 INCL INCLM: 424/085.100

NCL INCLS: 530/351.000; 530/395.000
NCLM: 424/085.100
NCLS: 530/351.000; 530/395.000
IC [6]
ICM: C07K014-535
EXF 530/395; 530/351; 424/85.1; 514/2; 514/8; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 162 OF 362 USPATFULL on STN
AN 1999:78758 USPATFULL
TI Methods for treating bone deficit conditions with benzothiazole
IN Petrie, Charles, Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
Baindur, Nand, Edmonds, WA, United States
Robbins, Kirk G., Renton, WA, United States
Hurley, Laurence H., Austin, TX, United States
Kerwin, Sean M., Round Rock, TX, United States
Mundy, Gregory R., San Antonio, TX, United States
PA Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation)
OsteoScreen, Inc., San Antonio, TX, United States (U.S. corporation)
University of Texas at Austin, Austin, TX, United States (U.S. corporation)
PI US 5922753 19990713 <--
AI US 1997-808742 19970228 (8)
RLI Continuation of Ser. No. US 1996-735881, filed on 23 Oct 1996, now abandoned
DT Utility
FS Granted
LN.CNT 965
INCL INCLM: 514/447.000
INCLS: 514/430.000; 514/439.000; 514/443.000
NCL NCLM: 514/447.000
NCLS: 514/430.000; 514/439.000; 514/443.000
IC [6]
ICM: A61K031-38
ICS: A61K031-385
EXF 514/447; 514/430; 514/439; 514/443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 163 OF 362 USPATFULL on STN
AN 1999:78555 USPATFULL
TI Process for screening substances having a modulating effect on an interleukin-5 receptor mediated cellular signal transmission pathway
IN Czernilofsky, Armin Peter, Vienna, Austria
Weyer, Ulrike, Vienna, Austria
Young, Ian G., Hawker, Australia
PA Boehringer Ingelheim International GmbH, Germany, Federal Republic of (non-U.S. corporation)
PI US 5922549 19990713 <--
WO 9428170 19941208 <--
AI US 1996-553304 19960529 (8)
WO 1994-EP1735 19940527
19960529 PCT 371 date
19960529 PCT 102(e) date
PRAI DE 1993-4317577 19930527
DT Utility
FS Granted
LN.CNT 1279
INCL INCLM: 435/007.200
INCLS: 435/007.100; 435/007.210; 435/007.330; 435/069.100; 435/325.000;
435/352.000; 435/363.000; 435/366.000; 435/252.300
NCL NCLM: 435/007.200
NCLS: 435/007.100; 435/007.210; 435/007.330; 435/069.100; 435/252.300;
435/325.000; 435/352.000; 435/363.000; 435/366.000
IC [6]
ICM: G01N033-566
EXF 435/7.1; 435/7.21; 435/7.33; 435/69.1; 435/325; 435/352; 435/363;
435/366; 435/252.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 164 OF 362 USPATFULL on STN
AN 1999:75664 USPATFULL
TI Compositions and methods for treating bone deficit conditions
IN Petrie, Charles, Woodinville, WA, United States
Orme, Mark W., Seattle, WA, United States
Baindur, Nand, Edmonds, WA, United States

Robbins, Kirk G., Renton, WA, United States
Kontoyianni, Maria, Seattle, WA, United States
Mundy, Gregory R., San Antonio, TX, United States
PA Zymogenetics, Inc., Seattle, WA, United States (U.S. corporation)
Osteoscreen, Inc., San Antonio, TX, United States (U.S. corporation)
PI US 5919808 19990706 <--
AI US 1997-808743 19970228 (8)
RLI Continuation of Ser. No. US 1996-735876, filed on 23 Oct 1996, now
abandoned
DT Utility
FS Granted
LN.CNT 975
INCL INCLM: 514/372.000
INCLS: 514/369.000; 514/399.000; 514/398.000; 514/376.000; 514/377.000;
514/385.000; 514/374.000; 514/395.000
NCL NCLM: 514/372.000
NCLS: 514/369.000; 514/374.000; 514/376.000; 514/377.000; 514/385.000;
514/395.000; 514/398.000; 514/399.000
IC [6]
ICM: A61K031-425
ICS: A61K031-415; A61K031-42
EXF 514/369; 514/399; 514/398; 514/372; 514/374; 514/376; 514/377; 514/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 165 OF 362 USPATFULL on STN
AN 1999:75500 USPATFULL
TI Methods and compositions for the use of apurinic/aprimidinic
endonucleases
IN Kelley, Mark R., Zionsville, IN, United States
Duguid, John, Brownsburg, IN, United States
Eble, John, Indianapolis, IN, United States
PA Advanced Research & Technology Institute, Bloomington, IN, United States
(U.S. corporation)
PI US 5919643 19990706 <--
AI US 1997-872719 19970611 (8)
PRAI US 1996-19561P 19960611 (60)
US 1996-19602P 19960611 (60)
DT Utility
FS Granted
LN.CNT 4677
INCL INCLM: 435/019.000
INCLS: 435/199.000
NCL NCLM: 435/019.000
NCLS: 435/199.000
IC [6]
ICM: C12Q001-44
ICS: C12N009-22
EXF 435/19; 435/199
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 166 OF 362 USPATFULL on STN
AN 1999:72602 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and
uses therefore
IN Lai, Ching-San, Encinitas, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5916910 19990629 <--
AI US 1997-869158 19970604 (8)
DT Utility
FS Granted
LN.CNT 1842
INCL INCLM: 514/423.000
INCLS: 514/514.000; 548/564.000; 548/573.000; 558/235.000
NCL NCLM: 514/423.000
NCLS: 514/514.000; 548/564.000; 548/573.000; 558/235.000
IC [6]
ICM: C07D207-04
ICS: C07D207-30; A61K031-27; A61K031-40
EXF 514/514; 514/423; 548/565; 548/573; 558/235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 167 OF 362 USPATFULL on STN
AN 1999:72563 USPATFULL
TI Compositions and therapeutic methods using morphogenic proteins and
stimulatory factors
IN Lee, John C., San Antonio, TX, United States

Yeh, Lee-Chuan C., San Antonio, TX, United States
PA Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)
PI US 5916870 19990629 <--
AI US 1998-158220 19980922 (9)
RLI Division of Ser. No. US 1998-27873, filed on 23 Feb 1998 which is a
division of Ser. No. US 1995-570752, filed on 12 Dec 1995
DT Utility
FS Granted
LN.CNT 3176
INCL INCLM: 514/002.000
INCLS: 514/021.000; 623/011.000; 623/012.000; 623/016.000
NCL NCLM: 514/002.000
NCLS: 514/021.000
IC [6]
ICM: A61K038-00
ICS: A61F002-02; A61F002-04; A61F002-28
EXF 514/2; 514/21; 623/11; 623/12; 623/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 168 OF 362 USPATFULL on STN
AN 1999:69622 USPATFULL
TI Screening assay for the identification of agents which alter expression
of PTH-rP
IN Mundy, Gregory R., San Antonio, TX, United States
Gallwitz, Wolfgang E., San Antonio, TX, United States
PA Osteo Screen, San Antonio, TX, United States (U.S. corporation)
PI US 5914233 19990622 <--
AI US 1997-915868 19970821 (8)
PRAI US 1996-25215P 19960823 (60)
DT Utility
FS Granted
LN.CNT 1391
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/007.210; 435/007.230; 435/069.100; 435/029.000;
435/375.000; 436/501.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/007.210; 435/007.230; 435/029.000; 435/069.100;
435/375.000; 436/501.000
IC [6]
ICM: C12Q001-68
ICS: G01N033-566; C12N005-10
EXF 435/6; 435/7.1; 435/7.2; 435/7.21; 435/7.23; 435/69.1; 435/29; 435/375;
436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 169 OF 362 USPATFULL on STN
AN 1999:63096 USPATFULL
TI Compositions and methods for the delivery of biologically active
molecules using genetically altered cells contained in biocompatible
immunoisulatory capsules
IN Baetge, Edward E., Barrington, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Gentile, Frank T., Warwick, RI, United States
Lindner, Mark D., Bristol, RI, United States
Winn, Shelley R., Smithfield, RI, United States
Emerich, Dwaine F., Providence, RI, United States
PA CytoTherapeutics, Inc., Lincoln, RI, United States (U.S. corporation)
PI US 5908623 19990601 <--
AI US 1995-450862 19950525 (8)
RLI Continuation-in-part of Ser. No. WO 1994-US9299, filed on 12 Aug 1994
which is a continuation-in-part of Ser. No. US 1993-105278, filed on 12
Aug 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2408
INCL INCLM: 424/093.210
INCLS: 424/093.200
NCL NCLM: 424/093.210
NCLS: 424/093.200
IC [6]
ICM: A01N063-00
EXF 424/93.21; 424/408; 424/422; 424/424; 424/93.1; 424/93.2; 435/284.1;
435/285.1; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 170 OF 362 USPATFULL on STN

AN 1999:56457 USPATFULL
 TI Cartilage induction by bone morphogenetic proteins
 IN Hattersley, Gary, Cambridge, MA, United States
 Wolfman, Neil M., Dover, MA, United States
 Morris, Elisabeth A., Southboro, MA, United States
 Rosen, Vicki A., Chestnut Hill, MA, United States
 PA Genetics Institute, Inc., Cambridge, MA, United States (U.S.
 corporation)
 PI US 5902785 19990511 <--
 AI US 1996-646193 19960507 (8)
 RLI Continuation-in-part of Ser. No. US 1995-467110, filed on 6 Jun 1995,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 811
 INCL INCLM: 514/002.000
 INCLS: 514/008.000; 514/012.000
 NCL NCLM: 514/002.000
 NCLS: 514/008.000; 514/012.000
 IC [6]
 ICM: A61K038-16
 ICS: A61K038-18
 EXF 514/2; 514/8; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 171 OF 362 USPATFULL on STN
 AN 1999:40569 USPATFULL
 TI Carbohydrate-directed cross-linking reagents
 IN Ashkenazi, Avi J., San Mateo, CA, United States
 Chamow, Steven M., San Mateo, CA, United States
 Kogan, Timothy P., Sugar Land, TX, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 5889155 19990330 <--
 AI US 1995-415018 19950331 (8)
 RLI Continuation of Ser. No. US 1993-115404, filed on 1 Sep 1993, now
 abandoned which is a division of Ser. No. US 1992-926077, filed on 5 Aug
 1992, now patented, Pat. No. US 5329028, issued on 12 Jul 1994
 DT Utility
 FS Granted
 LN.CNT 1075
 INCL INCLM: 530/351.000
 INCLS: 530/391.100; 530/391.300; 530/391.500; 530/391.700; 530/391.900;
 530/395.000; 530/396.000; 530/397.000; 530/398.000; 514/008.000;
 514/012.000; 514/021.000; 424/085.100; 424/178.100; 424/179.100;
 424/194.100; 424/195.110
 NCL NCLM: 530/351.000
 NCLS: 424/085.100; 424/178.100; 424/179.100; 424/194.100; 424/195.110;
 530/391.100; 530/391.300; 530/391.500; 530/391.700; 530/391.900;
 530/395.000; 530/396.000; 530/397.000; 530/398.000
 IC [6]
 ICM: C07K015-14
 EXF 548/546; 530/351; 530/391.1; 530/391.3; 530/391.5; 530/391.7; 530/391.9;
 530/395; 530/396; 530/397; 530/398; 514/8; 514/12; 514/21; 424/85.1;
 424/178.1; 424/179.1; 424/194.1; 424/195.11
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 172 OF 362 USPATFULL on STN
 AN 1999:40383 USPATFULL
 TI Treatment of bone disorders with adrenomedullin
 IN Coy, David H., New Orleans, LA, United States
 Cornish, Jillian, Mission Bay, New Zealand
 Reid, Ian Reginald, Mt. Albert, New Zealand
 Cooper, Garth James Smith, Herne Bay, New Zealand
 PA Auckland Uniservices Limited, Auckland, New Zealand (non-U.S.
 corporation)
 The Administrators of The Tulane Educational Fund, New Orleans, LA,
 United States (U.S. corporation)
 PI US 5888963 19990330 <--
 AI US 1996-634562 19960418 (8)
 DT Utility
 FS Granted
 LN.CNT 517
 INCL INCLM: 514/002.000
 INCLS: 514/012.000; 424/198.100; 424/422.000; 424/434.000; 530/300.000;
 530/324.000; 530/325.000; 530/336.000; 530/326.000; 930/010.000

NCL NCLM: 514/002.000
NCLS: 424/198.100; 424/422.000; 424/434.000; 514/012.000; 530/300.000;
530/324.000; 530/325.000; 530/326.000; 530/336.000; 930/010.000
IC [6]
ICM: A01N037-18
ICS: C07K014-00; C07K014-51
EXF 424/434; 424/422; 424/198.1; 514/2; 514/12; 530/300; 530/324; 530/325;
530/333; 530/326; 930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 173 OF 362 USPATFULL on STN
AN 1999:40236 USPATFULL
TI Cell cultures of and cell culturing method for nontransformed
pancreatic, thyroid, and ***parathyroid*** cells
IN Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impiomato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PA Human Cell Cultures Inc., East Sebago, ME, United States (U.S.
corporation)
PI US 5888816 19990330 <--
AI US 1995-480022 19950607 (8)
RLI Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1993-44010,
filed on 8 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1992
INCL INCLM: 435/366.000
INCLS: 435/325.000; 435/378.000; 435/382.000; 435/383.000; 435/391.000;
435/392.000; 435/404.000; 435/408.000
NCL NCLM: 435/366.000
NCLS: 435/325.000; 435/378.000; 435/382.000; 435/383.000; 435/391.000;
435/392.000; 435/404.000; 435/408.000
IC [6]
ICM: C12N005-00
ICS: C12N005-02
EXF 435/240.2; 435/240.21; 435/240.3; 435/240.31; 435/404; 435/408; 435/325;
435/366; 435/378; 435/382; 435/383; 435/391; 435/392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 174 OF 362 USPATFULL on STN
AN 1999:40233 USPATFULL
TI Monoclonal antibodies against human pancreatic islet cells
IN Endl, Josef, Weilheim, Germany, Federal Republic of
Brandt, Michael, Iffendorf, Germany, Federal Republic of
Jungfer, Herbert, Starnberg, Germany, Federal Republic of
Albert, Winfried, Eberfing, Germany, Federal Republic of
Kientsch-Engel, Rosemarie, Feldafing, Germany, Federal Republic of
Scherbaum, Werner, Ulm, Germany, Federal Republic of
Richter, Wiltrud, Ulm, Germany, Federal Republic of
Eiermann, Thomas, Ulm, Germany, Federal Republic of
PA Boehringer Mannheim GmbH, Germany, Federal Republic of (non-U.S.
corporation)
PI US 5888813 19990330 <--
AI US 1995-554796 19951107 (8)
RLI Continuation of Ser. No. US 1993-173490, filed on 27 Dec 1993, now
abandoned which is a continuation of Ser. No. US 1992-835755, filed on
13 Feb 1992, now abandoned
PRAI DE 1991-4104498 19910214
DE 1991-4129849 19910907
DT Utility
FS Granted
LN.CNT 711
INCL INCLM: 435/338.000
INCLS: 435/372.200; 436/506.000; 530/388.150; 530/413.000
NCL NCLM: 435/338.000
NCLS: 435/372.200; 436/506.000; 530/388.150; 530/413.000
IC [6]
ICM: C12N005-08
ICS: C07K016-18
EXF 435/7.1; 435/7.4; 435/7.5; 435/7.9; 435/70.21; 435/965; 435/338;
435/372.2; 424/85.8; 436/506; 436/548; 530/303; 530/413; 530/845;
530/388.15; 530/387.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 175 OF 362 USPATFULL on STN

AN 1999:40186 USPATFULL
TI Human fas gene promoter region
IN Mountz, John D., Birmingham, AL, United States
Liu, Changdan, Alabaster, AL, United States
Cheng, Jianhua, Alabaster, AL, United States
Koopman, William J., Indian Springs, AL, United States
Zhou, Tong, W. Stonebrook Pl., AL, United States
PA UAB Research Foundation, Birmingham, AL, United States (U.S.
corporation)
PI US 5888764 19990330 <--
AI US 1995-377522 19950120 (8)
DT Utility
FS Granted
LN.CNT 2944
INCL INCLM: 435/069.100
INCLS: 435/172.300; 435/252.300; 435/320.100; 435/325.000; 536/023.500;
536/023.510; 536/024.100; 536/024.310
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 435/455.000; 435/458.000;
435/471.000; 435/472.000; 435/476.000; 536/023.500; 536/023.510;
536/024.100; 536/024.310
IC [6]
ICM: C12N001-21
ICS: C12N005-10; C12N015-11; C12P021-00
EXF 536/24.1; 536/24.31; 536/23.5; 536/23.51; 435/320.1; 435/325; 435/69.1;
435/252.3; 435/172.3; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 176 OF 362 USPATFULL on STN
AN 1999:37140 USPATFULL
TI Anti-angiogenic compositions and methods of use
IN Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
Arsenault, A. Larry, Paris, Canada
PA Angiotech Pharmaceuticals Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5886026 19990323 <--
AI US 1995-472413 19950607 (8)
RLI Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned
which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19
Jul 1993, now abandoned
PRAI WO 1994-CA373 19940719
DT Utility
FS Granted
LN.CNT 4997
INCL INCLM: 514/449.000
NCL NCLM: 514/449.000
IC [6]
ICM: A61K031-335
EXF 514/250; 514/210; 514/449; 514/886; 514/825
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 177 OF 362 USPATFULL on STN
AN 1999:30363 USPATFULL
TI Administration of thrombopoietin on a single day only
IN Thomas, Griffith Roger, Burlingame, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5879673 19990309 <--
AI US 1996-697631 19960828 (8)
RLI Continuation-in-part of Ser. No. US 1996-591925, filed on 25 Jan 1996,
now abandoned And a continuation of Ser. No. US 1996-641443, filed on
29 Apr 1996, now abandoned
DT Utility
FS Granted
LN.CNT 1818
INCL INCLM: 424/085.100
INCLS: 424/192.100; 424/193.100; 435/069.500; 435/069.700; 530/351.000;
530/402.000
NCL NCLM: 424/085.100
NCLS: 424/192.100; 424/193.100; 435/069.500; 435/069.700; 530/351.000;
530/402.000
IC [6]
ICM: A61K038-19
EXF 530/351; 530/402; 435/69.1; 435/69.5; 435/172.1; 435/69.7; 424/85.1;
424/192.1; 424/193.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 178 OF 362 USPATFULL on STN
 AN 1999:27758 USPATFULL
 TI Compacted nucleic acids and their delivery to cells
 IN Hanson, Richard W., Cleveland Heights, OH, United States
 Perales, Jose C., Cleveland Heights, OH, United States
 Ferkol, Thomas W., Euclid, OH, United States
 PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
 Ohio University, Athens, OH, United States (U.S. corporation)
 PI US 5877302 19990302 <--
 WO 9525809 19950928 <--
 AI US 1997-716415 19970212 (8)
 WO 1995-US3677 19950323
 19970212 PCT 371 date
 19970212 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1994-216534, filed on 23 Mar 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 3650
 INCL INCLM: 536/023.100
 NCL NCLM: 536/023.100
 IC [6]
 ICM: C12N015-11
 EXF 435/172.3; 435/91.1; 536/23.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 179 OF 362 USPATFULL on STN
 AN 1999:27435 USPATFULL
 TI Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation
 IN Spengler, Dietmar, Munich, Germany, Federal Republic of
 Journot, Laurent, Pignan, France
 PA Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Berlin, Germany, Federal Republic of (non-U.S. corporation)
 CNRS, Montpellier, France (non-U.S. corporation)
 PI US 5876972 19990302 <--
 AI US 1996-718661 19960923 (8)
 DT Utility
 FS Granted
 LN.CNT 2193
 INCL INCLM: 435/069.100
 INCLS: 435/172.300; 435/252.300; 435/325.000; 435/410.000; 435/320.100; 536/023.500
 NCL NCLM: 435/069.100
 NCLS: 435/006.000; 435/252.300; 435/320.100; 435/325.000; 435/410.000; 536/023.500
 IC [6]
 ICM: C12P021-00
 ICS: C12N015-12
 EXF 435/172.3; 435/320.1; 435/252.3; 435/325; 435/410; 435/69.1; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 180 OF 362 USPATFULL on STN
 AN 1999:22200 USPATFULL
 TI Antibody having binding specificity to ***parathyroid*** hormone related protein (PTHrP) and kit comprising the same
 IN Martin, Thomas J., Kew, Australia
 Moseley, Jane M., North Balwyn, Australia
 Kemp, Bruce E., Kew, Australia
 Wettenhall, Richard E. H., Camberwell, Australia
 PA The University of Melbourne, Victoria, Australia (non-U.S. corporation)
 PI US 5872221 19990216 <--
 AI US 1993-8696 19930125 (8)
 RLI Division of Ser. No. US 1991-715280, filed on 14 Jun 1991, now patented, Pat. No. US 5460978 which is a division of Ser. No. US 1988-199235, filed on 9 May 1988, now patented, Pat. No. US 5116952
 PRAI AU 1987-349 19870213
 AU 1996-702786 19960718
 DT Utility
 FS Granted
 LN.CNT 942
 INCL INCLM: 530/388.850
 INCLS: 530/387.700; 530/387.900; 530/389.100; 530/389.200; 530/389.700; 530/388.240; 530/388.230; 530/388.800; 530/391.100; 530/391.300;

530/326.000; 530/327.000; 530/324.000; 530/350.000; 530/388.260;
436/518.000; 435/975.000
NCL NCLM: 530/388.850
NCLS: 435/975.000; 436/518.000; 530/324.000; 530/326.000; 530/327.000;
530/350.000; 530/387.700; 530/387.900; 530/388.230; 530/388.240;
530/388.260; 530/388.800; 530/389.100; 530/389.200; 530/389.700;
530/391.100; 530/391.300

IC [6]

ICM: C07K016-18

ICS: C07K016-24; C07K016-44; C07K016-40

EXF 530/387.7; 530/387.9; 530/389.1; 530/389.2; 530/389.7; 530/388.24;
530/388.23; 530/388.8; 530/391.1; 530/391.3; 530/326; 530/327; 530/324;
530/350; 530/288.26; 530/388.85; 436/518; 435/240.27; 435/70.21;
435/975; 435/326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 181 OF 362 USPATFULL on STN

AN 1999:18912 USPATFULL

TI Method of determining DNA sequence preference of a DNA-binding molecule

IN Edwards, Cynthia A., Menlo Park, CA, United States

Cantor, Charles R., Boston, MA, United States

Andrews, Beth M., Maynard, MA, United States

Turin, Lisa M., Redwood City, CA, United States

Fry, Kirk E., Palo Alto, CA, United States

PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
corporation)

PI US 5869241 19990209 <--

AI US 1995-475228 19950607 (8)

RLI Division of Ser. No. US 1993-171389, filed on 20 Dec 1993, now patented,
Pat. No. US 5578444 which is a continuation-in-part of Ser. No. US
1993-123936, filed on 17 Sep 1993, now patented, Pat. No. US 5726014
which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23
Dec 1992, now patented, Pat. No. US 5693463 which is a
continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
now abandoned

DT Utility

FS Granted

LN.CNT 9840

INCL INCLM: 435/006.000

INCLS: 435/911.000; 435/912.000; 935/077.000; 935/078.000

NCL NCLM: 435/006.000

NCLS: 435/091.100; 435/091.200

IC [6]

ICM: C12Q001-68

ICS: C12P019-34

EXF 435/6; 435/91.1; 435/91.2; 935/77; 935/78

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 182 OF 362 USPATFULL on STN

AN 1999:18720 USPATFULL

TI Altered polypeptides with increased half-life

IN Presta, Leonard G., San Francisco, CA, United States

Snedecor, Bradley R., Portola Valley, CA, United States

PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)

PI US 5869046 19990209 <--

AI US 1995-422092 19950414 (8)

DT Utility

FS Granted

LN.CNT 3287

INCL INCLM: 424/133.100

INCLS: 424/153.100; 435/172.100; 530/387.300; 530/388.150; 530/388.700;
530/391.100

NCL NCLM: 424/133.100

NCLS: 424/153.100; 530/387.300; 530/388.150; 530/388.700; 530/391.100

IC [6]

ICM: A61K039-395

ICS: C12N015-13; C12P021-08; C07K016-28

EXF 435/69.7; 435/172.1; 530/387.3; 530/388.15; 530/391.1; 424/133.1;
424/153.1; 935/15

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 183 OF 362 USPATFULL on STN

AN 1999:15698 USPATFULL

TI Compositions and methods for screening drug libraries

IN Spinella, Dominic Gregory, San Diego, CA, United States

Becherer, Kathleen Ann, San Diego, CA, United States

Brown, Steven Joel, San Diego, CA, United States
PA Chugai Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5866341 19990202 <--
AI US 1996-627151 19960403 (8)
DT Utility
FS Granted
LN.CNT 2082
INCL INCLM: 435/071.000
INCLS: 435/004.000; 435/005.000; 435/006.000; 435/007.200; 435/007.920
NCL NCLM: 435/007.100
NCLS: 435/004.000; 435/005.000; 435/006.000; 435/007.200; 435/007.920
IC [6]
ICM: G01N033-53
EXF 435/4; 435/5; 435/6; 435/7.1; 435/7.2; 435/7.92
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 184 OF 362 USPATFULL on STN
AN 1999:12753 USPATFULL
TI Methods of antagonizing OP-1 binding to a cell surface receptor
utilizing ALK polypeptides
IN Dijke, Peter ten, Upsala, Sweden
Heldin, Carl-Henrik, Upsala, Sweden
Miyazono, Kohei, Tokyo, Japan
Sampath, Kuber T., Medway, MA, United States
PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S.
corporation)
PI US 5863738 19990126 <--
WO 9530003 19951109 <--
AI US 1995-481337 19950602 (8)
WO 1995-US5467 19950428
19960422 PCT 371 date
19960422 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-236428, filed on 29 Apr 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 2755
INCL INCLM: 435/007.100
INCLS: 435/007.200; 436/501.000
NCL NCLM: 435/007.100
NCLS: 435/007.200; 436/501.000
IC [6]
ICM: G01N033-53
EXF 435/7.1; 435/7.2; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 185 OF 362 USPATFULL on STN
AN 1999:12558 USPATFULL
TI Compositions for targeting the vasculature of solid tumors
IN Thorpe, Philip E., Dallas, TX, United States
Burrows, Francis J., San Diego, CA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United
States (U.S. corporation)
PI US 5863538 19990126 <--
AI US 1995-457487 19950601 (8)
RLI Division of Ser. No. US 1994-350212, filed on 5 Dec 1994 which is a
continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994,
now patented, Pat. No. US 5855866 which is a continuation-in-part of
Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 5977
INCL INCLM: 424/136.100
INCLS: 424/138.100; 424/141.100; 424/154.100; 424/155.100; 424/172.100;
424/173.100; 424/174.100; 424/181.100; 530/388.220; 530/387.700;
530/387.300
NCL NCLM: 424/136.100
NCLS: 424/138.100; 424/141.100; 424/154.100; 424/155.100; 424/172.100;
424/173.100; 424/174.100; 424/181.100; 530/387.300; 530/387.700;
530/388.220
IC [6]
ICM: A61K039-395
ICS: C12P021-08; C07K016-00
EXF 424/136.1; 424/138.1; 424/141.1; 424/154.1; 424/155.1; 424/172.1;
424/173.1; 424/174.1; 424/181.1; 530/387.3; 530/387.7; 530/388.22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 186 OF 362 USPATFULL on STN
AN 1999:7466 USPATFULL
TI Morphogen cell surface receptor
IN Jin, Donald F., Shrewsbury, MA, United States
Oppermann, Hermann, Medway, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
Smart, John E., Weston, MA, United States
PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S.
corporation)
PI US 5861479 19990119 <--
AI US 1995-459009 19950602 (8)
RLI Division of Ser. No. US 1994-357533, filed on 16 Dec 1994 which is a
continuation of Ser. No. US 1993-73199, filed on 7 Jun 1993, now
abandoned
DT Utility
FS Granted
LN.CNT 1931
INCL INCLM: 530/324.000
INCLS: 530/399.000; 435/007.230; 435/006.000; 536/023.510; 536/023.500;
536/024.330
NCL NCLM: 530/324.000
NCLS: 435/006.000; 435/007.230; 530/399.000; 536/023.500; 536/023.510;
536/024.330
IC [6]
ICM: A61K038-00
ICS: A61K038-24; G01N033-574; C12Q001-68
EXF 435/7.2; 435/7.23; 435/6; 424/185.1; 530/399; 536/23.51; 536/23.5;
536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 187 OF 362 USPATFULL on STN
AN 1999:4408 USPATFULL
TI Control of cell growth in a bioartificial organ with extracellular
matrix coated microcarriers
IN Schinstine, Malcolm, Ben Salem, PA, United States
Shoichet, Molly S., Toronto, Canada
Gentile, Frank T., Warwick, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Holland, Laura M., Horsham, PA, United States
Cain, Brian M., Everett, MA, United States
Doherty, Edward J., Mansfield, MA, United States
Winn, Shelley R., Smithfield, RI, United States
Aebischer, Patrick, Lutry, Switzerland
PA CytoTherapeutics, Inc., United States (U.S. corporation)
PI US 5858747 19990112 <--
AI US 1995-447810 19950523 (8)
RLI Division of Ser. No. US 1995-432698, filed on 9 May 1995 which is a
continuation-in-part of Ser. No. US 1994-279773, filed on 20 Jul 1994
DT Utility
FS Granted
LN.CNT 2333
INCL INCLM: 435/182.000
INCLS: 424/093.210; 424/093.700; 424/422.000; 435/176.000; 435/177.000;
435/178.000; 435/377.000; 435/382.000; 435/395.000; 435/403.000;
435/289.100
NCL NCLM: 435/182.000
NCLS: 424/093.210; 424/093.700; 424/422.000; 435/176.000; 435/177.000;
435/178.000; 435/289.100; 435/377.000; 435/382.000; 435/395.000;
435/403.000
IC [6]
ICM: C12N011-04
ICS: C12N005-06; C12N005-08; C12N011-02
EXF 435/178; 435/240.2; 435/240.22; 435/240.23; 435/240.24; 435/240.241;
435/240.242; 435/240.243; 435/182; 435/176; 435/177; 435/377; 435/382;
435/395; 435/403; 435/289.1; 424/93.7; 424/93.21; 424/422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 188 OF 362 USPATFULL on STN
AN 1999:1209 USPATFULL
TI Methods for treating the vasculature of solid tumors
IN Thorpe, Philip E., Dallas, TX, United States
Burrows, Francis J., Dallas, TX, United States
PA Board of Regenis, The University of Texas System, Austin, TX, United
States (U.S. corporation)
PI US 5855866 19990105 <--

AI US 1994-205330 19940302 (8)
RLI Continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992,
now abandoned
DT Utility
FS Granted
LN.CNT 5207
INCL INCLM: 424/001.490
INCLS: 424/178.100; 424/156.100; 424/183.100; 424/142.100; 424/155.100;
424/181.100; 530/391.700; 530/391.900; 530/387.100; 530/388.150;
530/388.220; 530/388.800; 530/391.300
NCL NCLM: 424/001.490
NCLS: 424/142.100; 424/155.100; 424/156.100; 424/178.100; 424/181.100;
424/183.100; 530/387.100; 530/388.150; 530/388.220; 530/388.800;
530/391.300; 530/391.700; 530/391.900
IC [6]
ICM: A61K051-10
ICS: A61K039-395; C07K016-00
EXF 530/391.7; 530/391.9; 530/387.1; 530/388.15; 530/388.22; 530/388.8;
530/391.3; 424/139.1; 424/156.1; 424/183.1; 424/1.49; 424/1.53;
424/178.1; 424/9.34; 424/142.1; 424/155.1; 424/181.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 189 OF 362 USPATFULL on STN
AN 1998:162472 USPATFULL
TI Compositions and therapeutic methods using morphogenic proteins and
stimulatory factors
IN Lee, John C., San Antonio, TX, United States
Yeh, Lee-Chuan C., San Antonio, TX, United States
PA Stryker Corporation, Kalamazoo, MI, United States (U.S. corporation)
PI US 5854207 19981229 <--
AI US 1998-27873 19980223
RLI Division of Ser. No. US 1995-570752, filed on 12 Dec 1995
DT Utility
FS Granted
LN.CNT 3072
INCL INCLM: 514/002.000
INCLS: 514/021.000
NCL NCLM: 514/002.000
NCLS: 514/021.000
IC [6]
ICM: A01N037-18
ICS: A01N038-00
EXF 514/2; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 190 OF 362 USPATFULL on STN
AN 1998:162340 USPATFULL
TI OP-3- induced morphogenesis
IN Oppermann, Hermann, Medway, MA, United States
Ozkaynak, Engin, Milford, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
Rueger, David C., Hopkinton, MA, United States
Pang, Roy H. L., Etna, NH, United States
Cohen, Charles M., Medway, MA, United States
PA Creative BioMolecules, Inc., Boston, MA, United States (U.S.
corporation)
PI US 5854071 19981229 <--
AI US 1997-901200 19970728 (8)
RLI Division of Ser. No. US 1995-479666, filed on 7 Jun 1995, now patented,
Pat. No. US 5652337 which is a division of Ser. No. US 1992-971091,
filed on 3 Nov 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1992-922813, filed on 31 Jul 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1991-752964, filed on 29 Aug 1991,
now abandoned which is a continuation-in-part of Ser. No. US
1991-667274, filed on 11 Mar 1991, now abandoned And a
continuation-in-part of Ser. No. US 1992-923780, filed on 31 Jul 1992,
now abandoned which is a continuation-in-part of Ser. No. US
1991-752764, filed on 30 Aug 1991, now abandoned And a
continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991,
now abandoned which is a continuation-in-part of Ser. No. US
1992-946238, filed on 16 Sep 1992, now abandoned And a
continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991,
now abandoned And a continuation-in-part of Ser. No. US 1992-938336,
filed on 28 Aug 1992, now abandoned And a continuation-in-part of Ser.
No. US 1992-938337, filed on 28 Aug 1992, now abandoned And a
continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991,

now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned And a continuation of Ser. No. US 1992-938021, filed on 28 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-752861, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned which is a continuation-in-part of Ser. No. US 1992-945285, filed on 15 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-945286, filed on 15 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1992-946235, filed on 16 Sep 1992, now abandoned

DT Utility
FS Granted
LN.CNT 3245
INCL INCLM: 435/353.000
INCLS: 435/325.000; 435/366.000; 530/350.000; 530/399.000
NCL NCLM: 435/353.000
NCLS: 435/325.000; 435/366.000; 530/350.000; 530/399.000
IC [6]
ICM: C12N005-06
ICS: C12N005-08; C07K014-00; C07K014-51
EXF 530/350; 530/399; 435/325; 435/353; 435/366; 435/372
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 191 OF 362 USPATFULL on STN
AN 1998:162276 USPATFULL
TI Process for screening substances capable of modulating a
receptor-dependent cellular signal transmission path
IN Czernilofsky, Armin Peter, Vienna, Austria
Himmler, Adolf, Vienna, Austria
Stratowa, Christian, Vienna, Austria
Weyer, Ulrike, Vienna, Austria
Lamche, Herbert, Alland, Austria
Schafer, Renate, Vienna, Austria
PA Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, Federal Republic
of (non-U.S. corporation)
PI US 5854004 19981229 <--
WO 9311257 19930610 <--
AI US 1994-244434 19940525 (8)
WO 1992-EP2718 19921125
19940525 PCT 371 date
19940525 PCT 102(e) date
PRAI DE 1991-4138621 19911125
DT Utility
FS Granted
LN.CNT 2899
INCL INCLM: 435/007.210
INCLS: 435/006.000; 435/008.000
NCL NCLM: 435/007.210
NCLS: 435/006.000; 435/008.000
IC [6]
ICM: C12Q001-68
ICS: G01N033-566
EXF 435/7.21; 435/8; 435/320.1; 435/240.1; 435/325; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 192 OF 362 USPATFULL on STN
AN 1998:161993 USPATFULL
TI Methods and compositions of growth control for cells encapsulated within
bioartificial organs
IN Schinstine, Malcolm, Ben Salem, PA, United States
Shoichet, Molly S., Toronto, Canada
Gentile, Frank T., Warwick, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Holland, Laura M., Horsham, PA, United States
Cain, Brian M., Everett, MA, United States
Doherty, Edward J., Mansfield, MA, United States
Winn, Shelley R., Smithfield, RI, United States
Aebischer, Patrick, Lutry, Canada
PA CytoTherapeutics, Inc., Lincoln, RI, United States (U.S. corporation)
PI US 5853717 19981229 <--
AI US 1995-447356 19950523 (8)
RLI Division of Ser. No. US 1995-432698, filed on 9 May 1995 which is a
continuation-in-part of Ser. No. US 1994-279773, filed on 20 Jul 1994
DT Utility

FS Granted
LN.CNT 2340
INCL INCLM: 424/093.210
INCLS: 435/326.000; 435/372.200; 435/372.300; 435/382.000
NCL NCLM: 424/093.210
NCLS: 435/326.000; 435/372.200; 435/372.300; 435/382.000
IC [6]
ICM: A01N063-00
EXF 435/240; 435/243; 435/402; 435/395; 435/382; 435/372.3; 435/372.2;
435/382.2; 435/326; 424/93.21; 427/2.24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 193 OF 362 USPATFULL on STN
AN 1998:159916 USPATFULL
TI Method of enhancing proliferation or differentiation of hematopoietic
stem cells using wnt polypeptides
IN Matthews, William, Woodside, CA, United States
Austin, Timothy W., Morgan Hill, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5851984 19981222 <--
AI US 1996-696566 19960816 (8)
DT Utility
FS Granted
LN.CNT 3923
INCL INCLM: 514/002.000
INCLS: 435/002.000; 424/085.100
NCL NCLM: 514/002.000
NCLS: 424/085.100; 435/002.000
IC [6]
ICM: A61K038-18
EXF 435/2; 424/85.1; 424/85.2; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 194 OF 362 USPATFULL on STN
AN 1998:157466 USPATFULL
TI Peptides for altering bone resorption, angiogenesis and restenosis
IN Cheng, Soan, San Diego, CA, United States
Ingram, Ronald, Oceanside, CA, United States
Mullen, Daniel, San Diego, CA, United States
Tschopp, Juerg F., San Diego, CA, United States
PA La Jolla Cancer Research Foundation, San Diego, CA, United States (U.S.
corporation)
PI US 5849865 19981215 <--
AI US 1995-421695 19950412 (8)
RLI Continuation-in-part of Ser. No. US 1994-303052, filed on 8 Sep 1994
which is a continuation-in-part of Ser. No. US 1994-227316, filed on 13
Apr 1994, now abandoned
DT Utility
FS Granted
LN.CNT 3379
INCL INCLM: 530/317.000
INCLS: 514/011.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
530/330.000
NCL NCLM: 530/317.000
NCLS: 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000
IC [6]
ICM: A61K038-08
ICS: C07K007-06; C07K007-07; C07K007-54
EXF 514/9; 514/11; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 530/317;
530/321; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329; 530/330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 195 OF 362 USPATFULL on STN
AN 1998:157191 USPATFULL
TI Cell cultures of and cells culturing method for nontransformed parotid
cells
IN Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impimbatto, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PA Human Cell Cultures Inc., East Sebago, ME, United States (U.S.
corporation)
PI US 5849584 19981215 <--
AI US 1995-485650 19950607 (8)
RLI Continuation of ser. No. US 1993-83772, filed on 30 Jun 1993, now

abandoned which is a continuation-in-part of Ser. No. US 1993-44010,
filed on 8 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1832
INCL INCLM: 435/366.000
INCLS: 435/325.000; 435/378.000; 435/382.000; 435/383.000; 435/391.000
NCL NCLM: 435/366.000
NCLS: 435/325.000; 435/378.000; 435/382.000; 435/383.000; 435/391.000
IC [6]
ICM: C12N005-00
EXF 435/240.2; 435/240.21; 435/240.3; 435/325; 435/366; 435/378; 435/382;
435/383; 435/391; 623/1.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 196 OF 362 USPATFULL on STN
AN 1998:156909 USPATFULL
TI Autoimmune disease treatment with sertoli cells and in vitro co-culture
of mammal cells with sertoli cells
IN Selawry, Helena P., Memphis, TN, United States
PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
corporation)
PI US 5849285 19981215 <--
AI US 1995-485340 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-421641, filed on 13 Apr 1995,
now patented, Pat. No. US 5725854 which is a continuation-in-part of
Ser. No. US 1994-211695, filed on 13 Apr 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1599
INCL INCLM: 424/093.700
INCLS: 435/325.000; 435/347.000; 435/354.000
NCL NCLM: 424/093.700
NCLS: 435/325.000; 435/347.000; 435/354.000
IC [6]
ICM: A01N063-00
EXF 424/93.7; 435/284; 435/284.1; 435/325; 435/347; 435/354; 604/891.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 197 OF 362 USPATFULL on STN
AN 1998:154240 USPATFULL
TI Compositions comprising bone morphogenic proteins and truncated
parathyroid hormone related peptide and methods of inducing
cartilage by administration of same
IN Hattersley, Gary, 10 Rogers St., #303, Cambridge, MA, United States
02142
Rosen, Vicki A., 2 Cedar Rd., Chestnut Hill, MA, United States 02167
PI US 5846931 19981208 <--
AI US 1997-926942 19970910 (8)
RLI Continuation of Ser. No. US 1996-622101, filed on 26 Mar 1996, now
patented, Pat. No. US 5700774
DT Utility
FS Granted
LN.CNT 637
INCL INCLM: 514/002.000
INCLS: 514/008.000; 514/012.000; 424/085.100; 530/350.000; 530/351.000;
530/397.000; 530/399.000; 530/300.000; 530/324.000
NCL NCLM: 514/002.000
NCLS: 424/085.100; 514/008.000; 514/012.000; 530/300.000; 530/324.000;
530/350.000; 530/351.000; 530/397.000; 530/399.000
IC [6]
ICM: C07K014-495
ICS: C07K014-51; C07K014-635; A61K038-17
EXF 530/350; 530/351; 530/397; 530/399; 530/300; 530/324; 424/85.1; 514/2;
514/8; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 198 OF 362 USPATFULL on STN
AN 1998:151105 USPATFULL
TI Compacted nucleic acids and their delivery to cells
IN Hanson, Richard W., Cleveland Heights, OH, United States
Perales, Jose C., Cleveland Heights, OH, United States
Ferkol, Jr., Thomas W., Euclid, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S.
corporation)
PI US 5844107 19981201 <--

AI US 1996-721094 19960927 (8)
RLI Continuation-in-part of Ser. No. US 1996-716415, filed on 20 Sep 1996
which is a continuation-in-part of Ser. No. US 1994-216534, filed on 23
Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 3823
INCL INCLM: 536/023.100
INCLS: 424/493.000; 424/093.210; 514/044.000
NCL NCLM: 536/023.100
NCLS: 424/093.210; 424/493.000
IC [6]
ICM: C12N015-11
EXF 435/6; 435/172.3; 435/320.1; 530/330; 530/345; 530/350; 530/326;
424/93.21; 424/49.3; 514/2; 514/44; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 199 OF 362 USPATFULL on STN
AN 1998:150695 USPATFULL
TI Osteoprotegerin binding proteins
IN Boyle, William J., Moorpark, CA, United States
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI US 5843678 19981201 <--
AI US 1997-842842 19970416 (8)
DT Utility
FS Granted
LN.CNT 1022
INCL INCLM: 435/007.100
INCLS: 514/002.000; 530/350.000; 530/300.000
NCL NCLM: 435/007.100
NCLS: 514/002.000; 530/300.000; 530/350.000
IC [6]
ICM: C12Q001-00
ICS: C07K014-00
EXF 530/300; 530/350; 514/2; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 200 OF 362 USPATFULL on STN
AN 1998:150462 USPATFULL
TI Cellular and serum protein anchors for modulating pharmacokinetics
IN Pouletty, Philippe, Atherton, CA, United States
Pouletty, Christine, Atherton, CA, United States
PA RedCell Canada, Inc., Montreal, Canada (non-U.S. corporation)
PI US 5843440 19981201 <--
AI US 1996-702127 19960814 (8)
RLI Continuation of Ser. No. US 1993-137821, filed on 15 Oct 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1993-70092,
filed on 27 May 1993, now abandoned which is a continuation-in-part of
Ser. No. US 1990-592214, filed on 3 Oct 1990, now abandoned
DT Utility
FS Granted
LN.CNT 765
INCL INCLM: 424/133.100
INCLS: 424/136.100; 424/153.100; 424/173.100; 424/175.100; 530/387.300;
530/388.700; 530/388.850; 530/388.900; 530/389.600; 530/389.100;
530/389.800
NCL NCLM: 424/133.100
NCLS: 424/136.100; 424/153.100; 424/173.100; 424/175.100; 530/387.300;
530/388.700; 530/388.850; 530/388.900; 530/389.100; 530/389.600;
530/389.800
IC [6]
ICM: A61K039-395
ICS: C07K016-18; C07K016-28; C07K016-44
EXF 424/132.1; 424/133.1; 424/136.1; 424/153.1; 424/173.1; 424/175.1;
530/387.3; 530/388.7; 530/388.9; 530/388.85; 530/389.6; 530/389.1;
530/389.8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 201 OF 362 USPATFULL on STN
AN 1998:150454 USPATFULL
TI Controlling proliferation of cells before and after encapsulation in a
bioartificial organ by gene transformation
IN Schinstine, Malcolm, Ben Salem, PA, United States
Shoichet, Molly S., Toronto, Canada
Gentile, Frank T., Warwick, RI, United States
Hammang, Joseph P., Barrington, RI, United States

Holland, Laura M., Horsham, PA, United States
 Cain, Brian M., Everett, MA, United States
 Doherty, Edward J., Mansfield, MA, United States
 Winn, Shelley R., Smithfield, RI, United States
 Aebischer, Patrick, Lutry, Switzerland
 PA CytoTherapeutics, Inc., United States (U.S. corporation)
 PI US 5843431 19981201 <--
 AI US 1995-432698 19950509 (8)
 RLI Continuation-in-part of Ser. No. US 1994-279773, filed on 20 Jul 1994
 DT Utility
 FS Granted
 LN.CNT 2352
 INCL INCLM: 424/093.210
 INCLS: 435/172.300; 435/174.000; 435/178.000; 435/377.000; 435/382.000;
 435/395.000; 424/093.700; 424/422.000
 NCL NCLM: 424/093.210
 NCLS: 424/093.700; 424/422.000; 435/174.000; 435/178.000; 435/377.000;
 435/382.000; 435/395.000; 435/467.000
 IC [6]
 ICM: A61K048-00
 ICS: C12N011-00; C12N005-00; C12N011-10
 EXF 435/174; 435/178; 435/172.3; 435/240.7; 435/240.22; 435/240.23;
 435/240.24; 435/240.241; 435/240.242; 435/240.243; 435/377; 435/382;
 435/395; 424/93.21; 424/93.7; 424/422
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 202 OF 362 USPATFULL on STN
 AN 1998:150453 USPATFULL
 TI Methods of treating disease using sertoli cells and allografts or
 xenografts
 IN Selawry, Helena P., Memphis, TN, United States
 PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
 corporation)
 PI US 5843430 19981201 <--
 AI US 1995-467341 19950606 (8)
 RLI Continuation of Ser. No. US 1995-421641, filed on 13 Apr 1995 which is a
 continuation-in-part of Ser. No. US 1994-211695, filed on 13 Apr 1994,
 now abandoned
 DT Utility
 FS Granted
 LN.CNT 1337
 INCL INCLM: 424/093.700
 INCLS: 435/325.000; 435/326.000; 435/336.000; 435/343.000; 435/373.000;
 435/374.000; 435/395.000; 435/404.000; 435/410.000; 435/975.000
 NCL NCLM: 424/093.700
 NCLS: 435/325.000; 435/326.000; 435/336.000; 435/343.200; 435/373.000;
 435/374.000; 435/395.000; 435/404.000; 435/410.000; 435/975.000
 IC [6]
 ICM: A01N063-00
 ICS: G01N033-53
 EXF 435/240.1; 435/299; 435/297; 435/300; 435/975; 435/325; 435/326;
 435/336; 435/343.2; 435/373; 435/374; 435/395; 435/404; 435/410;
 424/93.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 203 OF 362 USPATFULL on STN
 AN 1998:147298 USPATFULL
 TI Methods and compositions of growth control for cells encapsulated within
 bioartificial organs
 IN Schinstine, Malcolm, Ben Salem, PA, United States
 Shoichet, Molly S., Toronto, Canada
 Gentile, Frank T., Warwick, RI, United States
 Hammang, Joseph P., Barrington, RI, United States
 Holland, Laura M., Horsham, PA, United States
 Cain, Brian M., Everett, MA, United States
 Doherty, Edward J., Mansfield, MA, United States
 Winn, Shelley R., Smithfield, RI, United States
 Aebischer, Patrick, Lutry, Switzerland
 PA CytoTherapeutics, Inc., United States (U.S. corporation)
 PI US 5840576 19981124 <--
 AI US 1995-445193 19950523 (8)
 RLI Division of Ser. No. US 1995-432698, filed on 9 May 1995 which is a
 continuation-in-part of Ser. No. US 1994-279773, filed on 20 Jul 1994
 DT Utility
 FS Granted
 LN.CNT 2293

INCL INCLM: 435/325.000
INCLS: 435/375.000; 435/377.000; 435/400.000
NCL NCLM: 435/325.000
NCLS: 435/375.000; 435/377.000; 435/400.000
IC [6]
ICM: C12N005-00
EXF 435/240.2; 435/240.22; 435/240.23; 435/240.242; 435/240.243; 435/325;
435/375; 435/377; 435/400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 204 OF 362 USPATFULL on STN
AN 1998:138628 USPATFULL
TI Morphogenic protein compositions of matter
IN Jones, William K., Brookline, MA, United States
Tucker, Ronald F., Holliston, MA, United States
Rueger, David C., Hopkinton, MA, United States
Oppermann, Hermann, Medway, MA, United States
Ozkaynak, Engin, Milford, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
PA Creative BioMolecules, Hopkinton, MA, United States (U.S. corporation)
PI US 5834179 19981110 <--
AI US 1995-459346 19950602 (8)
RLI Division of Ser. No. US 1995-402542, filed on 13 Mar 1995 which is a
continuation of Ser. No. US 1993-40510, filed on 31 Mar 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1993-29335,
filed on 4 Mar 1993, now abandoned And a continuation-in-part of Ser.
No. US 1993-27070, filed on 4 Mar 1993, now abandoned Ser. No. Ser. No. US
1992-971091, filed on 3 Nov 1992, now abandoned Ser. No. Ser. No. US
1992-946235, filed on 16 Sep 1992, now abandoned Ser. No. Ser. No. US
1992-938336, filed on 28 Aug 1992, now abandoned And Ser. No. US
1992-923780, filed on 31 Jul 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991,
now abandoned And a continuation-in-part of Ser. No. US 1991-752764,
filed on 30 Aug 1991, now abandoned which is a continuation-in-part of
Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned
DT Utility
FS Granted
LN.CNT 2263
INCL INCLM: 435/004.000
INCLS: 435/007.900; 435/007.100; 435/007.200; 435/007.920; 435/007.940;
435/007.950; 435/975.000; 436/503.000; 436/161.000; 436/518.000;
436/523.000; 436/524.000; 436/525.000; 436/526.000; 436/527.000;
436/528.000; 436/529.000; 436/530.000; 436/531.000; 436/536.000;
436/881.000; 436/815.000; 530/350.000
NCL NCLM: 435/004.000
NCLS: 435/007.100; 435/007.200; 435/007.900; 435/007.920; 435/007.940;
435/007.950; 435/975.000; 436/161.000; 436/503.000; 436/518.000;
436/523.000; 436/524.000; 436/525.000; 436/526.000; 436/527.000;
436/528.000; 436/529.000; 436/530.000; 436/531.000; 436/536.000;
436/811.000; 436/815.000; 530/350.000
IC [6]
ICM: C12Q001-00
ICS: G01N033-53; G01N033-542; G01N033-537
EXF 436/503; 436/518; 436/523-531; 436/536; 436/811; 436/815; 436/161;
530/350; 435/4; 435/7.1; 435/7.2; 435/7.9; 435/7.92; 435/7.94; 435/7.95;
435/975
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 205 OF 362 USPATFULL on STN
AN 1998:138431 USPATFULL
TI Methods and compositions of growth control for cells encapsulated within
bioartificial organs
IN Schinstine, Malcolm, Ben Salem, PA, United States
Shoichet, Molly S., Toronto, Canada
Gentile, Frank T., Warwick, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Holland, Laura M., Horsham, PA, United States
Cain, Brian M., Everett, MA, United States
Doherty, Edward J., Mansfield, MA, United States
Winn, Shelley R., Smithfield, RI, United States
Aebischer, Patrick, Lutry, Switzerland
PA CytoTherapeutics, Inc., Lincoln, RI, United States (U.S. corporation)
PI US 5833979 19981110 <--
AI US 1995-447771 19950523 (8)
RLI Division of Ser. No. US 1995-432698, filed on 9 May 1995 which is a
continuation-in-part of Ser. No. US 1994-279773, filed on 20 Jul 1994

DT Utility
FS Granted
LN.CNT 2266
INCL INCLM: 424/093.210
INCLS: 424/553.000; 424/556.000; 435/174.000; 435/352.000
NCL NCLM: 424/093.210
NCLS: 424/553.000; 424/556.000; 435/174.000; 435/352.000
IC [6]
ICM: A01N063-00
EXF 435/240; 435/243; 435/174; 435/352; 424/93.21; 424/553; 424/556
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 206 OF 362 USPATFULL on STN
AN 1998:135191 USPATFULL
TI Morphogen cell surface receptor
IN Jin, Donald F., Shrewsbury, MA, United States
Oppermann, Hermann, Medway, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
Smart, John E., Weston, MA, United States
PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)
PI US 5831050 19981103 <--
AI US 1994-357533 19941216 (8)
RLI Continuation of Ser. No. US 1993-73199, filed on 7 Jun 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1943
INCL INCLM: 536/235.000
INCLS: 536/024.310; 536/024.330; 530/350.000; 530/395.000; 935/009.000; 935/011.000
NCL NCLM: 536/023.500
NCLS: 530/350.000; 530/395.000; 536/024.310; 536/024.330
IC [6]
ICM: C07H021-04
ICS: C07K014-705
EXF 435/6; 435/91.2; 435/69.1; 435/172.3; 435/240.1; 435/252.3; 536/23.5; 536/24.31; 536/24.33; 935/8; 935/78; 935/9; 935/11; 530/350; 530/395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 207 OF 362 USPATFULL on STN
AN 1998:134836 USPATFULL
TI Preparation of immortalized cells
IN Moore, Emma E., Seattle, WA, United States
PA ZymoGenetics, Seattle, WA, United States (U.S. corporation)
PI US 5830682 19981103 <--
AI US 1996-770895 19961213 (8)
RLI Continuation-in-part of Ser. No. US 1995-479882, filed on 7 Jun 1995, now patented, Pat. No. US 5648219 And a continuation-in-part of Ser. No. US 1994-303983, filed on 9 Sep 1994, now patented, Pat. No. US 5683906
DT Utility
FS Granted
LN.CNT 1676
INCL INCLM: 435/029.000
INCLS: 435/352.000; 435/354.000; 435/377.000; 435/384.000
NCL NCLM: 435/029.000
NCLS: 435/352.000; 435/354.000; 435/377.000; 435/384.000
IC [6]
ICM: C12N005-06
ICS: C12Q001-02
EXF 435/352; 435/354; 435/377; 435/384; 435/7.21; 435/29
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 208 OF 362 USPATFULL on STN
AN 1998:134803 USPATFULL
TI Hybridization and amplification of nucleic acids encoding mpl ligand
IN Eaton, Dan L., San Rafael, CA, United States
de Sauvage, Frederic J., Foster City, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5830647 19981103 <--
AI US 1995-429764 19950426 (8)
RLI Division of Ser. No. US 1994-348658, filed on 2 Dec 1994 which is a continuation of Ser. No. US 1994-185607, filed on 21 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-176553, filed on 3 Jan 1994, now abandoned

DT Utility
FS Granted
LN.CNT 3338
INCL INCLM: 435/006.000
INCLS: 435/091.100; 435/091.200; 435/091.500; 536/024.300; 536/024.310;
536/024.320; 536/024.330; 530/351.000; 530/399.000
NCL NCLM: 435/006.000
NCLS: 435/091.100; 435/091.200; 435/091.500; 530/351.000; 530/399.000;
536/024.300; 536/024.310; 536/024.320; 536/024.330

IC [6]
ICM: C12Q001-68
ICS: C12P019-34; C07H021-04; C07K013-00
EXF 435/6; 435/91.2; 435/91.1; 435/91.5; 536/24.3; 536/24.31; 536/24.32;
536/24.33; 530/351; 530/399; 530/830
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 209 OF 362 USPATFULL on STN
AN 1998:134612 USPATFULL
TI Compositions and methods for the treatment of tumors
IN Vohar, Gordon A., San Carlos, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)

PI US 5830448 19981103 <--
AI US 1995-470777 19950606 (8)
RLI Division of Ser. No. US 1994-260850, filed on 16 Jun 1994

DT Utility
FS Granted
LN.CNT 1698
INCL INCLM: 424/085.200
INCLS: 514/002.000; 530/351.000; 530/381.000; 424/085.500; 424/085.100
NCL NCLM: 424/085.200
NCLS: 424/085.100; 424/085.500; 514/002.000; 530/351.000; 530/381.000

IC [6]
ICM: A61K045-05
ICS: A61K038-00
EXF 514/2; 530/351; 530/381; 424/85.2; 424/85.5; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 210 OF 362 USPATFULL on STN
AN 1998:124655 USPATFULL
TI Method for making heteromultimeric polypeptides
IN Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PA Genetech, Inc., South San Francisco, CA, United States (U.S.
corporation)

PI US 5821333 19981013 <--
AI US 1995-434869 19950503 (8)
RLI Division of Ser. No. US 1995-399106, filed on 1 Mar 1995

DT Utility
FS Granted
LN.CNT 2573
INCL INCLM: 530/350.000
INCLS: 530/300.000; 530/387.100; 530/387.300; 435/172.100; 435/172.300;
435/069.100; 435/069.700; 435/070.100; 435/071.100
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/069.700; 435/070.100; 435/071.100; 530/300.000;
530/387.100; 530/387.300

IC [6]
ICM: C07K001-00
EXF 435/172.1; 435/172.3; 435/69.1; 435/69.7; 435/70.1; 435/71.1; 530/300;
530/350; 530/387.1; 530/387.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 211 OF 362 USPATFULL on STN
AN 1998:124583 USPATFULL
TI H.sub.3 -receptor agonists as therapeutic agents
IN Theoharides, Theoharis C., 14 Parkman St., #2, Brookline, MA, United
States 02146

PI US 5821259 19981013 <--
AI US 1995-524023 19950906 (8)
RLI Continuation of Ser. No. US 1994-284041, filed on 1 Aug 1994, now
abandoned which is a continuation of Ser. No. US 1993-37697, filed on 24
Mar 1993, now abandoned which is a continuation of Ser. No. US
1991-790343, filed on 12 Nov 1991, now abandoned
DT Utility

FS Granted
LN.CNT 572
INCL INCLM: 514/396.000
INCLS: 514/397.000; 514/400.000
NCLM: 514/396.000
NCLS: 514/397.000; 514/400.000
IC [6]
ICM: A61K031-415
EXF 514/396; 514/397; 514/400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 212 OF 362 USPATFULL on STN
AN 1998:124415 USPATFULL
TI Osteoblast-testicular protein tyrosine phosphatase
IN Olmsted, Elizabeth Ann, Devon, PA, United States
Mauro, Laura Jeanne, Ann Arbor, MI, United States
Davis, Alan Robert, Wayne, PA, United States
Dixon, Jack Edward, Ann Arbor, MI, United States
PA The Regents of the University of Michigan, Ann Arbor, MI, United States
(U.S. corporation)
American Home Products Corporation, Madison, NJ, United States (U.S.
corporation)
PI US 5821084 19981013 <--
AI US 1994-342930 19941121 (8)
DT Utility
FS Granted
LN.CNT 1892
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/252.300; 435/325.000; 536/023.500; 536/024.300
NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.500; 536/024.300
IC [6]
ICM: C12N015-52
EXF 536/23.2; 536/24.3; 435/69.1; 435/320.1; 435/252.3; 435/240.2; 435/325;
935/23; 935/55; 935/70; 935/72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 213 OF 362 USPATFULL on STN
AN 1998:115417 USPATFULL
TI Antibodies to HER4, human receptor tyrosine kinase
IN Plowman, Gregory D., San Carlos, CA, United States
Culouscou, Jean-Michel, Seattle, WA, United States
Shoyab, Mohammed, Seattle, WA, United States
Siegall, Clay B., Seattle, WA, United States
Hellstrom, Ingegerd, Seattle, WA, United States
Hellstrom, Karl E., Seattle, WA, United States
PA Bristol-Myers Squibb Company, New York, NY, United States (U.S.
corporation)
PI US 5811098 19980922 <--
AI US 1995-484438 19950607 (8)
RLI Division of Ser. No. US 1994-323442, filed on 14 Oct 1994 which is a
continuation-in-part of Ser. No. US 1993-150704, filed on 10 Nov 1993,
now abandoned which is a continuation-in-part of Ser. No. US
1992-981165, filed on 24 Nov 1992, now abandoned
DT Utility
FS Granted
LN.CNT 4231
INCL INCLM: 424/178.100
INCLS: 530/387.300; 530/387.700; 530/389.900; 530/388.850; 530/389.100;
530/391.700; 530/388.220; 530/391.300; 435/330.000; 424/149.000
NCLM: 424/178.100
NCLS: 424/001.490; 435/330.000; 530/387.300; 530/387.700; 530/387.900;
530/388.220; 530/388.850; 530/389.700; 530/391.300; 530/391.700
IC [6]
ICM: A61K039-00
EXF 530/387.3; 530/387.1; 530/388.1; 530/388.22; 530/388.8; 530/289.1;
530/391.1; 530/391.3; 530/391.7; 424/178.1; 424/1.49
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 214 OF 362 USPATFULL on STN
AN 1998:111900 USPATFULL
TI Peptides useful for altering bone resorption
IN Cheng, Soan, San Diego, CA, United States
Ingram, Ronald, Oceanside, CA, United States
Mullen, Daniel, San Diego, CA, United States
Tschopp, Juerg F., San Diego, CA, United States

PA La Jolla Cancer Research Center, La Jolla, CA, United States (U.S.
corporation)
PI US 5807819 19980915 <--
AI US 1995-421698 19950412 (8)
RLI Continuation-in-part of Ser. No. US 1994-303052, filed on 8 Sep 1994
which is a continuation-in-part of Ser. No. US 1994-227316, filed on 15
Apr 1994, now abandoned
DT Utility
FS Granted
LN.CNT 3235
INCL INCLM: 514/011.000
INCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/317.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000
NCL NCLM: 514/011.000
NCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/324.000; 530/326.000; 530/328.000
IC [6]
ICM: A61K038-08
ICS: A61K038-10; A61K038-12; A61K038-16
EXF 514/9; 514/11; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 530/317;
530/321; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 215 OF 362 USPATFULL on STN
AN 1998:111793 USPATFULL
TI Method for making heteromultimeric polypeptides
IN Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5807706 19980915 <--
AI US 1995-433105 19950503 (8)
RLI Division of Ser. No. US 1995-399106, filed on 1 Mar 1995
DT Utility
FS Granted
LN.CNT 2576
INCL INCLM: 435/069.100
INCLS: 435/172.100; 435/172.300; 435/069.700; 435/070.100; 435/071.100;
530/300.000; 530/350.000; 530/387.100; 530/387.300
NCL NCLM: 435/069.100
NCLS: 435/069.700; 435/070.100; 435/071.100; 530/300.000; 530/350.000;
530/387.100; 530/387.300
IC [6]
ICM: C12P021-06
EXF 435/172.1; 435/172.3; 435/69.1; 435/69.7; 435/70.1; 435/71.1; 530/300;
530/350; 530/387.1; 530/387.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 216 OF 362 USPATFULL on STN
AN 1998:108394 USPATFULL
TI Synthetic receptors, libraries and uses thereof
IN Still, W. Clark, Clinton, NY, United States
Li, Ge, Plainsboro, NJ, United States
PA The Trustees of Columbia University in The City of New York, New York,
NY, United States (U.S. corporation)
PI US 5804563 19980908 <--
AI US 1996-628972 19960408 (8)
RLI Continuation of Ser. No. US 1994-181628, filed on 13 Jan 1994, now
abandoned
DT Utility
FS Granted
LN.CNT 1877
INCL INCLM: 514/026.000
INCLS: 530/333.000; 530/334.000; 530/300.000; 536/001.110; 536/004.100;
536/023.100; 536/025.300; 536/025.320; 536/005.000; 514/044.000;
514/048.000; 552/101.000; 552/200.000; 552/208.000; 564/001.000
NCL NCLM: 514/026.000
NCLS: 514/044.000; 514/048.000; 530/300.000; 530/333.000; 530/334.000;
536/001.110; 536/004.100; 536/005.000; 536/023.100; 536/025.300;
536/025.320; 552/101.000; 552/200.000; 552/208.000; 564/001.000
IC [6]
ICM: A01N045-00
EXF 435/6; 435/7.1; 436/501; 436/518; 436/528; 436/529; 436/531; 436/534;
530/333; 530/334; 530/300; 536/1.11; 536/4.1; 536/23.1; 536/25.3;

536/25.32; 536/5; 514/26; 514/44; 514/48; 552/101; 552/200; 552/208;
564/1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 217 OF 362 USPATFULL on STN
AN 1998:98815 USPATFULL
TI Method for controlling proliferation and differentiation of cells
encapsulated within bioartificial organs
IN Schinstine, Malcolm, Ben Salem, PA, United States
Shoichet, Molly S., Toronto, Canada
Gentile, Frank T., Warwick, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Holland, Laura M., Horsham, PA, United States
Cain, Brian M., Everett, MA, United States
Doherty, Edward J., Mansfield, MA, United States
Winn, Shelley R., Smithfield, RI, United States
Aebischer, Patrick, Lutry, Switzerland
PA Cytotherapeutics, Inc., Lincoln, RI, United States (U.S. corporation)
PI US 5795790 19980818 <--
AI US 1995-448201 19950523 (8)
RLI Division of Ser. No. US 1995-432698, filed on 9 May 1995 which is a
continuation-in-part of Ser. No. US 1994-279773, filed on 20 Jul 1994
DT Utility
FS Granted
LN.CNT 2311
INCL INCLM: 435/382.000
INCLS: 424/093.700; 435/177.000; 435/178.000; 435/180.000; 435/182.000
NCL NCLM: 435/382.000
NCLS: 424/093.700; 435/177.000; 435/178.000; 435/180.000; 435/182.000
IC [6]
ICM: C12N005-00
ICS: C12N011-02; C12N011-04; A61K035-12
EXF 435/177; 435/178; 435/240.7; 435/240.22; 435/240.23; 435/240.24;
435/240.241; 435/240.242; 435/240.243; 435/180; 435/182; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 218 OF 362 USPATFULL on STN
AN 1998:98600 USPATFULL
TI Method of containing core material in microcapsules
IN Weber, Collin J., Atlanta, GA, United States
Ayres-Price, Jennifer, Mooresville, NC, United States
PA Emory University, Atlanta, GA, United States (U.S. corporation)
PI US 5795570 19980818 <--
AI US 1995-418953 19950407 (8)
DT Utility
FS Granted
LN.CNT 1536
INCL INCLM: 424/093.700
INCLS: 264/004.000; 264/004.300; 264/004.320; 424/424.000; 424/572.000;
428/402.200; 428/402.240; 435/178.000; 435/182.000; 435/325.000;
435/363.000; 435/366.000; 435/382.000
NCL NCLM: 424/093.700
NCLS: 264/004.000; 264/004.300; 264/004.320; 424/424.000; 424/572.000;
428/402.200; 428/402.240; 435/178.000; 435/182.000; 435/325.000;
435/363.000; 435/366.000; 435/382.000
IC [6]
ICM: A61K035-12
ICS: C12N011-10; B01J013-20
EXF 424/93.7; 424/424; 424/572; 435/174; 435/177; 435/178; 435/182;
435/240.22; 435/325; 435/363; 435/366; 435/382; 435/424; 435/572; 264/4;
264/4.3; 264/4.32; 428/402.2; 428/402.24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 219 OF 362 USPATFULL on STN
AN 1998:95620 USPATFULL
TI Hematopoietic cytokine receptor
IN Baumgartner, James W., Seattle, WA, United States
Foster, Donald C., Seattle, WA, United States
Grant, Frank J., Seattle, WA, United States
Sprecher, Cindy A., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5792850 19980811 <--
AI US 1996-653740 19960523 (8)
DT Utility
FS Granted
LN.CNT 2312

INCL INCLM: 536/023.500
INCLS: 435/069.500; 435/335.000
NCL NCLM: 536/023.500
NCLS: 435/069.500; 435/335.000
IC [6]
ICM: C07H021-04
ICS: C12N015-00; C12P021-02
EXF 435/69.5; 435/335; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 220 OF 362 USPATFULL on STN
AN 1998:95518 USPATFULL
TI Use of peptides for altering bone resorption
IN Cheng, Soan, San Diego, CA, United States
Ingram, Ronald, Oceanside, CA, United States
Mullen, Daniel, San Diego, CA, United States
Tschopp, Juerg F., San Diego, CA, United States
PA La Jolla Cancer Research Center, La Jolla, CA, United States (U.S.
corporation)
PI US 5792745 19980811 <--
AI US 1995-421697 19950412 (8)
RLI Continuation-in-part of Ser. No. US 1994-303052, filed on 8 Sep 1994
which is a continuation-in-part of Ser. No. US 1994-227316, filed on 13
Apr 1994, now abandoned
DT Utility
FS Granted
LN.CNT 3298
INCL INCLM: 514/011.000
INCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/317.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000
NCL NCLM: 514/011.000
NCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/317.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000
IC [6]
ICM: A61K038-08
ICS: A61K038-12; C07K007-06; C07K007-54
EXF 514/9; 514/11; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 530/317;
530/321; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 221 OF 362 USPATFULL on STN
AN 1998:91830 USPATFULL
TI Process for bacterial production of polypeptides
IN Joly, John C., San Mateo, CA, United States
Swartz, James R., Menlo Park, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5789199 19980804 <--
AI US 1996-741727 19961031 (8)
RLI Continuation-in-part of Ser. No. US 1994-333912, filed on 3 Nov 1994,
now patented, Pat. No. US 5639635
DT Utility
FS Granted
LN.CNT 2148
INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/252.330; 935/011.000; 935/043.000
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/252.330
IC [6]
ICM: C12N015-63
EXF 435/69.1; 435/252.3; 435/252.33; 935/11; 935/43
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 222 OF 362 USPATFULL on STN
AN 1998:82596 USPATFULL
TI Method of altering blood sugar levels using non-transformed human
pancreatic cells that have been expanded in culture
IN Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impimbatto, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PA Human Cell Cultures Inc., East Sebago, ME, United States (U.S.
corporation)
PI US 5780299 19980714 <--
AI US 1995-480027 19950607 (8)

RLI Division of Ser. No. US 1993-83772, filed on 30 Jun 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1993-44010, filed on 8
Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1828
INCL INCLM: 435/366.000
INCLS: 435/325.000; 435/382.000; 435/383.000; 435/391.000
NCL NCLM: 435/366.000
NCLS: 435/325.000; 435/382.000; 435/383.000; 435/391.000
IC [6]
ICM: C12N005-00
EXF 435/240.2; 435/240.21; 435/240.3; 435/325; 435/366; 435/382; 435/383;
435/391; 623/11
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 223 OF 362 USPATFULL on STN
AN 1998:79024 USPATFULL
TI Growth factor preparation of thymocyte cell culture medium its
production and use
IN Kajander, Olavi, FIN-71310, Vehmersalmi, Finland
Kuronen, Ilpo, Lataajanpolku 1F 43, FIN070460 Kuopio, Finland
Tikkanen, Kaarina, Maaherrankatu 35 as 9, FIN-70100 Kuopio, Finland
PI US 5776778 19980707 <--
AI US 1996-762830 19961210 (8)
PRAI FI 1994-2773 19940610
DT Utility
FS Granted
LN.CNT 581
INCL INCLM: 435/405.000
INCLS: 435/384.000; 435/326.000; 435/352.000; 435/353.000; 435/354.000;
435/355.000; 435/372.200; 435/372.300; 530/399.000; 530/351.000;
530/300.000; 530/387.100; 436/547.000
NCL NCLM: 435/405.000
NCLS: 435/326.000; 435/352.000; 435/353.000; 435/354.000; 435/355.000;
435/372.200; 435/372.300; 435/384.000; 436/547.000; 530/300.000;
530/351.000; 530/387.100; 530/399.000
IC [6]
ICM: C12N005-02
ICS: C12N005-06; C12N005-08; C07K014-475
EXF 530/399; 530/351; 530/300; 530/387.1; 424/578; 424/579; 424/580;
435/326; 435/352; 435/353; 435/354; 435/355; 435/366; 435/372.3;
435/384; 435/405; 436/547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 224 OF 362 USPATFULL on STN
AN 1998:78994 USPATFULL
TI Method for controlling the distribution of cells within a bioartificial
organ using polyethylene oxide-poly (dimethylsiloxane) copolymer
IN Schinstine, Malcolm, Bensalem, PA, United States
Shoichet, Molly S., Toronto, Canada
Gentile, Frank T., Warwick, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Holland, Laura M., Horsham, PA, United States
Cain, Brian M., Everett, MA, United States
Doherty, Edward J., Mansfield, MA, United States
Winn, Shelley R., Smithfield, RI, United States
Aebischer, Patrick, Lutry, Switzerland
PA Cytotherapeutics, Inc., United States (U.S. corporation)
PI US 5776747 19980707 <--
AI US 1995-447778 19950523 (8)
RLI Division of Ser. No. US 1995-432692, filed on 9 May 1995
Continuation-in-part of Ser. No. US 1994-279973, filed on 20 Jul 1994
DT Utility
FS Granted
LN.CNT 2264
INCL INCLM: 435/177.000
INCLS: 435/180.000; 435/181.000; 435/182.000
NCL NCLM: 435/177.000
NCLS: 435/180.000; 435/181.000; 435/182.000
IC [6]
ICM: C12N011-02
ICS: C12N011-08; C12N011-06; C12N011-04
EXF 435/182; 435/177; 435/180; 435/181
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 225 OF 362 USPATFULL on STN
 AN 1998:78955 USPATFULL
 TI Polymeric particles having a biodegradable gelatin or aminodextran
 coating and processes for making same
 IN Siiman, Olavi, Davie, FL, United States
 Burshteyn, Alexander, Hialeah, FL, United States
 Gupta, Ravinder K., Pembroke Pines, FL, United States
 PA Coulter Corporation, Miami, FL, United States (U.S. corporation)
 PI US 5776706 19980707 <--
 AI US 1997-813022 19970306 (8)
 RLI Division of Ser. No. US 1994-336725, filed on 9 Nov 1994, now patented,
 Pat. No. US 5639620 which is a continuation of Ser. No. US 1992-961157,
 filed on 15 Oct 1992, now abandoned which is a continuation-in-part of
 Ser. No. US 1990-607253, filed on 31 Oct 1990, now patented, Pat. No. US
 5169754
 DT Utility
 FS Granted
 LN.CNT 1851
 INCL INCLM: 435/007.210
 INCLS: 427/002.110; 427/002.130; 427/002.140; 427/127.000; 427/128.000;
 427/129.000; 427/130.000; 427/131.000; 427/213.350; 427/215.000;
 427/216.000; 427/337.000; 428/403.000; 428/407.000; 435/005.000;
 436/518.000; 436/524.000; 436/525.000; 436/526.000; 436/529.000;
 436/531.000; 436/532.000; 436/533.000
 NCL NCLM: 435/007.210
 NCLS: 427/002.110; 427/002.130; 427/002.140; 427/127.000; 427/128.000;
 427/129.000; 427/130.000; 427/131.000; 427/213.350; 427/215.000;
 427/216.000; 427/337.000; 428/403.000; 428/407.000; 435/005.000;
 436/518.000; 436/524.000; 436/525.000; 436/526.000; 436/529.000;
 436/531.000; 436/532.000; 436/533.000
 IC [6]
 ICM: G01N033-569
 ICS: G01N033-545; G01N033-553
 EXF 427/2.11; 427/2.13; 427/2.14; 427/127-131; 427/213.35; 427/215.216;
 427/337; 427/338; 428/403; 428/407; 435/5; 435/7.21; 436/518; 436/524;
 436/525; 436/526; 436/529; 436/531; 436/532; 436/533; 436/534
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 226 OF 362 USPATFULL on STN
 AN 1998:78687 USPATFULL
 TI Methods for targeting the vasculature of solid tumors
 IN Thorpe, Philip E., Dallas, TX, United States
 Burrows, Francis J., San Diego, CA, United States
 PA Board of Regents, The University of Texas System, Austin, TX, United
 States (U.S. corporation)
 PI US 5776427 19980707 <--
 AI US 1995-456495 19950601 (8)
 RLI Division of Ser. No. US 1994-350212, filed on 5 Dec 1994 which is a
 continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994
 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5
 Mar 1992, now abandoned
 DT Utility
 FS Granted
 LN.CNT 5943
 INCL INCLM: 424/001.490
 INCLS: 424/178.100; 424/143.100; 424/179.100; 424/093.210; 424/138.100;
 424/145.100; 424/181.100; 424/183.100; 530/391.700; 530/387.200;
 530/388.220; 530/388.730
 NCL NCLM: 424/001.490
 NCLS: 424/093.210; 424/138.100; 424/143.100; 424/145.100; 424/178.100;
 424/179.100; 424/181.100; 424/183.100; 530/387.200; 530/388.200;
 530/388.730; 530/391.700
 IC [6]
 ICM: A61K051-10
 ICS: A61K035-395; C07K016-00
 EXF 424/1.49; 424/1.69; 424/138.1; 424/143.1; 424/145.1; 424/179.1;
 424/181.1; 424/183.1; 424/178.1; 424/93.21; 530/387.2; 530/387.3;
 530/388.22; 530/388.73; 530/389.1; 530/391.7; 530/391.9
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 227 OF 362 USPATFULL on STN
 AN 1998:75558 USPATFULL
 TI Use of peptides for altering .alpha..sub.V .beta..sub.3 -mediated
 binding
 IN Cheng, Soan, San Diego, CA, United States
 Ingram, Ronald, Oceanside, CA, United States

Mullen, Daniel, San Diego, CA, United States
Tschopp, Juerg F., San Diego, CA, United States
PA La Jolla Cancer Research Center, La Jolla, CA, United States (U.S.
corporation)
PI US 5773412 19980630 <--
AI US 1995-421696 19950412 (8)
RLI Continuation-in-part of Ser. No. US 1994-303052, filed on 8 Sep 1994
which is a continuation-in-part of Ser. No. US 1994-227316, filed on 13
Apr 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2586
INCL INCLM: 514/011.000
INCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/317.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000
NCL NCLM: 514/011.000
NCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/317.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000
IC [6]
ICM: A61K038-08
ICS: A61K038-10; A61K038-12; A61K038-16
EXF 514/9; 514/11; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 530/317;
530/321; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 228 OF 362 USPATFULL on STN
AN 1998:72727 USPATFULL
TI Receptor activation with inactive hepatocyte growth factor ligands
IN Godowski, Paul J., Pacifica, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5770704 19980623 <--
AI US 1997-792078 19970131 (8)
RLI Continuation of Ser. No. US 1995-423291, filed on 17 Apr 1995, now
abandoned which is a division of Ser. No. US 1994-268880, filed on 30
Jun 1994, now abandoned which is a continuation of Ser. No. US
1992-950572, filed on 22 Sep 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1992-884811, filed on 18 May 1992,
now patented, Pat. No. US 5316921 And Ser. No. US 1992-885971, filed on
18 May 1992, now patented, Pat. No. US 5328837
DT Utility
FS Granted
LN.CNT 2643
INCL INCLM: 530/402.000
INCLS: 424/194.100; 424/195.110; 530/399.000
NCL NCLM: 530/402.000
NCLS: 424/194.100; 424/195.110; 530/399.000
IC [6]
ICM: A61K038-18
ICS: C07K014-475
EXF 530/402; 530/399; 530/350; 424/194.1; 424/195.11; 424/185.1; 424/198.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 229 OF 362 USPATFULL on STN
AN 1998:72591 USPATFULL
TI Peptides for reducing or inhibiting bone resorption
IN Cheng, Soan, San Diego, CA, United States
Ingram, Ronald, Oceanside, CA, United States
Mullen, Daniel, San Diego, CA, United States
Tschopp, Juerg, San Diego, CA, United States
PA La Jolla Cancer Research Center, La Jolla, CA, United States (U.S.
corporation)
PI US 5770565 19980623 <--
AI US 1994-303052 19940908 (8)
RLI Continuation-in-part of Ser. No. US 1994-227316, filed on 13 Apr 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 2392
INCL INCLM: 514/011.000
INCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000;
530/328.000; 530/329.000
NCL NCLM: 514/011.000

NCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000;
530/328.000; 530/329.000

IC [6]
ICM: A61K038-08
ICS: A61K038-10; C07K007-06; C07K007-08

EXF 514/9; 514/11; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 530/317;
530/321; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 230 OF 362 USPATFULL on STN
AN 1998:65362 USPATFULL
TI Receptor activation with hepatocyte growth factor agonists
IN Godowski, Paul J., Burlingame, CA, United States
PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)
PI US 5763584 19980609 <--
AI US 1995-435764 19950505 (8)
RLI Continuation of Ser. No. US 1993-87784, filed on 13 Jul 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1992-950572,
filed on 21 Sep 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1992-884811, filed on 18 May 1992, now patented, Pat. No. US
5316921 And a continuation-in-part of Ser. No. US 1992-885971, filed on
18 May 1992, now patented, Pat. No. US 5328837
DT Utility
FS Granted
LN.CNT 2955
INCL INCLM: 530/402.000
INCLS: 530/399.000; 424/195.110; 424/194.100
NCL NCLM: 530/402.000
NCLS: 424/194.100; 424/195.110; 530/399.000
IC [6]
ICM: C07K014-475
ICS: A61K038-18
EXF 424/185.1; 424/195.11; 424/198.1; 424/194.1; 435/68.1; 530/402; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 231 OF 362 USPATFULL on STN
AN 1998:64993 USPATFULL
TI Methods of detecting prostate carcinoma using a monoclonal antibody to a
new antigenic marker in epithelial prostatic cells alone or with a
monoclonal antibody to an antigen of LNCaP cells
IN Horoszewicz, Julius S., Williamsville, NY, United States
PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
PI US 5763202 19980609 <--
AI US 1995-482515 19950607 (8)
RLI Continuation of Ser. No. US 1994-307544, filed on 16 Sep 1994, now
patented, Pat. No. US 5578484 which is a continuation of Ser. No. US
1992-822500, filed on 17 Jan 1992, now abandoned which is a division of
Ser. No. US 1988-202869, filed on 3 Jun 1988, now patented, Pat. No. US
5162504
DT Utility
FS Granted
LN.CNT 1420
INCL INCLM: 435/007.230
INCLS: 435/070.210; 435/172.200; 435/344.000; 530/388.800
NCL NCLM: 435/007.230
NCLS: 435/070.210; 435/344.000; 530/388.800
IC [6]
ICM: G01N033-574
ICS: C12P021-04; C12N015-00; C07K016-00
EXF 530/388.8; 435/240.27; 435/7.23; 435/70.21; 435/172.2; 435/344
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 232 OF 362 USPATFULL on STN
AN 1998:64717 USPATFULL
TI Composition and methods for the treatment of tumors
IN Vehar, Gordon A., San Carlos, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5762921 19980609 <--
AI US 1996-594360 19960130 (8)
RLI Continuation of Ser. No. US 1994-260850, filed on 16 Jun 1994, now
abandoned
DT Utility
FS Granted
LN.CNT 1824

INCL INCLM: 424/085.100
INCLS: 424/198.100; 424/085.200; 424/085.500; 424/158.100; 514/012.000;
530/350.000; 530/351.000; 530/381.000
NCL NCLM: 424/085.100
NCLS: 424/085.200; 424/085.500; 424/158.100; 424/198.100; 514/012.000;
530/350.000; 530/351.000; 530/381.000
IC [6]
ICM: A61K045-05
ICS: A61K038-19; A61K038-06; C07K001-00
EXF 424/198.1; 424/85.2; 424/85.5; 424/85.1; 424/158.1; 514/12; 530/350;
530/351; 530/381
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 233 OF 362 USPATFULL on STN
AN 1998:61612 USPATFULL
TI Peptides useful for altering .alpha..sub.v .beta..sub.3 -mediated
binding
IN Cheng, Soan, San Diego, CA, United States
Ingram, Ronald, Oceanside, CA, United States
Mullen, Daniel, San Diego, CA, United States
Tschopp, Juerg F., San Diego, CA, United States
PA La Jolla Cancer Research Center, La Jolla, CA, United States (U.S.
corporation)
PI US 5759996 19980602 <--
AI US 1995-421702 19950412 (8)
RLI Continuation-in-part of Ser. No. US 1994-303052, filed on 8 Sep 1994
which is a continuation-in-part of Ser. No. US 1994-227316, filed on 13
Apr 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2699
INCL INCLM: 514/011.000
INCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/317.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000
NCL NCLM: 514/011.000
NCLS: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;
514/017.000; 530/317.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000
IC [6]
ICM: A61K038-08
ICS: A61K038-10; A61K038-12; A61K038-16
EXF 514/9; 514/11; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 530/317;
530/321; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 234 OF 362 USPATFULL on STN
AN 1998:61154 USPATFULL
TI Methods of treating disease using sertoli cells and allografts or
xenografts
IN Selawry, Helena P., Memphis, TN, United States
PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
corporation)
PI US 5759534 19980602 <--
AI US 1995-467338 19950606 (8)
RLI Continuation of Ser. No. US 1995-421641, filed on 13 Apr 1995 which is a
continuation-in-part of Ser. No. US 1994-211695, filed on 13 Apr 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 1368
INCL INCLM: 424/093.700
INCLS: 424/093.100; 435/325.000
NCL NCLM: 424/093.700
NCLS: 424/093.100; 435/325.000
IC [6]
ICM: A01N063-00
ICS: A01N065-00
EXF 424/93.1; 424/93.7; 435/240.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 235 OF 362 USPATFULL on STN
AN 1998:57716 USPATFULL
TI Aptamers specific for biomolecules and methods of making
IN Griffin, Linda, Atherton, CA, United States
Albrecht, Glenn, Redwood City, CA, United States

Latham, John, Palo Alto, CA, United States
Leung, Lawrence, Hillsborough, CA, United States
Vermaas, Eric, Oakland, CA, United States
Toole, John J., Burlingame, CA, United States
PA Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)
PI US 5756291 19980526 <--
AI US 1995-484192 19950607 (8)
RLI Continuation of Ser. No. US 1992-934387, filed on 21 Aug 1992, now
abandoned
DT Utility
FS Granted
LN.CNT 8242
INCL INCLM: 435/006.000
INCLS: 536/023.100; 530/413.000; 935/077.000; 935/078.000
NCL NCLM: 435/006.000
NCLS: 530/413.000; 536/023.100
IC [6]
ICM: C12Q001-68
ICS: C07K001-14; C07H021-04; C07H021-02
EXF 435/6; 935/77; 935/78; 530/413; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 236 OF 362 USPATFULL on STN
AN 1998:47965 USPATFULL
TI Polypeptides with increased half-life for use in treating disorders
involving the LFA-1 receptor
IN Presta, Leonard G., San Francisco, CA, United States
Snedecor, Bradley R., Portola Valley, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5747035 19980505 <--
AI US 1995-422091 19950414 (8)
DT Utility
FS Granted
LN.CNT 3305
INCL INCLM: 424/144.100
INCLS: 424/130.100; 424/133.100; 424/135.100; 424/141.100; 424/143.100;
424/153.100; 424/154.100; 424/173.100; 514/002.000; 514/008.000;
514/885.000; 530/387.100
NCL NCLM: 424/144.100
NCLS: 424/130.100; 424/133.100; 424/135.100; 424/141.100; 424/143.100;
424/153.100; 424/154.100; 424/173.100; 514/002.000; 514/008.000;
514/885.000; 530/387.100
IC [6]
ICM: A61K039-395
ICS: A61K038-02; A61K038-17
EXF 424/130.1; 424/133.1; 424/135.1; 424/144.1; 424/173.1; 424/141.1;
424/143.1; 424/153.1; 424/154.1; 514/2; 514/8; 514/835; 530/387.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 237 OF 362 USPATFULL on STN
AN 1998:45180 USPATFULL
TI HPTH-fragment-(1-37), the preparation thereof, medicaments containing
same and the use thereof
IN Forssmann, Wolf-Georg, Hanover, Germany, Federal Republic of
Herbst, Franz, Nussloch, Germany, Federal Republic of
Schulz-Knappe, Peter, Neustadt, Germany, Federal Republic of
Adermann, Knut, Hanover, Germany, Federal Republic of
Gagelmann, Michael, Schriersheim, Germany, Federal Republic of
PA HaemoPep Pharma GmbH, Hanover, Germany, Federal Republic of (non-U.S.
corporation)
PI US 5744444 19980428 <--
AI US 1995-440117 19950512 (8)
RLI Continuation of Ser. No. US 1993-155658, filed on 22 Nov 1993, now
abandoned which is a continuation of Ser. No. US 1992-863291, filed on
29 Jun 1992, now abandoned
PRAI DE 1989-3935738 19891027
WO 1990-EP1807 19901025
DT Utility
FS Granted
LN.CNT 858
INCL INCLM: 514/012.000
INCLS: 530/324.000; 530/412.000; 435/069.100; 514/002.000
NCL NCLM: 514/012.000
NCLS: 435/069.100; 514/002.000; 530/324.000; 530/412.000
IC [6]

ICM: A61K038-17
 ICS: C07K004-435
 EXF 530/300; 530/324; 530/412; 435/69.1; 514/2; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 238 OF 362 USPATFULL on STN
 AN 1998:44877 USPATFULL
 TI Sequence-directed DNA-binding molecules compositions and methods
 IN Edwards, Cynthia A., Menlo Park, CA, United States
 Fry, Kirk E., Palo Alto, CA, United States
 Cantor, Charles R., Boston, MA, United States
 Andrews, Beth M., Maynard, MA, United States
 PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S. corporation)
 PI US 5744131 19980428 <--
 AI US 1995-476876 19950607 (8)
 RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 5113
 INCL INCLM: 424/078.080
 INCLS: 436/501.000; 514/001.000
 NCL NCLM: 424/078.080
 NCLS: 436/501.000; 514/001.000
 IC [6]
 ICM: A61K031-74
 ICS: G01N033-566; G01N033-558
 EXF 536/23.1; 536/27.1; 546/109; 436/501; 514/1; 424/78.08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 239 OF 362 USPATFULL on STN
 AN 1998:39666 USPATFULL
 TI Altered polypeptides with increased half-life
 IN Presta, Leonard G., San Francisco, CA, United States
 Snedecor, Bradley R., Portola Valley, CA, United States
 PA Genentech Inc., San Francisco, CA, United States (U.S. corporation)
 PI US 5739277 19980414 <--
 AI US 1995-422101 19950414 (8)
 DT Utility
 FS Granted
 LN.CNT 3251
 INCL INCLM: 530/326.000
 INCLS: 530/300.000; 530/350.000; 530/387.100
 NCL NCLM: 530/326.000
 NCLS: 530/300.000; 530/350.000; 530/387.100
 IC [6]
 ICM: C07K007-08
 ICS: C07K014-47; C07K016-00; C07K016-46
 EXF 530/327; 530/328; 530/387.1; 530/300; 530/350; 530/326
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 240 OF 362 USPATFULL on STN
 AN 1998:39664 USPATFULL
 TI Active component of ***parathyroid*** hypertensive factor
 IN Pang, Peter K. T., Sherwood Park, Canada
 Benishin, Christina G., Androssan, Canada
 Jie, Shan, Edmonton, Canada
 Lewanczuk, Richard Z., Edmonton, Canada
 PA CV Technologies, Inc., Alberta, Canada (non-U.S. corporation)
 PI US 5739274 19980414 <--
 WO 9325577 19931223
 AI US 1995-387820 19950224 (8)
 WO 1993-US5626 19930614
 19950224 PCT 371 date
 19950224 PCT 102(e) date
 DT Utility
 FS Granted
 LN.CNT 1571
 INCL INCLM: 530/324.000
 INCLS: 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
 530/333.000; 514/002.000; 514/007.000
 NCL NCLM: 530/324.000
 NCLS: 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
 530/333.000

IC [6]
ICM: C07K007-04
EXF 514/2; 514/12; 514/14; 514/13; 514/15; 514/16; 514/7; 530/324; 530/325;
530/326; 530/327; 530/328; 530/329; 530/333
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 241 OF 362 USPATFULL on STN
AN 1998:39383 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
corporation)
PI US 5738990 19980414 <--
AI US 1995-475221 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a
continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
now abandoned
DT Utility
FS Granted
LN.CNT 5040
INCL INCLM: 435/006.000
INCLS: 435/691.000; 435/172.300; 435/320.100; 536/024.100; 935/036.000;
935/039.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 536/024.100
IC [6]
ICM: C12P021-02
ICS: C12N015-67; C07H021-04
EXF 435/172.1; 435/69.1; 435/6; 435/320.1; 435/172.3; 536/24.1; 935/36;
935/39
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 242 OF 362 USPATFULL on STN
AN 1998:33576 USPATFULL
TI Hematopoietic cells: compositions and methods
IN Taichman, Russell S., Ann Arbor, MI, United States
Emerson, Stephen G., Wayne, PA, United States
PA The Regent of the University of Michigan, Ann Arbor, MI, United States
(U.S. corporation)
PI US 5733541 19980331 <--
AI US 1995-426792 19950421 (8)
DT Utility
FS Granted
LN.CNT 3768
INCL INCLM: 424/093.100
INCLS: 424/093.700; 435/325.000; 435/347.000; 435/377.000; 435/373.000;
435/375.000
NCL NCLM: 424/093.100
NCLS: 424/093.700; 435/325.000; 435/347.000; 435/373.000; 435/375.000;
435/377.000
IC [6]
ICM: A01N063-02
ICS: C12N005-00; C12N005-06
EXF 435/325; 435/347; 435/355; 435/373; 435/375; 435/384; 435/385; 435/386;
435/240.1; 424/93.1; 424/93.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 243 OF 362 USPATFULL on STN
AN 1998:30879 USPATFULL
TI Method for making heteromultimeric polypeptides
IN Carter, Paul J., San Francisco, CA, United States
Presta, Leonard G., San Francisco, CA, United States
Ridgway, John B., San Francisco, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5731168 19980324 <--
AI US 1995-399106 19950301 (8)
DT Utility
FS Granted
LN.CNT 2657
INCL INCLM: 435/069.100
INCLS: 435/172.100; 435/172.300; 435/070.100; 435/071.100; 435/069.700;
530/300.000; 530/350.000; 530/387.100; 530/387.300; 536/023.100;

NCL 536/023.400; 536/023.500; 536/023.530
NCLM: 435/069.100
NCLS: 435/069.700; 435/070.100; 435/071.100; 530/300.000; 530/350.000;
530/387.100; 530/387.300; 536/023.100; 536/023.400; 536/023.500;
536/023.530
IC [6]
ICM: C12D021-06
EXF 435/172.1; 435/172.3; 435/69.1; 435/70.1; 435/71.1; 435/69.7; 530/300;
530/350; 530/387.1; 530/387.3; 536/23.1; 536/23.4; 536/23.5; 536/23.53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 244 OF 362 USPATFULL on STN
AN 1998:25204 USPATFULL
TI Method of treating metabolic bone diseases with an IL-1 receptor
IN Katoh, Masakazu, Hiki-gun, Japan
Kitamura, Kazuyuki, Sakado, Japan
PA Hoechst Japan Limited, Tokyo, Japan (non-U.S. corporation)
PI US 5726148 19980310 <--
AI US 1995-487646 19950607 (8)
PRAI JP 1994-135275 19940611
DT Utility
FS Granted
LN.CNT 260
INCL INCLM: 514/002.000
INCLS: 514/008.000; 514/012.000; 424/085.200
NCL NCLM: 514/002.000
NCLS: 424/085.200; 514/008.000; 514/012.000
IC [6]
ICM: A61K045-05
EXF 514/2; 514/8; 514/12; 424/85.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 245 OF 362 USPATFULL on STN
AN 1998:25075 USPATFULL
TI Screening assay for the detection of DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
Turin, Lisa M., Berkeley, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
corporation)
PI US 5726014 19980310 <--
AI US 1993-123936 19930917 (8)
RLI Continuation-in-part of Ser. No. US 1992-996783, filed on 23 Dec 1992
which is a continuation-in-part of Ser. No. US 1991-723618, filed on 27
Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 5659
INCL INCLM: 435/006.000
INCLS: 435/091.200; 436/501.000
NCL NCLM: 435/006.000
NCLS: 435/091.200; 436/501.000
IC [6]
ICM: C12Q001-68
ICS: C12P019-34; G01N033-566
EXF 435/6; 435/235; 435/91.1; 435/91.2; 435/91.5; 536/23.1; 536/23.2;
436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 246 OF 362 USPATFULL on STN
AN 1998:24918 USPATFULL
TI Methods of treating disease using sertoli cells an allografts or
xenografts
IN Selawry, Helena P., Memphis, TN, United States
PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
corporation)
PI US 5725854 19980310 <--
AI US 1995-421641 19950413 (8)
RLI Continuation-in-part of Ser. No. US 1994-211695, filed on 13 Apr 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 1461
INCL INCLM: 424/093.700
INCLS: 435/240.100

NCL NCLM: 424/093.700
NCLS: 435/373.000
IC [6]
ICM: A01N063-00
ICS: C12N005-00
EXF 424/93.7; 435/240.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 247 OF 362 USPATFULL on STN
AN 1998:24868 USPATFULL
TI Non-crosslinked protein particles for therapeutic and diagnostic use
IN Yen, Richard C. K., Yorba Linda, CA, United States
PA Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)
PI US 5725804 19980310 <--
AI US 1995-471650 19950606 (8)
RLI Continuation-in-part of Ser. No. US 1994-212546, filed on 14 Mar 1994, now patented, Pat. No. US 5616311 which is a continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DT Utility
FS Granted
LN.CNT 2178
INCL INCLM: 252/314.000
INCLS: 252/311.000; 424/484.000; 424/491.000; 514/776.000; 514/937.000; 514/965.000
NCL NCLM: 516/077.000
NCLS: 424/484.000; 424/491.000; 514/776.000; 514/937.000; 514/965.000; 516/917.000; 516/922.000
IC [6]
ICM: A61K009-64
ICS: A61K047-42; B01J013-00
EXF 264/4.3; 427/213.3; 427/213.33; 427/2.14; 427/2.21; 514/965; 514/937; 514/776; 252/311; 252/314; 424/491
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 248 OF 362 USPATFULL on STN
AN 1998:19596 USPATFULL
TI Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
IN Etcheverry, Tina, Berkeley, CA, United States
PA Ryll, Thomas, San Mateo, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5721121 19980224 <--
AI US 1995-466845 19950606 (8)
DT Utility
FS Granted
LN.CNT 1576
INCL INCLM: 435/069.700
INCLS: 435/325.000; 435/328.000; 435/358.000; 435/361.000; 530/395.000; 530/387.300
NCL NCLM: 435/069.700
NCLS: 435/325.000; 435/328.000; 435/358.000; 435/361.000; 530/387.300; 530/395.000
IC [6]
ICM: C12N015-62
ICS: C12N015-12; C12N005-16; C07K014-715
EXF 435/69.7; 435/240.2; 435/240.25; 435/325; 435/328; 435/334; 435/358; 435/360; 435/361; 530/395; 530/387.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 249 OF 362 USPATFULL on STN
AN 1998:14828 USPATFULL
TI Anti-angiogenic compositions and methods of use
IN Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
PA Arsenault, A. Larry, Paris, Canada
PA Angiogenesis Technologies, Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5716981 19980210 <--
AI US 1995-478203 19950607 (8)
RLI Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, now abandoned

PRAI WO 1994-CA373 19940719
DT Utility
FS Granted
LN.CNT 5084
INCL INCLM: 514/449.000
INCLS: 128/898.000; 526/304.000; 528/421.000; 604/053.000; 604/020.000;
604/021.000; 604/096.000; 604/269.000; 606/198.000; 623/012.000
NCL NCLM: 514/449.000
NCLS: 128/898.000; 526/304.000; 528/421.000; 604/020.000; 604/021.000;
604/269.000; 604/508.000; 606/198.000; 623/001.150
IC [6]
ICM: A61K031-335
ICS: A61M029-00
EXF 604/53; 604/20; 604/21; 604/96; 604/269; 128/898; 514/449; 606/198;
623/12; 528/421; 526/304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 250 OF 362 USPATFULL on STN
AN 1998:14634 USPATFULL
TI Method of constructing sequence-specific DNA-binding molecules
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Watertown, MA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
corporation)
PI US 5716780 19980210 <--
AI US 1995-484499 19950607 (8)
RLI Division of Ser. No. US 1992-996783, filed on 23 Dec 1992 which is a
continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
now abandoned
DT Utility
FS Granted
LN.CNT 4929
INCL INCLM: 435/006.000
INCLS: 436/501.000
NCL NCLM: 435/006.000
NCLS: 436/501.000
IC [6]
ICM: C12Q001-68
ICS: G01N033-566
EXF 435/6; 536/24.5; 935/33; 935/34; 935/36; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 251 OF 362 USPATFULL on STN
AN 1998:4755 USPATFULL
TI Secreted proteins and polynucleotides encoding them
IN Jacobs, Kenneth, Newton, MA, United States
McCoy, John M., Reading, MA, United States
LaVallie, Edward R., Tewksbury, MA, United States
Racie, Lisa A., Acton, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Evans, Cheryl, Brookline, MA, United States
Spaulding, Vikki, Billerica, MA, United States
PA Genetics Institute, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 5708157 19980113 <--
AI US 1996-686878 19960726 (8)
DT Utility
FS Granted
LN.CNT 3204
INCL INCLM: 536/023.500
INCLS: 435/691.000; 435/320.100; 435/325.000; 435/252.300; 435/254.110;
530/300.000; 530/350.000; 530/850.000; 424/559.000; 514/012.000
NCL NCLM: 536/023.500
NCLS: 424/559.000; 435/069.100; 435/252.300; 435/254.110; 435/320.100;
435/325.000; 530/300.000; 530/350.000; 530/850.000
IC [6]
ICM: C12N015-10
ICS: C12N005-10; C12N015-12; C07K014-47
EXF 435/69.1; 435/325; 435/252.3; 435/254.11; 435/320.1; 424/78.01;
424/185.1; 424/278.1; 424/559; 514/44-46; 530/300; 530/350; 530/351;
530/380; 530/850; 530/252; 530/853; 536/23.1; 536/26.13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 252 OF 362 USPATFULL on STN
 AN 1998:4476 USPATFULL
 TI Biodegradable gelatin-aminodextran particle coatings of and processes
 for making same
 IN Siiman, Olavi, Davie, FL, United States
 Burshteyn, Alexander, Hialeah, FL, United States
 Gupta, Ravinder K., Pembroke Pines, FL, United States
 PA Coulter Corporation, Miami, FL, United States (U.S. corporation)
 PI US 5707877 19980113 <--
 AI US 1995-493973 19950623 (8)
 RLI Division of Ser. No. US 1992-968158, filed on 29 Oct 1992, now patented,
 Pat. No. US 5466609, issued on 14 Nov 1995 which is a
 continuation-in-part of Ser. No. US 1990-607253, filed on 31 Oct 1990,
 now patented, Pat. No. US 5169754, issued on 8 Dec 1992
 DT Utility
 FS Granted
 LN.CNT 1928
 INCL INCLM: 436/518.000
 INCLS: 436/528.000; 436/529.000; 536/051.000; 536/112.000
 NCL NCLM: 436/518.000
 NCLS: 436/528.000; 436/529.000; 536/051.000; 536/112.000
 IC [6]
 ICM: G01N033-543
 EXF 536/112; 536/51; 436/518; 436/528; 436/529
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 253 OF 362 USPATFULL on STN
 AN 1998:1651 USPATFULL
 TI Mammalian cell culture process
 IN Etcheverry, Tina, Berkeley, CA, United States
 Ryll, Thomas, San Mateo, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)
 PI US 5705364 19980106 <--
 AI US 1995-469348 19950606 (8)
 DT Utility
 FS Granted
 LN.CNT 1610
 INCL INCLM: 435/070.300
 INCLS: 435/383.000; 435/395.000; 435/375.000
 NCL NCLM: 435/070.300
 NCLS: 435/375.000; 435/383.000; 435/395.000
 IC [6]
 ICM: C12N005-06
 EXF 435/70.3; 435/240.2; 435/240.27; 435/240.3; 435/375; 435/383; 435/395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 254 OF 362 USPATFULL on STN
 AN 1998:1637 USPATFULL
 TI Methods for preparing polynucleotides encoding orphan receptor ligands
 IN Holly, Richard D., Seattle, WA, United States
 Burkhead, Steven K., Seattle, WA, United States
 PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5705349 19980106 <--
 AI US 1995-490803 19950615 (8)
 RLI Division of Ser. No. US 1994-250859, filed on 27 May 1994, now patented,
 Pat. No. US 5541085 which is a continuation-in-part of Ser. No. US
 1994-196025, filed on 14 Feb 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1649
 INCL INCLM: 435/007.200
 INCLS: 435/007.200; 435/007.210; 435/006.000; 435/069.100; 435/069.500;
 435/172.100; 435/372.000; 435/372.100; 435/405.000; 436/501.000;
 536/023.100; 536/023.500
 NCL NCLM: 435/007.200
 NCLS: 435/006.000; 435/007.210; 435/069.100; 435/069.500; 435/372.000;
 435/372.100; 435/405.000; 436/501.000; 536/023.100; 536/023.500
 IC [6]
 ICM: C12N015-12
 ICS: C12N015-19
 EXF 435/69.1; 435/69.5; 435/6; 435/7.2; 435/7.21; 435/172.1; 435/405;
 435/372; 435/372.1; 436/501; 536/23.1; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 255 OF 362 USPATFULL on STN

AN 97:123341 USPATFULL
TI Protein active in humoral hypercalcemia of malignancy-PTHrP
IN Martin, Thomas J., Kew, Australia
Moseley, Jane M., North Balwyn, Australia
Kemp, Bruce E., Kew, Australia
Wettenhall, Richard E. H., Camberwell, Australia
PA The University of Melbourne, Victoria, Australia (non-U.S. corporation)
PI US 5703207 19971230 <--
AI US 1994-352622 19941209 (8)
RLI Division of Ser. No. US 1991-715280, filed on 14 Jun 1991, now patented,
Pat. No. US 5460978 which is a division of Ser. No. US 1988-199235,
filed on 18 Mar 1988, now patented, Pat. No. US 5116952
PRAI AU 1986-7027 19860718
AU 1987-349 19870213
DT Utility
FS Granted
LN.CNT 941
INCL INCLM: 530/324.000
INCLS: 530/326.000; 530/399.000
NCL NCLM: 530/324.000
NCLS: 530/326.000; 530/399.000
IC [6]
ICM: C07K014-635
ICS: C07K007-06; C07K007-08; C07K009-00
EXF 530/399; 530/324; 530/326; 530/327
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 256 OF 362 USPATFULL on STN
AN 97:123061 USPATFULL
TI DNA encoding canine granulocyte macrophage colony stimulating factor
IN Nash, Richard A., Seattle, WA, United States
Storb, Rainer, Seattle, WA, United States
PA Fred Hutchinson Cancer Research Center, Seattle, WA, United States (U.S.
corporation)
PI US 5702919 19971230 <--
AI US 1994-259696 19940614 (8)
RLI Continuation of Ser. No. US 1990-616678, filed on 21 Nov 1990, now
abandoned
DT Utility
FS Granted
LN.CNT 1140
INCL INCLM: 435/069.500
INCLS: 536/023.500; 435/320.100; 435/172.300; 435/252.300; 435/240.100;
435/254.200
NCL NCLM: 435/069.500
NCLS: 435/252.300; 435/254.200; 435/320.100; 435/360.000; 435/364.000;
435/365.100; 435/367.000; 536/023.500
IC [6]
ICM: C12N015-27
ICS: C07K014-535
EXF 536/23.1; 536/23.5; 435/252.3; 435/320.1; 435/69.5; 435/172.3;
435/240.1; 435/254.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 257 OF 362 USPATFULL on STN
AN 97:123034 USPATFULL
TI Inhibitors of alternative alleles of genes as a basis for cancer
therapeutic agents
IN Housman, David E., Newton, MA, United States
PA K.O. Technology, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5702890 19971230 <--
WO 9503335 19950202 <--
AI US 1995-379680 19950404 (8)
WO 1994-US8473 19940726
19950404 PCT 371 date
19950404 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1993-95597, filed on 26 Jul 1993,
now abandoned
DT Utility
FS Granted
LN.CNT 1226
INCL INCLM: 435/006.000
INCLS: 530/300.000; 530/387.100; 536/023.100; 536/024.500
NCL NCLM: 435/006.000
NCLS: 530/300.000; 530/387.100; 536/023.100; 536/024.500
IC [6]

ICM: C12Q001-68
ICS: C07K002-00; C07K016-00; C07H021-04
EXF 424/143.1; 424/146.1; 424/155.1; 514/44; 530/388.22; 530/388.26;
530/388.8; 530/388.85; 530/300; 530/387.1; 536/24.5; 536/23.1; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 258 OF 362 USPATFULL on STN
AN 97:120591 USPATFULL
TI Compositions comprising bone morphogenic proteins and truncated
parathyroid hormone related peptide, and methods of inducing
cartilage by administration of same
IN Hattersley, Gary, Cambridge, MA, United States
Rosen, Vicki A., Chestnut Hill, MA, United States
PA Genetics Institute, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 5700774 19971223 <--
AI US 1996-622101 19960326 (8)
DT Utility
FS Granted
LN.CNT 668
INCL INCLM: 514/002.000
INCLS: 514/008.000; 514/012.000; 530/350.000; 530/397.000; 530/399.000
NCL NCLM: 514/002.000
NCLS: 514/008.000; 514/012.000; 530/350.000; 530/397.000; 530/399.000
IC [6]
ICM: A61K038-22
ICS: A61K038-18; A61K038-29
EXF 514/2; 514/8; 514/12; 530/350; 530/397; 530/399; 435/69.1; 435/69.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 259 OF 362 USPATFULL on STN
AN 97:118013 USPATFULL
TI Native calcitonin mimetics
IN McKernan, Patricia A., Woodinville, WA, United States
Chen, Lennie, Renton, WA, United States
Petrie, Charles, Woodinville, WA, United States
Piggott, James, Bothell, WA, United States
West, Robert R., Seattle, WA, United States
Gasper, Shirley, Carnation, WA, United States
Lellis, Colin, Lansdale, PA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5698521 19971216 <--
AI US 1995-416602 19950404 (8)
DT Utility
FS Granted
LN.CNT 1385
INCL INCLM: 514/013.000
INCLS: 530/307.000; 530/326.000
NCL NCLM: 514/013.000
NCLS: 530/307.000; 530/326.000
IC [6]
ICM: A61K038-00
ICS: C07K005-00; C07K007-00
EXF 514/13; 530/307; 530/326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 260 OF 362 USPATFULL on STN
AN 97:112300 USPATFULL
TI Method of ordering sequence binding preferences of a DNA-binding
molecule
IN Edwards, Cynthia A., Menlo Park, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States4)
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
corporation)
PI US 5693463 19971202 <--
AI US 1992-996783 19921223 (7)
RLI Continuation-in-part of Ser. No. US 1991-723618, filed on 27 Jun 1991,
now abandoned
DT Utility
FS Granted
LN.CNT 4908
INCL INCLM: 435/006.000
INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000
NCL NCLM: 435/006.000

NCLS: 435/007.230; 536/023.100
IC [6]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-02; C12N015-00
EXF 435/6; 435/235; 536/23.1; 536/23.2; 514/44; 530/350; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 261 OF 362 USPATFULL on STN
AN 97:106824 USPATFULL
TI Method for regulating bone forming cells
IN Benayahu, Dafna, Herzlia, Israel
Wientroub, Shlomo, Tel-Aviv, Israel
PA Ramot University Authority for Applied Research and Industrial
Development, Ltd., Tel-Aviv, Israel (non-U.S. corporation)
PI US 5688531 19971118 <--
AI US 1994-363354 19941223 (8)
DT Utility
FS Granted
LN.CNT 676
INCL INCLM: 424/574.000
INCLS: 435/240.200
NCL NCLM: 424/574.000
IC [6]
ICM: A61K035-28
EXF 424/529; 424/574; 424/577; 435/240.2

L3 ANSWER 262 OF 362 USPATFULL on STN
AN 97:104145 USPATFULL
TI Microcapsules of predetermined peptide(s) specificity (ies), their
preparation and uses
IN Speaker, Tully J., Philadelphia, PA, United States
Sultzbaugh, Kenneth J., Philadelphia, PA, United States
PA Temple University of the Commonwealth System of Higher Education,
Philadelphia, PA, United States (U.S. corporation)
PI US 5686113 19971111 <--
AI US 1995-408052 19950321 (8)
DT Utility
FS Granted
LN.CNT 1708
INCL INCLM: 424/490.000
INCLS: 424/491.000; 424/492.000; 424/493.000; 424/494.000; 424/497.000
NCL NCLM: 424/490.000
NCLS: 424/491.000; 424/492.000; 424/493.000; 424/494.000; 424/497.000
IC [6]
ICM: A61K009-16
ICS: A61K009-50
EXF 424/490; 424/491; 424/492; 424/493; 424/494; 424/495; 424/497
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 263 OF 362 USPATFULL on STN
AN 97:101887 USPATFULL
TI Chimeric hepatocyte growth factor (HGF) ligand variants
IN Godowski, Paul J., Burlingame, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5684136 19971104 <--
AI US 1995-435501 19950505 (8)
RLI Continuation of Ser. No. US 1993-87784, filed on 13 Jul 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1992-950572,
filed on 21 Sep 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1992-884811, filed on 18 May 1992, now patented, Pat. No. US
5316921 And Ser. No. US 1992-885971, filed on 18 May 1992, now patented,
Pat. No. US 5328837
DT Utility
FS Granted
LN.CNT 2916
INCL INCLM: 530/399.000
INCLS: 530/387.300
NCL NCLM: 530/399.000
NCLS: 530/387.300
IC [6]
ICM: C07K014-475
EXF 530/350; 530/399; 530/387.3; 530/402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 264 OF 362 USPATFULL on STN

AN 97:101641 USPATFULL
 TI Methods for identifying modulators of human calcitonin mediated metabolism
 IN Moore, Emma E., Seattle, WA, United States
 Sheppard, Paul O., Redmond, WA, United States
 Kuestner, Rolf E., Bothell, WA, United States
 PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5683884 19971104 <--
 AI US 1995-452802 19950530 (8)
 RLI Division of Ser. No. US 1993-100887, filed on 2 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-954804, filed on 30 Sep 1992, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2344
 INCL INCLM: 435/007.100
 INCLS: 435/007.100; 435/007.210; 435/240.100; 435/240.200; 530/350.000; 530/399.000; 530/395.000; 536/023.100; 536/023.500
 NCL NCLM: 435/007.100
 NCLS: 435/007.200; 435/007.210; 530/350.000; 530/395.000; 530/399.000; 536/023.100; 536/023.500
 IC [6]
 ICM: G01N033-53
 ICS: C12N015-12; C12N015-63; C07K014-72
 EXF 435/7.1; 435/7.21; 435/240.1; 435/240.2; 435/325; 530/350; 530/399; 530/395; 536/23.1; 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 265 OF 362 USPATFULL on STN
 AN 97:96899 USPATFULL
 TI Epoxysuccinic acid derivatives, their production and use
 IN Tsubotani, Shigetoshi, Ibaraki, Japan
 Takizawa, Masayuki, Ibaraki, Japan
 Mizoguchi, Junji, Osaka, Japan
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
 PI US 5679708 19971021 <--
 WO 9532954 19941207 <--
 AI US 1995-513895 19950905 (8)
 WO 1995-JP1004 19950525
 19950905 PCT 371 date
 19950905 PCT 102(e) date
 PRAI JP 1994-119206 19940531
 JP 1994-186166 19940808
 DT Utility
 FS Granted
 LN.CNT 1785
 INCL INCLM: 514/475.000
 INCLS: 549/548.000; 549/549.000
 NCL NCLM: 514/475.000
 NCLS: 549/548.000; 549/549.000
 IC [6]
 ICM: C07D303-48
 ICS: C07D405-12; A61K031-335
 EXF 514/475; 549/548; 549/549
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 266 OF 362 USPATFULL on STN
 AN 97:93884 USPATFULL
 TI Compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisulatory capsules
 IN Baetge, Edward E., Barrington, RI, United States
 Hammang, Joseph P., Barrington, RI, United States
 Gentile, Frank T., Warwick, RI, United States
 Lindner, Mark D., Bristol, RI, United States
 Winn, Shelley R., Smithfield, RI, United States
 Emerich, Dwaine F., Providence, RI, United States
 PA CytoTherapeutics, Inc., Providence, RI, United States (U.S. corporation)
 PI US 5676943 19971014 <--
 AI US 1995-450316 19950525 (8)
 RLI Continuation-in-part of Ser. No. US 1993-105278, filed on 12 Aug 1993, now abandoned
 DT Utility
 FS Granted
 LN.CNT 2545
 INCL INCLM: 424/093.210

INCLS: 424/093.300; 435/172.300
NCL NCLM: 424/093.210
NCLS: 424/093.300
IC [6]
ICM: A01N063-00
ICS: C62N015-00
EXF 424/93.21; 424/408; 424/425; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 267 OF 362 USPATFULL on STN
AN 97:93872 USPATFULL
TI Aerosol drug formulations for use with non CFC propellants
IN Adjei, Akwete L., Wadsworth, IL, United States
Gupta, Pramod K., Gurnee, IL, United States
Lu, Mou-Ying Fu, Lake Bluff, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5676931 19971014 <--
AI US 1996-655275 19960515 (8)
RLI Continuation of Ser. No. US 1993-161115, filed on 2 Dec 1993, now
abandoned
DT Utility
FS Granted
LN.CNT 620
INCL INCLM: 424/045.000
INCLS: 424/046.000; 514/937.000
NCL NCLM: 424/045.000
NCLS: 424/046.000; 514/937.000
IC [6]
ICM: A61K009-12
EXF 424/43; 424/45; 424/46; 514/958; 514/937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 268 OF 362 USPATFULL on STN
AN 97:91636 USPATFULL
TI Human calcitonin receptor polypeptides
IN Moore, Emma E., Seattle, WA, United States
Sheppard, Paul O., Redmond, WA, United States
Kuestner, Rolf E., Bothell, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5674981 19971007 <--
AI US 1995-453222 19950530 (8)
RLI Division of Ser. No. US 1993-100887, filed on 2 Aug 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1992-954804, filed on 30
Sep 1992, now abandoned
DT Utility
FS Granted
LN.CNT 2330
INCL INCLM: 530/350.000
INCLS: 536/023.500; 536/024.100
NCL NCLM: 530/350.000
NCLS: 536/023.500; 536/024.100
IC [6]
ICM: C07K014-435
ICS: C12N015-12
EXF 534/350; 536/23.5; 536/24.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 269 OF 362 USPATFULL on STN
AN 97:91352 USPATFULL
TI Human calcitonin receptor polypeptides and methods of use
IN Moore, Emma E., Seattle, WA, United States
Sheppard, Paul O., Redmond, WA, United States
Kuestner, Rolf E., Bothell, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5674689 19971007 <--
AI US 1995-454464 19950530 (8)
RLI Division of Ser. No. US 1993-100887, filed on 2 Aug 1993, now abandoned
which is a continuation-in-part of Ser. No. US 1992-954804, filed on 30
Sep 1992, now abandoned
DT Utility
FS Granted
LN.CNT 2343
INCL INCLM: 435/007.100
INCLS: 435/007.920; 435/072.000; 530/810.000; 536/023.500
NCL NCLM: 435/007.100
NCLS: 435/007.200; 435/007.920; 530/810.000; 536/023.500

IC [6]
ICM: G01N033-566
ICS: C07K017-00; C12N015-12
EXF 435/7.21; 435/69.1; 435/7.2; 435/6; 435/240.6; 435/320.1; 435/252.3;
435/7.1; 435/7.92; 435/7.29; 435/240.2; 536/23.1; 536/23.5; 530/350;
530/812; 530/810
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 270 OF 362 USPATFULL on STN
AN 97:83955 USPATFULL
TI Aziridine derivatives, their production and use
IN Tsubotani, Shigetoshi, Ibaraki, Japan
Takizawa, Masayuki, Ibaraki, Japan
Shirasaki, Mikio, Ibaraki, Japan
Mizoguchi, Junji, Osaka, Japan
Shimizu, Yoshiaki, Ibaraki, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5668128 19970916 <--
WO 9528416 19951026 <--
AI US 1995-513896 19950905 (8)
WO 1995-JP718 19950412
19950905 PCT 371 date
19950905 PCT 102(e) date
PRAI JP 1994-74621 19940413
JP 1994-269175 19941101
DT Utility
FS Granted
LN.CNT 4333
INCL INCLM: 514/183.000
INCLS: 514/235.500; 514/326.000; 514/336.000; 514/371.000; 514/422.000;
544/111.000; 546/208.000; 546/268.100; 548/195.000; 548/518.000;
548/966.000
NCL NCLM: 514/183.000
NCLS: 514/235.500; 514/326.000; 514/336.000; 514/371.000; 514/422.000;
544/111.000; 546/208.000; 546/268.100; 548/195.000; 548/518.000;
548/966.000

IC [6]
ICM: C07D203-16
ICS: C07D413-00; A61K031-33; A61K031-535
EXF 548/966; 548/195; 548/518; 514/183; 514/235.5; 514/326; 514/336;
514/371; 514/422; 544/111; 546/208; 546/268.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 271 OF 362 USPATFULL on STN
AN 97:80910 USPATFULL
TI Antibodies recognizing tumor associated antigen CA 55.1
IN Rose, Michael Samuel, Wilmslow, United Kingdom
Boot, Christopher, Northwich, United Kingdom
Copley, Clive Graham, Macclesfield, United Kingdom
Paterson, Douglas Stephen, Macclesfield, United Kingdom
Hall, Susan Margaret, Adlington, United Kingdom
Wright, Andrew Firman, Macclesfield, United Kingdom
Blakey, David Charles, Macclesfield, United Kingdom
PA Zeneca Limited, London, United Kingdom (non-U.S. corporation)
PI US 5665357 19970909 <--
AI US 1994-353400 19941202 (8)
PRAI GB 1993-24819 19931203
GB 1994-11089 19940603
DT Utility
FS Granted
LN.CNT 2937
INCL INCLM: 424/178.100
INCLS: 530/387.100; 530/300.000; 530/328.000; 530/387.300; 530/388.800;
530/391.300; 530/391.700; 530/391.900; 536/023.530; 435/320.100;
435/252.300; 435/344.000; 435/007.920; 435/069.700; 435/091.100;
435/172.100; 435/172.300; 435/331.000; 435/332.000; 435/344.100;
424/183.100; 424/130.100; 424/181.100; 424/182.100
NCL NCLM: 424/178.100
NCLS: 424/130.100; 424/181.100; 424/182.100; 424/183.100; 435/007.920;
435/069.700; 435/091.100; 435/252.300; 435/320.100; 435/331.000;
435/332.000; 435/344.000; 435/344.100; 530/300.000; 530/328.000;
530/387.100; 530/387.300; 530/388.800; 530/391.300; 530/391.700;
530/391.900; 536/023.530

IC [6]
ICM: A61K039-395
ICS: C07K019-00; G01N033-53; C12N005-12

EXF 424/130.1; 424/133.1; 424/152.1; 424/155.1; 424/156.1; 424/179.1;
424/180.1; 424/181.1; 424/182.1; 424/183.1; 424/178.1; 435/7.92;
435/69.7; 435/91.1; 435/172.2; 435/240.27; 435/240.1; 435/252.3;
435/320.1; 530/387.1; 530/300; 530/328; 530/387.3; 530/388.8; 530/391.3;
530/391.7; 530/391.9; 536/23.53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 272 OF 362 USPATFULL on STN
AN 97:75816 USPATFULL
TI Antibodies that bind to endoglin
IN Thorpe, Philip E., Dallas, TX, United States
Burrows, Francis J., San Diego, CA, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 5660827 19970826 <--
AI US 1995-457229 19950601 (8)
RLI Division of Ser. No. US 1994-350212, filed on 5 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994 which is a continuation-in-part of Ser. No. US 1994-295868, filed on 6 Sep 1994 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 5787
INCL INCLM: 424/152.100
INCLS: 424/141.100; 424/130.100; 424/138.100; 530/387.100; 530/388.100
NCL NCLM: 424/152.100
NCLS: 424/130.100; 424/138.100; 424/141.100; 530/387.100; 530/388.100
IC [6]
ICM: A61K039-395
ICS: C07K016-00
EXF 530/387.1; 530/388.1; 530/388.85; 424/130.1; 424/138.1; 424/141.1; 424/152.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 273 OF 362 USPATFULL on STN
AN 97:73285 USPATFULL
TI Cytotoxic drug therapy
IN Bagshawe, Kenneth Dawson, London, United Kingdom
PA AEPACT Limited, United Kingdom (non-U.S. corporation)
PI US 5658568 19970819 <--
WO 9313805 19930722 <--
AI US 1994-256475 19940708 (8)
WO 1993-GB39 19930111
19940708 PCT 371 date
19940708 PCT 102(e) date
PRAI GB 1992-417 19920109
DT Utility
FS Granted
LN.CNT 1261
INCL INCLM: 424/134.100
INCLS: 424/136.100; 424/155.100; 424/183.100; 424/809.000; 424/094.100; 436/819.000; 514/002.000; 530/350.000; 530/387.300; 530/387.700; 530/389.700; 530/391.700
NCL NCLM: 424/134.100
NCLS: 424/094.100; 424/136.100; 424/155.100; 424/183.100; 424/809.000; 436/819.000; 514/002.000; 530/350.000; 530/387.300; 530/387.700; 530/389.700; 530/391.700
IC [6]
ICM: A61K039-395
ICS: A61K038-43; C07K016-28; C07K017-00
EXF 424/178.1; 424/134.1; 424/136.1; 424/155.1; 424/183.1; 424/809; 424/94.1; 514/2; 436/819; 530/350; 530/387.3; 530/387.7; 530/389.7; 530/391.7

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 274 OF 362 USPATFULL on STN
AN 97:70922 USPATFULL
TI Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules
IN Baetge, Edward E., Barrington, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Gentile, Frank T., Warwick, RI, United States
Lindner, Mark D., Bristol, RI, United States
Winn, Shelley R., Smithfield, RI, United States
Emerich, Dwaine F., Providence, RI, United States

PA Cyto Therapeutics, Inc., Providence, RI, United States (U.S. corporation)
PI US 5656481 19970812 <--
AI US 1995-449946 19950525 (8)
RLI Continuation-in-part of Ser. No. US 1993-105278, filed on 12 Aug 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2543
INCL INCLM: 435/325.000
INCLS: 435/172.300; 435/347.000; 435/382.000; 435/373.000; 424/093.200; 424/093.210; 424/093.300; 424/093.700; 424/093.100
NCL NCLM: 435/325.000
NCLS: 424/093.100; 424/093.200; 424/093.210; 424/093.300; 424/093.700; 435/347.000; 435/373.000; 435/382.000
IC [6]
ICM: C12N015-00
ICS: C12N005-00; A01N063-00
EXF 424/93.21; 424/408; 424/425; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 275 OF 362 USPATFULL on STN
AN 97:68153 USPATFULL
TI Compositions and methods for the delivery of biologically active molecules using cells contained in biocompatible capsules
IN Baetge, Edward E., Barrington, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Gentile, Frank T., Warwick, RI, United States
Lindner, Mark D., Bristol, RI, United States
Winn, Shelley R., Smithfield, RI, United States
Emerich, Dwaine F., Providence, RI, United States
PA CytoTherapeutics, Inc., Providence, RI, United States (U.S. corporation)
PI US 5653975 19970805 <--
AI US 1995-451044 19950525 (8)
RLI Continuation-in-part of Ser. No. US 1993-105278, filed on 12 Aug 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2532
INCL INCLM: 424/093.100
INCLS: 424/093.200; 424/093.210; 424/093.300; 424/093.700; 435/172.300
NCL NCLM: 424/093.100
NCLS: 424/093.200; 424/093.210; 424/093.300; 424/093.700
IC [6]
ICM: C12N015-00
ICS: C12N005-00; A01N063-00
EXF 424/93.21; 424/408; 424/425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 276 OF 362 USPATFULL on STN
AN 97:66223 USPATFULL
TI OP-3-induced morphogenesis
IN Oppermann, Hermann, Medway, MA, United States
Ozkaynak, Engin, Milford, MA, United States
Kuberasampath, Thangavel, Medway, MA, United States
Rueger, David C., Hopkinton, MA, United States
Pang, Roy H. L., Etna, NH, United States
Cohen, Charles M., Medway, MA, United States
PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)
PI US 5652337 19970729 <--
AI US 1995-479666 19950607 (8)
RLI Division of Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-922813, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-752764, filed on 31 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned, said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-923780, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned, said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-938336, filed on 28 Aug 1992,

now abandoned And a continuation-in-part of Ser. No. US 1992-938337, filed on 28 Aug 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-938021, filed on 28 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-752861, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-945285, filed on 15 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-945286, filed on 15 Sep 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned , said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-946235, filed on 16 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-946238, filed on 16 Sep 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned

DT Utility
FS Granted

LN.CNT 2887

INCL INCLM: 530/350.000
INCLS: 530/399.000

NCL NCLM: 530/350.000
NCLS: 530/399.000

IC [6]

EXF ICM: C07K019-51
530/350; 530/399

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 277 OF 362 USPATFULL on STN

AN 97:66010 USPATFULL

TI Nucleic acid encoding a novel morphogenic protein, OP-3

IN Ozkaynak, Engin, Milford, MA, United States

PA Oppermann, Hermann, Medway, MA, United States

PI Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S.
corporation)

PI US 5652118 19970729 <--

AI US 1995-480528 19950607 (8)

RLI Continuation of Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-922813, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-752764, filed on 31 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-923780, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-752857, filed on 30 Aug 1991, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-938336, filed on 28 Aug 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-938337, filed on 28 Aug 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-753059, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-938021, filed on 28 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-752861, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991, now abandoned , said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-945285, filed on 15 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-945286, filed on 15 Sep 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-752764, filed on 30 Aug 1991, now abandoned , said Ser. No. US 1992-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-946235, filed on 16 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-946238, filed on 16 Sep 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of

Ser. No. US 1991-252764, filed on 30 Aug 1991, now abandoned
DT Utility
FS Granted
LN.CNT 3004
INCL INCLM: 435/069.100
INCLS: 435/252.300; 435/252.330; 435/070.100; 435/070.300; 435/071.100;
435/071.200; 435/320.100; 435/172.300; 435/325.000; 435/348.000;
435/358.000; 435/360.000; 435/365.100; 435/366.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/070.100; 435/070.300; 435/071.100; 435/071.200; 435/252.300;
435/252.330; 435/320.100; 435/325.000; 435/348.000; 435/358.000;
435/360.000; 435/365.100; 435/366.000; 536/023.500
IC [6]
ICM: C12N005-10
ICS: C12N015-12; C12N015-63; C07H021-04
EXF 435/69.1; 435/240.2; 435/320.1; 435/252.3; 435/252.33; 435/70.1;
435/70.3; 435/71.1; 435/71.2; 435/172.3; 536/23.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 278 OF 362 USPATFULL on STN
AN 97:59097 USPATFULL
TI Method for preparing an expanded culture and clonal strains of
pancreatic, thyroid or ***parathyroid*** cells
IN Coon, Hayden G., Gaithersburg, MD, United States
Ambesi-Impimbato, Francesco Saverio, Tricesimo, Italy
Curcio, Francesco, Pagnacco, Italy
PA Human Cell Cultures, Inc., Gaithersburg, MD, United States (U.S.
corporation)
PI US 5646035 19970708 <--
AI US 1995-480149 19950607 (8)
RLI Continuation of Ser. No. US 1993-83772, filed on 30 Jun 1993, now
abandoned which is a continuation-in-part of Ser. No. US 1993-44010,
filed on 8 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1831
INCL INCLM: 435/378.000
INCLS: 435/383.000; 435/397.000
NCL NCLM: 435/378.000
NCLS: 435/383.000; 435/397.000
IC [6]
ICM: C12N005-06
ICS: C12N005-08; C12N005-00
EXF 435/240.2; 435/240.21; 435/240.3; 435/240.31
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 279 OF 362 USPATFULL on STN
AN 97:56512 USPATFULL
TI Human epidermal gene promoter
IN Polakowska, Renata Regina, Pittsford, NY, United States
Goldsmith, Lowell Alan, Pittsford, NY, United States
PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
corporation)
PI US 5643746 19970701 <--
AI US 1994-216219 19940321 (8)
RLI Continuation of Ser. No. US 1993-73190, filed on 8 Jun 1993, now
abandoned which is a continuation of Ser. No. US 1992-826931, filed on
23 Jan 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1162
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/366.000; 435/371.000; 435/372.300; 935/062.000;
935/034.000; 935/070.000; 536/023.100
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/366.000; 435/371.000; 536/023.100
IC [6]
ICM: C12N015-63
ICS: C12N015-79; C12N015-09
EXF 536/23.1; 435/320.1; 435/240.2; 435/172.3; 935/22; 935/70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 280 OF 362 USPATFULL on STN
AN 97:52184 USPATFULL
TI Chimeric immunocompromised mammal comprising vascularized fetal organ
tissue

IN McCune, III, Joseph M., San Francisco, CA, United States
PA The Board of Trustees for the Leland Stanford Junior University, Palo
Alto, CA, United States (U.S. corporation)
PI US 5639939 19970617 <--
AI US 1994-205053 19940301 (8)
RLI Continuation-in-part of Ser. No. US 1991-737882, filed on 25 Jul 1991,
now abandoned which is a continuation of Ser. No. US 1989-343797, filed
on 26 Apr 1989, now abandoned which is a continuation-in-part of Ser.
No. US 1988-287075, filed on 20 Dec 1988, now abandoned which is a
continuation of Ser. No. US 1987-137173, filed on 23 Dec 1987, now
abandoned
DT Utility
FS Granted
LN.CNT 1597
INCL INCLM: 800/002.000
INCLS: 800/DIG.005; 623/011.000; 424/009.200; 424/553.000; 424/578.000;
424/579.000; 424/093.700; 424/577.000; 424/549.000; 424/582.000;
424/580.000
NCL NCLM: 800/011.000
NCLS: 424/009.200; 424/093.700; 424/549.000; 424/553.000; 424/577.000;
424/578.000; 424/579.000; 424/580.000; 424/582.000
IC [6]
ICM: A61K049-00
EXF 800/2; 800/DIG.5; 623/11; 424/9.2; 424/93.7; 424/580; 424/553; 424/578;
424/579; 424/577; 424/549; 424/582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 281 OF 362 USPATFULL on STN
AN 97:51873 USPATFULL
TI Polymeric particles having a biodegradable gelatin or aminodextran
coating and process for making same
IN Siiman, Olavi, Davie, FL, United States
Burshteyn, Alexander, Hialeah, FL, United States
Gupta, Ravinder K., Pembroke Pines, FL, United States
PA Coulter Corporation, Miami, FL, United States (U.S. corporation)
PI US 5639620 19970617 <--
AI US 1994-336725 19941109 (8)
RLI Continuation of Ser. No. US 1992-961157, filed on 15 Oct 1992, now
abandoned which is a continuation-in-part of Ser. No. US 1990-607253,
filed on 31 Oct 1990, now patented, Pat. No. US 5169754
DT Utility
FS Granted
LN.CNT 1903
INCL INCLM: 435/007.210
INCLS: 427/007.130; 427/007.140; 428/403.000; 428/407.000; 436/173.000;
436/518.000; 436/524.000; 436/525.000; 436/526.000; 436/529.000;
436/531.000; 436/532.000; 436/533.000; 436/534.000
NCL NCLM: 435/007.210
NCLS: 427/002.130; 427/002.140; 428/403.000; 428/407.000; 436/173.000;
436/518.000; 436/524.000; 436/525.000; 436/526.000; 436/529.000;
436/531.000; 436/532.000; 436/533.000; 436/534.000
IC [6]
ICM: G01N033-545
ICS: G01N033-546; G01N033-548; G01N033-547
EXF 427/2; 427/127-131; 427/213.35; 427/215; 427/216; 427/337; 427/338;
427/2.11; 427/2.13; 427/2.14; 428/403; 428/407; 435/5; 435/7.21;
436/173; 436/518; 436/524-526; 436/529; 436/531; 436/532-534
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 282 OF 362 USPATFULL on STN
AN 97:51534 USPATFULL
TI Delivery of biologically active molecules using cells contained in
biocompatible immunoisulatory capsules
IN Baetge, Edward E., Barrington, RI, United States
Hammang, Joseph P., Barrington, RI, United States
Gentile, Frank T., Warwick, RI, United States
Lindner, Mark D., Bristol, RI, United States
Winn, Shelley R., Smithfield, RI, United States
Emerich, Dwaine F., Providence, RI, United States
PA CytoTherapeutics, Inc., Providence, RI, United States (U.S. corporation)
PI US 5639275 19970617 <--
AI US 1995-449756 19950525 (8)
RLI Continuation-in-part of Ser. No. US 1993-105278, filed on 12 Aug 1993,
now abandoned
DT Utility
FS Granted

LN.CNT 2522
INCL INCLM: 604/891.100
INCLS: 424/422.000; 424/424.000; 424/093.100; 424/093.200; 435/172.300;
435/240.200
NCL NCLM: 604/891.100
NCLS: 424/093.100; 424/093.200; 424/422.000; 424/424.000; 435/325.000
IC [6]
ICM: A61K009-22
ICS: C12N015-00; C12N005-00; A01N063-00
EXF 424/93.21; 424/408; 604/891.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 283 OF 362 USPATFULL on STN
AN 97:47297 USPATFULL
TI Agonist antibodies against the flk2/flt3 receptor and uses thereof
IN Bennett, Brian D., Pacifica, CA, United States
Broz, Susan D., San Bruno, CA, United States
Matthews, William, Woodside, CA, United States
Zeigler, Francis C., San Mateo, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5635388 19970603 <--
AI US 1994-22299 19940404 (8)
DT Utility
FS Granted
LN.CNT 2015
INCL INCLM: 435/334.000
INCLS: 530/387.300; 530/388.220; 530/389.100; 530/351.000; 536/023.530;
435/070.210; 435/172.200; 435/320.100; 435/328.000; 424/085.100;
424/085.200; 424/085.500
NCL NCLM: 435/334.000
NCLS: 424/085.100; 424/085.200; 424/085.500; 435/070.210; 435/320.100;
435/328.000; 530/351.000; 530/387.300; 530/388.220; 530/389.100;
536/023.530
IC [6]
ICM: C12N005-20
ICS: C07K016-28; C07H015-12
EXF 530/388.22; 530/389.1; 530/387.3; 536/23.53; 435/240.27; 435/172.2;
435/70.21; 435/320.1; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 284 OF 362 USPATFULL on STN
AN 97:47078 USPATFULL
TI Aerosol drug formulations containing vegetable oils
IN Adjei, Akwete L., Wadsworth, IL, United States
Gupta, Pramod K., Gurnee, IL, United States
Lee, Dennis Y., Highland Park, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5635161 19970603 <--
AI US 1995-48522 19950607 (8)
DT Utility
FS Granted
LN.CNT 928
INCL INCLM: 424/045.000
INCLS: 424/046.000; 514/937.000
NCL NCLM: 424/045.000
NCLS: 424/046.000; 514/937.000
IC [6]
ICM: A61K009-12
EXF 424/43; 424/45; 424/46; 514/937
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 285 OF 362 USPATFULL on STN
AN 97:47076 USPATFULL
TI Aerosol drug formulations containing polyglycolyzed glycerides
IN Fu Lu, Mou-Ying, Lake Bluff, IL, United States
Adjei, Akwete L., Wadsworth, IL, United States
Gupta, Pramod K., Gurnee, IL, United States
PA Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)
PI US 5635159 19970603 <--
AI US 1994-296778 19940826 (8)
DT Utility
FS Granted
LN.CNT 663
INCL INCLM: 424/045.000
INCLS: 424/046.000

NCL NCLM: 424/045.000
NCLS: 424/046.000
IC [6]
ICM: A61K009-12
EXF 424/43; 424/45; 424/46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 286 OF 362 USPATFULL on STN
AN 97:44930 USPATFULL
TI Fermentor with vertical shaft
IN Swartz, James R., Menlo Park, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 5633165 19970527 <--
AI US 1995-451241 19950525 (8)
RLI Division of Ser. No. US 1994-240121, filed on 9 May 1994, now patented, Pat. No. US 5487980 which is a division of Ser. No. US 1992-989844, filed on 23 Nov 1992, now patented, Pat. No. US 5342763
DT Utility
FS Granted
LN.CNT 2261
INCL INCLM: 435/287.100
INCLS: 435/287.500; 435/289.100; 435/286.700
NCL NCLM: 435/287.100
NCLS: 435/286.700; 435/287.500; 435/289.100
IC [6]
ICM: C12M001-06
EXF 435/286.1; 435/286.5; 435/286.6; 435/286.7; 435/287.1; 435/287.5; 435/289.1; 435/302.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 287 OF 362 USPATFULL on STN
AN 97:33634 USPATFULL
TI Recombinant production of human calcitonin receptor polypeptides
IN Moore, Emma E., Seattle, WA, United States
Sheppard, Paul O., Redmond, WA, United States
Kuestner, Rolf E., Bothell, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5622839 19970422 <--
AI US 1995-453742 19950530 (8)
RLI Continuation of Ser. No. US 1993-100887, filed on 2 Aug 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-954804, filed on 30 Sep 1992, now abandoned
DT Utility
FS Granted
LN.CNT 2390
INCL INCLM: 435/069.100
INCLS: 536/023.500; 435/320.100; 435/254.110; 435/325.000; 435/419.000; 435/348.000; 435/349.000; 435/352.000; 435/365.000
NCL NCLM: 435/069.100
NCLS: 435/254.110; 435/320.100; 435/325.000; 435/348.000; 435/349.000; 435/352.000; 435/365.000; 435/419.000; 536/023.500
IC [6]
ICM: C12N015-12
ICS: C12N015-63; C12N005-10
EXF 536/23.5; 536/24.31; 435/69.1; 435/320.1; 435/240.2; 435/254.11; 530/415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 288 OF 362 USPATFULL on STN
AN 97:26904 USPATFULL
TI Non-crosslinked protein particles for therapeutic and diagnostic use
IN Yen, Richard C. K., Glendora, CA, United States
PA Hemosphere, Inc., Irvine, CA, United States (U.S. corporation)
PI US 5616311 19970401 <--
AI US 1994-212546 19940314 (8)
RLI Continuation-in-part of Ser. No. US 1993-69831, filed on 1 Jun 1993, now abandoned And Ser. No. US 1992-959560, filed on 13 Oct 1992, now patented, Pat. No. US 5308620 which is a continuation-in-part of Ser. No. US 1991-641720, filed on 15 Jan 1991, now abandoned
DT Utility
FS Granted
LN.CNT 2585
INCL INCLM: 424/001.330
INCLS: 424/001.290; 424/001.370; 424/484.000; 424/499.000; 424/002.140; 424/002.210; 424/213.300; 424/213.330; 428/402.200; 428/402.240; 435/177.000; 935/054.000

NCL NCLM: 424/001.330
 NCLS: 424/001.290; 424/001.370; 424/484.000; 424/499.000; 427/002.140;
 427/002.210; 427/213.300; 427/213.330; 428/402.200; 428/402.240;
 435/177.000

IC [6]
 ICM: A61K051-08
 ICS: A61K009-50; B01J013-08; C12N011-02

EXF 264/4.3; 427/213.33; 427/2; 427/2.14; 427/2.21; 427/3; 427/213.3;
 428/402.2; 428/402.24; 424/1.29; 424/1.33; 424/1.37; 424/484; 424/499;
 514/832; 514/965; 935/54; 435/177

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 289 OF 362 USPATFULL on STN
 AN 97:22481 USPATFULL
 TI Super-globuling for in vivo extended lifetimes
 IN Pouletty, Philippe, Atherton, CA, United States
 Pouletty, Christine, Atherton, CA, United States
 PA RedCell, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5612034 19970318 <--
 AI US 1994-237346 19940503 (8)
 RLI Continuation-in-part of Ser. No. US 1993-137821, filed on 15 Oct 1993
 which is a continuation-in-part of Ser. No. US 1993-70092, filed on 27
 May 1993 which is a continuation-in-part of Ser. No. US 1990-592214,
 filed on 3 Oct 1990

DT Utility
 FS Granted
 LN.CNT 699

INCL INCLM: 424/184.100
 INCLS: 530/402.000; 530/328.000; 530/327.000; 530/326.000; 514/001.000;
 424/193.100

NCL NCLM: 424/184.100
 NCLS: 424/193.100; 514/001.000; 530/326.000; 530/327.000; 530/328.000;
 530/402.000

IC [6]
 ICM: A61K039-00
 ICS: A61K038-00

EXF 424/136.1; 424/140.1; 424/130.1; 424/193.1; 424/184.1; 530/402; 530/328;
 530/327; 530/326; 514/1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 290 OF 362 USPATFULL on STN
 AN 97:20647 USPATFULL
 TI Monoclonal antibodies against melanoma
 IN Brandt, Michael, Iffeldorf, Germany, Federal Republic of
 Endl, Josef, weilheim, Germany, Federal Republic of
 Jungfer, Herbert, Starnberg, Germany, Federal Republic of
 Albert, winfried, Eberfing, Germany, Federal Republic of
 PA Boehringer Mannheim GmbH, Mannheim-Waldhof, Germany, Federal Republic of
 (non-U.S. corporation)
 PI US 5610280 19970311 <--
 AI US 1994-214020 19940315 (8)
 RLI Continuation of Ser. No. US 1991-773796, filed on 9 Oct 1991, now
 abandoned

PRAI DE 1990-4032312 19901011
 DE 1991-4107154 19910306

DT Utility
 FS Granted
 LN.CNT 622

INCL INCLM: 530/387.500
 INCLS: 530/388.800; 530/391.300; 435/070.210; 435/172.200

NCL NCLM: 530/387.500
 NCLS: 435/070.210; 530/388.800; 530/391.300

IC [6]
 ICM: A61K051-10
 ICS: C07K016-00; G01N033-53; C12N005-12

EXF 530/307.5; 530/391.3; 530/388.8; 435/70.21; 435/172.2; 435/240.27

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 291 OF 362 USPATFULL on STN
 AN 97:15948 USPATFULL
 TI Carbohydrate-directed cross-linking reagents
 IN Ashkenazi, Avi J., San Mateo, CA, United States
 Chamow, Steven M., San Mateo, CA, United States
 Kogan, Timothy P., Sugar Land, TX, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S.
 corporation)

PI US 5605791 19970225 <--
AI US 1995-416402 19950331 (8)
RLI Division of Ser. No. US 1993-115404, filed on 1 Sep 1993 which is a
division of Ser. No. US 1992-926077, filed on 5 Aug 1992, now patented,
Pat. No. US 5329028, issued on 12 Jul 1994
DT Utility
FS Granted
LN.CNT 1053
INCL INCLM: 435/005.000
INCLS: 435/007.100; 548/546.000
NCLM: 435/005.000
NCLS: 435/007.100; 548/546.000
IC [6]
ICM: C12Q001-68
ICS: C12Q001-70; G01N033-53
EXF 548/546; 435/5; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 292 OF 362 USPATFULL on STN
AN 97:7829 USPATFULL
TI Cadherin-specific antibodies and hybridoma cell lines
IN Suzuki, Shintaro, Torrance, CA, United States
PA Doheny Eye Institute, Los Angeles, CA, United States (U.S. corporation)
PI US 5597725 19970128 <--
AI US 1994-188228 19940126 (8)
RLI Continuation-in-part of Ser. No. US 1993-49460, filed on 19 Apr 1993,
now abandoned which is a continuation-in-part of Ser. No. US
1992-872643, filed on 17 Apr 1992, now abandoned
DT Utility
FS Granted
LN.CNT 2106
INCL INCLM: 435/328.000
INCLS: 435/070.210; 435/172.200; 435/331.000; 435/336.000; 435/332.000;
530/387.300; 530/388.100; 530/388.220; 530/389.100; 530/389.200
NCLM: 435/328.000
NCLS: 435/070.210; 530/387.300; 530/388.100; 530/388.220; 530/389.100;
530/389.200
IC [6]
ICM: C12N005-12
ICS: A61K051-10; C07K016-00; C07K016-28
EXF 530/388.1; 530/388.22; 530/389.1; 530/389.2; 530/387.3; 435/70.21;
435/172.2; 435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 293 OF 362 USPATFULL on STN
AN 97:1350 USPATFULL
TI Transduced mesenchymal stem cells
IN Gerson, Stanton L., Pepper Pike, OH, United States
Caplan, Arnold I., Cleveland Heights, OH, United States
Haynesworth, Stephen E., Cleveland Heights, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S.
corporation)
PI US 5591625 19970107 <--
AI US 1993-158000 19931124 (8)
DT Utility
FS Granted
LN.CNT 1205
INCL INCLM: 435/240.200
INCLS: 424/093.700; 424/093.210; 435/172.300; 435/320.100; 935/062.000;
935/070.000; 935/071.000
NCLM: 435/366.000
NCLS: 424/093.210; 424/093.700; 435/320.100
IC [6]
ICM: C12N005-10
ICS: C12N005-08; C12N015-86; A61K048-00
EXF 435/240.2; 435/172.3; 435/320.1; 424/93.7; 424/93.21; 935/62; 935/70;
935/71
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 294 OF 362 USPATFULL on STN
AN 96:118670 USPATFULL
TI Anti-erbB-2 antibodies, combinations thereof, and therapeutic and
diagnostic uses thereof
IN King, C. Richter, Washington, DC, United States
Kasprzyk, Philip G., Washington, DC, United States
Bird, Robert E., Rockville, MD, United States

PA Aronex Pharmaceuticals, Inc., The Woodlands, TX, United States (U.S. corporation)
 PI US 5587458 19961224 <--
 AI US 1993-61092 19930514 (8)
 RLI Continuation-in-part of Ser. No. US 1992-906555, filed on 30 Jun 1992 which is a continuation-in-part of Ser. No. US 1991-772270, filed on 7 Oct 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 1567
 INCL INCLM: 530/387.300
 INCLS: 530/387.700; 530/388.220; 530/389.700; 530/391.300; 530/391.700; 436/501.000; 436/512.000
 NCL NCLM: 530/387.300
 NCLS: 436/501.000; 436/512.000; 530/387.700; 530/388.220; 530/389.700; 530/391.300; 530/391.700
 IC [6]
 ICM: C07K016-00
 ICS: C07K016-46; C07K016-28
 EXF 530/387.1; 530/387.3; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/389.7; 530/391.1; 530/391.3; 530/391.7; 530/388.85; 530/409; 530/866; 530/367; 530/370; 530/300; 530/350; 424/86.91; 424/130.1; 424/133.1; 424/134.1; 424/135.1; 424/138.1; 424/141.1; 424/143.1; 424/155.1; 424/156.1; 424/192.1; 424/193.1; 436/501; 436/502; 436/536; 425/7.92; 425/7.1; 425/183
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 295 OF 362 USPATFULL on STN
 AN 96:116475 USPATFULL
 TI Substituted thioureas as bifunctional chelators
 IN Coughlin, Daniel J., Robbinsville, NJ, United States
 Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
 PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
 PI US 5585468 19961217 <--
 WO 9321151 19931028 <--
 AI US 1994-204197 19940627 (8)
 WO 1993-US3208 19930408
 19940627 PCT 371 date
 19940627 PCT 102(e) date
 RLI Continuation-in-part of Ser. No. US 1992-866375, filed on 9 Apr 1992, now patented, Pat. No. US 5326856, issued on 5 Jul 1994
 DT Utility
 FS Granted
 LN.CNT 1829
 INCL INCLM: 534/014.000
 INCLS: 534/014.000; 534/010.000; 530/300.000; 530/391.500; 530/408.000; 564/018.000; 564/023.000; 564/026.000; 564/028.000; 556/045.000; 556/064.000; 556/085.000; 556/110.000; 556/118.000; 560/018.000; 562/432.000; 536/026.600; 552/502.000; 552/504.000
 NCL NCLM: 534/014.000
 NCLS: 530/300.000; 530/391.500; 530/408.000; 534/010.000; 536/026.600; 552/502.000; 552/504.000; 556/045.000; 556/064.000; 556/081.000; 556/110.000; 556/118.000; 560/018.000; 562/432.000; 564/018.000; 564/023.000; 564/026.000; 564/028.000
 IC [6]
 ICM: C07C337-06
 ICS: C07C335-22; C07D207-44; C07D213-71
 EXF 424/1.65; 424/1.49; 424/1.69; 534/10; 534/14; 556/45; 556/110; 556/118; 556/81; 556/64; 564/18; 564/23; 564/26; 564/27; 564/28; 362/435; 362/432; 530/300; 530/391.5; 530/408; 536/26.6; 552/502; 552/504; 560/18
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 296 OF 362 USPATFULL on STN
 AN 96:108854 USPATFULL
 TI Hybridoma and monoclonal antibody 9H10-A4 specific to an antigen of LNCaP cells
 IN Horoszewicz, Julius S., Williamsville, NY, United States
 PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
 PI US 5578484 19961126 <--
 AI US 1994-307544 19940916 (8)
 RLI Continuation of Ser. No. US 1992-822500, filed on 17 Jan 1992, now abandoned which is a division of Ser. No. US 1988-202869, filed on 3 Jun 1988, now patented, Pat. No. US 5162504
 DT Utility
 FS Granted
 LN.CNT 1350

INCL INCLM: 435/240.270
INCLS: 530/388.200; 530/388.800; 530/388.850; 530/387.700; 435/070.210;
435/172.200
NCL NCLM: 435/344.000
NCLS: 435/070.210; 435/344.100; 530/387.700; 530/388.200; 530/388.800;
530/388.850
IC [6]
ICM: C12N015-20
ICS: C07K016-18
EXF 530/387.7; 530/388.8; 530/388.85; 530/388.2; 435/240.27; 435/172.2;
435/70.21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 297 OF 362 USPATFULL on STN
AN 96:108816 USPATFULL
TI Sequence-directed DNA-binding molecules compositions and methods
IN Edwards, Cynthia A., Menlo Park, CA, United States
Cantor, Charles R., Boston, MA, United States
Andrews, Beth M., Maynard, MA, United States
Turin, Lisa M., Redwood City, CA, United States
Fry, Kirk E., Palo Alto, CA, United States
PA Genelabs Technologies, Inc., Redwood City, CA, United States (U.S.
corporation)
PI US 5578444 19961126 <--
AI US 1993-171389 19931220 (8)
RLI Continuation-in-part of Ser. No. US 1993-123936, filed on 17 Sep 1993
which is a continuation-in-part of Ser. No. US 1992-996783, filed on 23
Dec 1992 which is a continuation-in-part of Ser. No. US 1991-723618,
filed on 27 Jun 1991, now abandoned
DT Utility
FS Granted
LN.CNT 5845
INCL INCLM: 435/006.000
INCLS: 435/007.230; 536/023.100; 935/076.000; 935/077.000
NCL NCLM: 435/006.000
NCLS: 435/007.230; 536/023.100
IC [6]
ICM: C12Q001-68
ICS: C12N015-00; G01N033-574; C07H021-02
EXF 435/6; 536/23.1; 536/23.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 298 OF 362 USPATFULL on STN
AN 96:87697 USPATFULL
TI Regulator regions of G proteins
IN Nishimoto, Ikuo, Brookline, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)
PI US 5559209 19960924 <--
AI US 1993-19073 19930218 (8)
DT Utility
FS Granted
LN.CNT 1179
INCL INCLM: 530/326.000
INCLS: 530/327.000; 530/328.000
NCL NCLM: 530/326.000
NCLS: 530/327.000; 530/328.000
IC [6]
ICM: A61K038-00
ICS: C07K007-06; C07K007-08; C07K007-10
EXF 530/324-326; 530/327; 530/328; 514/12-15

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 299 OF 362 USPATFULL on STN
AN 96:85133 USPATFULL
TI Epoxysuccinic acid derivatives
IN Tsubotani, Shigetoshi, Kawanishi, Japan
Masayuki, Takizawa, Kobe, Japan
Mikio, Shirasaki, Nishinomiya, Japan
Fujisawa, Yukio, Kobe, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5556853 19960917 <--
AI US 1994-330833 19941027 (8)
PRAI JP 1993-272806 19931029
JP 1993-272835 19931029
JP 1994-186165 19940808

DT Utility
FS Granted
LN.CNT 4712
INCL INCLM: 514/231.500
INCLS: 514/227.800; 514/252.000; 514/475.000; 544/584.000; 544/146.000;
544/147.000; 544/374.000; 549/548.000; 549/549.000
NCL NCLM: 514/231.500
NCLS: 514/227.800; 514/254.100; 514/475.000; 544/058.400; 544/146.000;
544/147.000; 544/374.000; 549/548.000; 549/549.000
IC [6]
ICM: A61K031-535
ICS: C07D413-12
EXF 544/147; 544/374; 549/548; 549/549; 514/231.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 300 OF 362 USPATFULL on STN
AN 96:67907 USPATFULL
TI Method for preparing orphan receptor ligands
IN Holly, Richard D., Seattle, WA, United States
Burkhead, Steven K., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5541085 19960730 <--
AI US 1994-250859 19940527 (8)
RLI Continuation-in-part of Ser. No. US 1994-196025, filed on 14 Feb 1994,
now abandoned
DT Utility
FS Granted
LN.CNT 1694
INCL INCLM: 435/069.100
INCLS: 435/006.000; 435/172.300; 435/069.500
NCL NCLM: 435/069.100
NCLS: 435/006.000; 435/069.500; 435/444.000; 435/461.000
IC [6]
ICM: C12N015-12
ICS: C12N015-19
EXF 436/501; 436/517; 435/6; 435/7.21; 435/69.1; 435/172.3; 435/69.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 301 OF 362 USPATFULL on STN
AN 96:62776 USPATFULL
TI Capillary electrophoresis assay method useful for the determination of
constituents of a clinical sample
IN Sunzeri, Franklin J., San Jose, CA, United States
PA Advanced Molecular Systems, Inc., San Jose, CA, United States (U.S.
corporation)
PI US 5536382 19960716 <--
AI US 1995-422017 19950412 (8)
RLI Continuation of Ser. No. US 1994-226173, filed on 23 May 1994, now
abandoned
DT Utility
FS Granted
LN.CNT 716
INCL INCLM: 204/451.000
INCLS: 436/538.000; 436/546.000; 436/548.000
NCL NCLM: 204/451.000
NCLS: 436/538.000; 436/546.000; 436/548.000
IC [6]
ICM: B01D057-02
ICS: B01D059-38; C07K001-26
EXF 204/299R; 204/180.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 302 OF 362 USPATFULL on STN
AN 96:60027 USPATFULL
TI Compositions and methods for stimulating the growth of osteoblasts
IN Moore, Emma E., Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5533836 19960709 <--
AI US 1995-408331 19950322 (8)
RLI Continuation of Ser. No. US 1993-38325, filed on 29 Mar 1993, now
abandoned
DT Utility
FS Granted
LN.CNT 864
INCL INCLM: 435/240.310
INCLS: 435/240.200; 435/240.250; 435/240.260; 514/012.000; 514/878.000

NCL NCLM: 435/384.000
NCLS: 514/012.000; 514/878.000
IC [6]
ICM: C12N005-02
ICS: C12N005-08
EXF 514/12; 514/878; 425/240.2; 425/240.25; 425/240.26
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 303 OF 362 USPATFULL on STN
AN 96:53400 USPATFULL
TI Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
IN Coughlin, Daniel J., Robbinsville, NJ, United States
Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
PI US 5527885 19960618 <--
AI US 1994-268445 19940630 (8)
RLI Continuation of Ser. No. US 1992-866375, filed on 9 Apr 1992, now patented, Pat. No. US 5326856
DT Utility
FS Granted
LN.CNT 1698
INCL INCLM: 534/014.000
INCLS: 534/010.000; 530/391.300; 530/391.500
NCL NCLM: 534/014.000
NCLS: 530/391.300; 530/391.500; 534/010.000
IC [6]
ICM: C07C337-06
ICS: C07C335-22; A61K035-14
EXF 534/14; 534/10; 424/1.49; 424/1.53; 530/391.3; 530/391.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 304 OF 362 USPATFULL on STN
AN 96:46169 USPATFULL
TI Olefin substituted long chain compounds
IN Underiner, Gail, Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon, WA, United States
Eiseman, Elisa, Seattle, WA, United States
Leigh, Alistair, Brier, WA, United States
Kumar, Anil, Seattle, WA, United States
Michnick, John, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5521315 19960528 <--
AI US 1993-59697 19930510 (8)
RLI Continuation-in-part of Ser. No. US 1993-3372, filed on 12 Jan 1993, now patented, Pat. No. US 5354756
DT Utility
FS Granted
LN.CNT 2761
INCL INCLM: 546/243.000
INCLS: 546/242.000; 544/285.000
NCL NCLM: 546/243.000
NCLS: 544/285.000; 546/242.000
IC [6]
ICM: C07D211-88
ICS: C07D239-80
EXF 548/545; 548/546; 548/547; 546/243; 544/285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 305 OF 362 USPATFULL on STN
AN 96:43679 USPATFULL
TI Antiviral preparations
IN Beljanski, Mirko, 46 Boulevard De Port Royal, 75005 Paris, France
PI US 5519028 19960521 <--
WO 9402146 19940203 <--
AI US 1994-196164 19940222 (8)
WO 1993-FR761 19930726
19940222 PCT 371 date
19940222 PCT 102(e) date
PRAI FR 1992-9284 19920728
DT Utility
FS Granted
LN.CNT 706
INCL INCLM: 514/285.000
INCLS: 514/307.000

NCL NCLM: 514/285.000
NCLS: 514/307.000
IC [6]
ICM: A61K031-44
ICS: A61K031-47
EXF 514/285; 514/307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 306 OF 362 USPATFULL on STN
AN 96:29438 USPATFULL
TI Selecting ligand agonists and antagonists
IN Cunningham, Brian C., Piedmont, CA, United States
DeVos, Abraham M., Oakland, CA, United States
Mulkerrin, Michael G., Redwood City, CA, United States
Ultsch, Mark, Mill Valley, CA, United States
Wells, James A., Burlingame, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5506107 19960409 <--
WO 9221029 19921126 <--
AI US 1993-122548 19930929 (8)
WO 1992-US3743 19920506
19930929 PCT 371 date
19930929 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1992-864120, filed on 6 Apr 1992,
now abandoned which is a continuation of Ser. No. US 1991-698753, filed
on 10 May 1991, now abandoned
DT Utility
FS Granted
LN.CNT 2546
INCL INCLM: 435/007.210
INCLS: 435/007.800; 436/501.000; 436/537.000
NCL NCLM: 435/007.210
NCLS: 435/007.800; 436/501.000; 436/537.000
IC [6]
ICM: G01N033-542
ICS: G01N033-566
EXF 435/7.21; 435/7.8; 435/7.24; 436/501; 436/537
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 307 OF 362 USPATFULL on STN
AN 96:14715 USPATFULL
TI Monocrystalline iron oxide particles for studying biological tissues
IN Weissleder, Ralph, Somerville, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S.
corporation)
PI US 5492814 19960220 <--
AI US 1992-970942 19921103 (7)
RLI Continuation of Ser. No. US 1991-725060, filed on 3 Jul 1991, now
abandoned which is a continuation-in-part of Ser. No. US 1990-549434,
filed on 6 Jul 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2021
INCL INCLM: 435/725.000
INCLS: 128/653.100; 128/653.200; 128/653.400; 428/402.000; 436/173.000;
436/512.000; 436/518.000; 436/524.000; 436/526.000
NCL NCLM: 435/007.250
NCLS: 428/402.000; 436/173.000; 436/512.000; 436/518.000; 436/524.000;
436/526.000; 600/420.000
IC [6]
ICM: G01N033-551
ICS: G01N033-553
EXF 427/2; 427/127; 428/402; 435/7.1; 435/7.21; 435/7.25; 436/173; 436/524;
436/525; 436/526; 436/529; 436/534; 436/538; 436/539; 436/541; 436/518;
436/512; 128/653.1; 128/653.2; 128/653.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 308 OF 362 USPATFULL on STN
AN 96:9356 USPATFULL
TI Method of determining propensity of dissolved oxygen instability
IN Swartz, James R., Menlo Park, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 5487980 19960130 <--
AI US 1994-240121 19940509 (8)

RLI Division of Ser. No. US 1992-989844, filed on 23 Nov 1992, now patented,
Pat. No. US 5342763
DT Utility
FS Granted
LN.CNT 2278
INCL INCLM: 435/029.000
INCLS: 435/069.100
NCL NCLM: 435/029.000
NCLS: 435/069.100
IC [6]
ICM: C12Q001-02
EXF 435/29; 435/69.6; 435/252.1; 435/257.6; 435/291; 435/313; 435/315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 309 OF 362 USPATFULL on STN
AN 95:101143 USPATFULL
TI Biodegradable gelatin-aminodextran particle coatings of and processes
for making same
IN Siiman, Olavi, Davie, FL, United States
Burshteyn, Alexander, Hialeah, FL, United States
Gupta, Ravinder K., Pembroke Pines, FL, United States
PA Coulter Corporation, Miami, FL, United States (U.S. corporation)
PI US 5466609 19951114 <--
AI US 1992-968158 19921029 (7)
RLI Continuation-in-part of Ser. No. US 1990-607253, filed on 31 Oct 1990,
now patented, Pat. No. US 5169754, issued on 8 Dec 1992
DT Utility
FS Granted
LN.CNT 2159
INCL INCLM: 436/518.000
INCLS: 427/002.110; 427/127.000; 427/212.000; 427/213.310; 427/213.330;
427/214.000; 427/216.000; 427/337.000; 427/402.000; 427/414.000;
427/002.130; 427/002.140; 428/403.000; 436/524.000; 436/525.000;
436/526.000; 436/528.000; 436/529.000; 436/532.000; 436/534.000;
530/391.100; 530/810.000; 530/812.000; 530/813.000
NCL NCLM: 436/518.000
NCLS: 427/002.110; 427/002.130; 427/002.140; 427/127.000; 427/212.000;
427/213.310; 427/213.330; 427/214.000; 427/216.000; 427/337.000;
427/402.000; 427/414.000; 428/403.000; 436/524.000; 436/525.000;
436/526.000; 436/528.000; 436/529.000; 436/532.000; 436/534.000;
530/391.100; 530/810.000; 530/812.000; 530/813.000
IC [6]
ICM: G01N033-531
ICS: G01N033-543; G01N033-548
EXF 427/2; 427/127-131; 427/212; 427/213.31; 427/213.33; 427/213.35;
427/214; 427/216; 427/337; 427/338; 427/339; 427/402; 427/414; 428/403;
428/407; 435/5; 436/524-526; 436/173; 436/532; 436/534; 436/518;
436/528; 436/529; 530/391.1; 530/810; 530/812; 530/813; 530/815; 530/816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 310 OF 362 USPATFULL on STN
AN 95:94844 USPATFULL
TI Protein active in humoral hypercalcemia of malignancy-Pthrp
IN Martin, Thomas J., Kew, Australia
Moseley, Jane M., North Balwyn, Australia
Kemp, Bruce E., Kew, Australia
Wettenhall, Richard E. H., Camberwell, Australia
PA The University of Melbourne, Parkville, Australia (non-U.S. corporation)
PI US 5460978 19951024 <--
AI US 1991-715280 19910614 (7)
RLI Division of Ser. No. US 1988-199235, filed on 9 May 1988, now patented,
Pat. No. US 5116952
PRAI AU 1986-7027 19860718
AU 1987-349 19870213
DT Utility
FS Granted
LN.CNT 914
INCL INCLM: 436/518.000
INCLS: 435/007.100
NCL NCLM: 436/518.000
NCLS: 435/007.100
IC [6]
ICM: G01N033-53
EXF 436/518; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 311 OF 362 USPATFULL on STN
AN 95:90516 USPATFULL
TI Methods of promoting bone growth in mammals comprising administration of
modified ***parathyroid*** hormone
IN Schluter, Klaus-Dieter, Braunschweig, Germany, Federal Republic of
Mayer, Hubert, Braunschweig, Germany, Federal Republic of
Wingender, Edgar, Braunschweig, Germany, Federal Republic of
PA Gesellschaft fur Biotechnologische Forschung mbH (GBF), Braunschweig,
Germany, Federal Republic of (non-U.S. corporation)
PI US 5457092 19951010 <--
AI US 1993-120248 19930913 (8)
RLI Continuation-in-part of Ser. No. US 1993-6702, filed on 21 Jan 1993, now
abandoned which is a continuation of Ser. No. US 1988-225344, filed on
28 Jul 1988, now abandoned
PRAI DE 1987-3725319 19870730
DT Utility
FS Granted
LN.CNT 709
INCL INCLM: 514/012.000
INCLS: 530/350.000; 530/324.000; 530/399.000; 435/069.700; 435/069.400;
514/013.000
NCL NCLM: 514/012.000
NCLS: 435/069.400; 435/069.700; 514/013.000; 530/324.000; 530/350.000;
530/399.000
IC [6]
ICM: C07K007-00
ICS: C07K014-635; A61K038-00; A61K038-29
EXF 514/12; 530/350; 530/324; 530/399; 435/69.7; 435/69.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 312 OF 362 USPATFULL on STN
AN 95:31855 USPATFULL
TI Treatment of bone disorders
IN MacIntyre, Iain, Heathfield, England
PA Amylin Pharmaceuticals, Inc., San Diego, CA, United States (U.S.
corporation)
PI US 5405831 19950411 <--
AI US 1993-98015 19930727 (8)
RLI Continuation of Ser. No. US 1992-964128, filed on 20 Oct 1992, now
abandoned which is a continuation of Ser. No. US 1991-646644, filed on
11 Feb 1991, now abandoned
PRAI GB 1989-15712 19890708
DT Utility
FS Granted
LN.CNT 549
INCL INCLM: 514/004.000
INCLS: 514/012.000; 530/303.000; 530/307.000; 530/324.000
NCL NCLM: 514/004.000
NCLS: 514/012.000; 530/303.000; 530/307.000; 530/324.000
IC [6]
ICM: A61K037-02
ICS: C07K007-08
EXF 514/12; 514/4; 530/307; 530/324; 530/303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 313 OF 362 USPATFULL on STN
AN 95:24928 USPATFULL
TI Method of treating skin diseases
IN Levy, Julia G., Vancouver, Canada
Dolphin, David, Vancouver, Canada
Chow, Jack J., Vancouver, Canada
Sternberg, Ethan, Vancouver, Canada
PA The University of British Columbia, Vancouver, Canada (non-U.S.
corporation)
PI US 5399583 19950321 <--
AI US 1994-187307 19940125 (8)
RLI Division of Ser. No. US 1992-943895, filed on 11 Sep 1992, now patented,
Pat. No. US 5283255 which is a division of Ser. No. US 1991-718393,
filed on 20 Jan 1991, now patented, Pat. No. US 5171749 which is a
continuation-in-part of Ser. No. US 1989-414201, filed on 28 Sep 1989,
now patented, Pat. No. US 5095030 which is a continuation-in-part of
Ser. No. US 1988-221161, filed on 19 Jul 1988, now patented, Pat. No. US
4920143 which is a continuation-in-part of Ser. No. US 1987-41680, filed
on 23 Apr 1987, now patented, Pat. No. US 4883790 which is a
continuation-in-part of Ser. No. US 1987-5204, filed on 20 Jan 1987, now
abandoned

DT Utility
FS Granted
LN.CNT 1823
INCL INCLM: 514/410.000
INCLS: 514/002.000; 514/185.000
NCL NCLM: 514/410.000
NCLS: 514/002.000; 514/185.000
IC [6]
ICM: A61K031-40
EXF 514/410; 514/185; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 314 OF 362 USPATFULL on STN
AN 95:5772 USPATFULL
TI Method for the stimulation of the immune system of an animal by use of
limulus test-positive plant glycolipid
IN Soma, Gen-Ichiro, 1-10-21, Higashi-Tamagawa Setagaya Ward, Tokyo, Japan
Yoshimura, Jun, Okamoto-18, Chiba, Japan
Tsukioka, Daisuke, Okamoto-18, Chiba, Japan
Mizuno, Den'ichi, Okamoto-18, Kamkura City, Kanagawa, Japan
Oshima, Haruyuki, Hachioji, Japan
PA Chiba Flour Milling Co., Ltd., Chiba, Japan (non-U.S. corporation)
Mizuno, Den'ichi, Kamakura, Japan (non-U.S. individual)
Soma, Gen-Ichiro, Tokyo, Japan (non-U.S. individual)
PI US 5382430 19950117 <--
AI US 1992-990640 19921214 (7)
RLI Division of Ser. No. US 1990-475890, filed on 6 Feb 1990, now patented,
Pat. No. US 5236709
PRAI JP 1989-25739 19890206
JP 1989-255210 19891002

DT Utility
FS Granted
LN.CNT 1380
INCL INCLM: 424/195.100
INCLS: 514/783.000
NCL NCLM: 424/195.150
NCLS: 424/195.170; 424/750.000; 514/783.000
IC [6]
ICM: A61K035-78
EXF 424/195.1; 424/85-92; 435/240-244; 514/783
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 315 OF 362 USPATFULL on STN
AN 94:75445 USPATFULL
TI Method for producing polypeptide via bacterial fermentation
IN Swartz, James R., Menlo Park, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
corporation)

PI US 5342763 19940830 <--
AI US 1992-989844 19921123 (7)

DT Utility
FS Granted
LN.CNT 2052
INCL INCLM: 435/069.100
INCLS: 435/071.200; 530/401.000
NCL NCLM: 435/069.100
NCLS: 435/071.200; 530/401.000
IC [5]

ICM: C12D021-00
EXF 435/69.1; 435/71.2; 530/401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 316 OF 362 USPATFULL on STN
AN 94:60277 USPATFULL
TI Carbohydrate-directed cross-linking reagents
IN Ashkenazi, Avi J., San Mateo, CA, United States
Chamow, Steven M., San Mateo, CA, United States
Kogan, Timothy P., Sugar Land, TX, United States
PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

PI US 5329028 19940712 <--
AI US 1992-926077 19920805 (7)

DT Utility
FS Granted
LN.CNT 1001
INCL INCLM: 548/548.000
INCLS: 548/536.000; 548/547.000; 548/549.000

NCL NCLM: 548/548.000
NCLS: 548/546.000; 548/547.000; 548/549.000
IC [5]
ICM: C07D207-452
EXF 548/546; 548/547; 548/548; 548/549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 317 OF 362 USPATFULL on STN
AN 94:57899 USPATFULL
TI Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
IN Coughlin, Daniel J., Robbinsville, NJ, United States
Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
PI US 5326856 19940705 <--
AI US 1992-866375 19920409 (7)
DT Utility
FS Granted
LN.CNT 1743
INCL INCLM: 534/014.000
INCLS: 534/010.000; 530/300.000; 530/391.500; 530/408.000; 564/018.000;
564/023.000; 564/026.000; 564/027.000; 564/028.000; 556/045.000;
556/064.000; 556/081.000; 556/110.000; 556/118.000; 560/018.000;
562/432.000; 536/026.600; 552/502.000; 552/504.000
NCL NCLM: 534/014.000
NCLS: 530/300.000; 530/391.500; 530/408.000; 534/010.000; 536/026.600;
552/502.000; 552/504.000; 556/045.000; 556/064.000; 556/081.000;
556/110.000; 556/118.000; 560/018.000; 562/432.000; 564/018.000;
564/023.000; 564/026.000; 564/027.000; 564/028.000
IC [5]
ICM: C07C337-06
ICS: C07C337; C07D207-44; C07D213-71
EXF 424/1.1; 534/10; 534/14; 530/391.1; 530/391.5; 530/300; 530/408;
536/22.1; 536/26.6; 554/502; 556/45; 556/110; 556/118; 556/81; 556/64;
560/9.18; 562/432; 564/18; 564/23; 564/26; 564/27; 564/28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 318 OF 362 USPATFULL on STN
AN 94:42344 USPATFULL
TI Method of combatting osteoporosis in mammalian subjects, utilizing organic boron compounds
IN Spielvogel, Bernard F., Raleigh, NC, United States
Sood, Anup, Durham, NC, United States
Hall, Iris H., Carrboro, NC, United States
PA Boron Biologicals, Inc., Raleigh, NC, United States (U.S. corporation)
PI US 5312816 19940517 <--
AI US 1993-121221 19930914 (8)
RLI Continuation of ser. No. US 1991-759222, filed on 13 Sep 1991, now abandoned
DT Utility
FS Granted
LN.CNT 1529
INCL INCLM: 514/064.000
INCLS: 568/001.000; 568/002.000
NCL NCLM: 514/064.000
NCLS: 568/001.000; 568/002.000
IC [5]
ICM: A61K031-69
ICS: C07F005-02
EXF 514/64; 568/1; 568/2; 423/227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 319 OF 362 USPATFULL on STN
AN 94:33208 USPATFULL
TI Use of platelet factor 4 to inhibit osteoblast proliferation
IN Tatakis, Dimitris N., Louisville, KY, United States
PA University of Louisville Research Foundation, Inc., Louisville, KY, United States (U.S. corporation)
PI US 5304542 19940419 <--
AI US 1992-938026 19920828 (7)
DT Utility
FS Granted
LN.CNT 374
INCL INCLM: 514/012.000
INCLS: 530/380.000; 530/824.000; 424/532.000; 424/085.200; 514/021.000
NCL NCLM: 514/012.000

IC NCLS: 424/085.200; 424/532.000; 514/021.000; 530/380.000; 530/824.000
[5]
ICM: A61K037-00
ICS: A61K045-05
EXF 424/85.2; 424/532; 514/12; 514/21; 530/380; 530/829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 320 OF 362 USPATFULL on STN
AN 94:33138 USPATFULL
TI Method of controlling polypeptide production in bacterial cells
IN Bass, Steven, Redwood City, CA, United States
Swartz, James R., Menlo Park, CA, United States
PA Genentech, Inc., S. San Francisco, CA, United States (U.S. corporation)
PI US 5304472 19940419 <--
AI US 1992-989845 19921120 (7)
DT Utility
FS Granted
LN.CNT 2052
INCL INCLM: 435/069.100
INCLS: 435/172.300; 435/252.300; 435/252.330; 435/320.100; 935/039.000;
935/040.000; 935/010.000; 935/061.000; 935/072.000; 935/073.000;
536/023.700
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/252.330; 435/320.100; 536/023.700
IC [5]
ICM: C12N001-00
ICS: C12N015-08; C12N015-31; C12N015-67
EXF 435/69.1; 435/252.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 321 OF 362 USPATFULL on STN
AN 94:9591 USPATFULL
TI Wavelength-specific cytotoxic agents
IN Levy, Julia G., Vancouver, Canada
Dolphin, David, Vancouver, Canada
Chow, Jack J., Vancouver, Canada
Sternberg, Ethan, Vancouver, Canada
PA The University of British Columbia, Vancouver, Canada (non-U.S.
corporation)
PI US 5283255 19940201 <--
AI US 1992-943895 19920911 (7)
RLI Division of Ser. No. US 1991-718393, filed on 20 Jun 1991, now patented,
Pat. No. US 5171749 which is a continuation-in-part of Ser. No. US
1989-414201, filed on 28 Sep 1989, now patented, Pat. No. US 5095030
which is a continuation-in-part of Ser. No. US 1988-221161, filed on 19
Jul 1988, now patented, Pat. No. US 4920143 which is a
continuation-in-part of Ser. No. US 1987-41680, filed on 23 Apr 1987,
now patented, Pat. No. US 4883790 which is a continuation-in-part of
Ser. No. US 1987-5204, filed on 20 Jan 1987, now abandoned
DT Utility
FS Granted
LN.CNT 1818
INCL INCLM: 514/410.000
INCLS: 424/009.000; 540/145.000
NCL NCLM: 514/410.000
NCLS: 424/001.650; 424/009.610; 540/145.000
IC [5]
ICM: A61K031-40
EXF 540/145; 514/410; 514/185; 424/9
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 322 OF 362 USPATFULL on STN
AN 94:7701 USPATFULL
TI Substituted tetrahydropyrido[3',4':4,5]-pyrrolo[3,2-c]quinolines
IN Skotnicki, Jerauld S., Allentown, NJ, United States
Kearney, Robert M., Lawrenceville, NJ, United States
PA American Home Products Corporation, New York, NY, United States (U.S.
corporation)
PI US 5281608 19940125 <--
AI US 1992-936827 19920828 (7)
DT Utility
FS Granted
LN.CNT 736
INCL INCLM: 514/287.000
INCLS: 514/886.000; 546/064.000
NCL NCLM: 514/287.000

NCLS: 514/886.000; 546/064.000
IC [5]
ICM: C07D295-10
ICS: A61K031-47
EXF 546/64; 514/287; 514/886
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 323 OF 362 USPATFULL on STN
AN 93:102352 USPATFULL
TI Techniques for controlling osteoporosis using non-invasive magnetic fields
IN Liboff, Abraham R., Birmingham, MI, United States
McLeod, Bruce R., Bozeman, MT, United States
Smith, Stephen D., Lexington, KY, United States
PA Life Resonances, Inc., Bozeman, MT, United States (U.S. corporation)
PI US 5267939 19931207 <--
AI US 1991-774439 19911010 (7)
RLI Continuation of Ser. No. US 1989-295164, filed on 9 Jan 1989, now patented, Pat. No. US 5100373
DT Utility
FS Granted
LN.CNT 1252
INCL INCLM: 600/013.000
INCLS: 600/015.000; 607/052.000
NCL NCLM: 600/013.000
NCLS: 600/015.000; 607/052.000
IC [5]
ICM: A61N001-00
EXF 600/9; 600/13; 600/14; 600/15; 128/419F; 128/424; 128/419R; 128/421; 128/422; 128/799; 128/82.1

L3 ANSWER 324 OF 362 USPATFULL on STN
AN 93:93701 USPATFULL
TI Blood-brain barrier model
IN Rubin, Lee L., Athena Neurosciences, Inc., 800F Gateway Blvd., So. San Francisco, CA, United States 94080
Porter, Seth, Athena Neurosciences, Inc., 800F Gateway Blvd., So. San Francisco, CA, United States 94080
Horner, Heidi C., Athena Neurosciences, Inc., 800F Gateway Blvd., So. San Francisco, CA, United States 94080
Yednick, Theodore A., Athena Neurosciences, Inc., 800F Gateway Blvd., So. San Francisco, CA, United States 94080
PI US 5260210 19931109 <--
AI US 1990-577650 19900904 (7)
RLI Continuation-in-part of Ser. No. US 1989-413274, filed on 27 Sep 1989
DT Utility
FS Granted
LN.CNT 2148
INCL INCLM: 435/240.230
INCLS: 435/240.240; 435/240.241; 435/240.242; 435/240.243
NCL NCLM: 435/325.000
NCLS: 435/398.000; 435/402.000
IC [5]
ICM: C12N005-06
EXF 435/240.2; 435/240.21; 435/240.23; 435/240.24; 435/240.241; 435/240.242; 435/240.243

L3 ANSWER 325 OF 362 USPATFULL on STN
AN 93:69868 USPATFULL
TI Compositions for photodynamic therapy
IN Liu, Daniel, Vancouver, Canada
Jiang, Frank, Vancouver, Canada
Hobbs, John, Vancouver, Canada
PA Quadra Logic Technologies Inc., Vancouver, Canada (non-U.S. corporation)
PI US 5238940 19930824 <--
AI US 1991-768810 19910930 (7)
RLI Continuation-in-part of Ser. No. US 1990-498042, filed on 22 Mar 1990, now patented, Pat. No. US 5053423
DT Utility
FS Granted
LN.CNT 1191
INCL INCLM: 514/410.000
INCLS: 514/002.000; 514/043.000; 540/145.000
NCL NCLM: 514/410.000
NCLS: 514/002.000; 514/043.000; 540/145.000
IC [5]

ICM: A61K031-40
ICS: C07D487-22
EXF 514/2.43; 514/410; 540/145
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 326 OF 362 USPATFULL on STN
AN 93:67411 USPATFULL
TI Limulus test-positive plant glycolipid and method of stimulating the
immunity system of an animal
IN Soma, Gen-Ichiro, Setagaya Ward, Tokyo, Japan
Yoshimura, Jun, Chiba, Japan
Tsukioka, Daisuke, Chiba, Japan
Mizuno, Den'Ichi, Kamura City, Kanagawa, Japan
Oshima, Haruyuki, Tokyo, Japan
PA Chiba Flour Milling Co., Ltd., Chiba, Japan (non-U.S. corporation)
Mizuno, Den'Ichi, Kamakura, Japan (non-U.S. individual)
Soma, Gen-Ichiro, Tokyo, Japan (non-U.S. individual)
PI US 5236709 19930817 <--
AI US 1990-475890 19900206 (7)
PRAI JP 1989-25739 19890206
JP 1989-255210 19891002
DT Utility
FS Granted
LN.CNT 1328
INCL INCLM: 424/195.100
INCLS: 514/783.000
NCL NCLM: 424/195.150
NCLS: 424/195.170; 424/750.000; 514/783.000
IC [5]
ICM: A61R035-78
EXF 424/195.1; 424/85-92; 435/240-244; 514/783
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 327 OF 362 USPATFULL on STN
AN 93:48412 USPATFULL
TI Process for continuously culturing adherent animal cells
IN Takazawa, Yoshiharu, Hino, Japan
Tokashiki, Michiyuki, Hachioji, Japan
PA Teijin, Limited, Osaka, Japan (non-U.S. corporation)
PI US 5219752 19930615 <--
AI US 1991-730386 19910715 (7)
RLI Continuation of Ser. No. US 1989-356366, filed on 24 May 1989, now
abandoned
PRAI JP 1988-125664 19880525
JP 1988-204733 19880819
DT Utility
FS Granted
LN.CNT 1098
INCL INCLM: 435/240.250
INCLS: 435/070.300
NCL NCLM: 435/394.000
NCLS: 435/070.300
IC [5]
ICM: C12N005-08
ICS: C12P021-00
EXF 435/240.24; 435/240.25; 435/240.31; 435/70.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 328 OF 362 USPATFULL on STN
AN 93:22794 USPATFULL
TI Molecular recognition units
IN Rodwell, John D., Yardley, PA, United States
McKearn, Thomas J., New Hope, PA, United States
Alvarez, Vernon L., Morrisville, PA, United States
Radcliffe, Robert D., Titusville, NJ, United States
PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
PI US 5196510 19930323 <--
AI US 1990-519702 19900507 (7)
RLI Continuation-in-part of Ser. No. US 1988-291730, filed on 29 Dec 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 1684
INCL INCLM: 530/324.000
INCLS: 530/326.000; 424/001.100; 424/002.000; 436/545.000; 436/546.000
NCL NCLM: 530/324.000

NCLS: 436/545.000; 436/546.000; 530/326.000

IC [5]

ICM: C07K007-08

ICS: C07K007-10; A61K043-00; G01N033-533

EXF 436/513; 436/545; 436/546; 530/324; 530/326; 424/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 329 OF 362 USPATFULL on STN

AN 92:103063 USPATFULL

TI Wavelength-specific cytotoxic agents

IN Levy, Julia G., Vancouver, Canada

Dolphin, David, Vancouver, Canada

Chow, Jack J., Vancouver, Canada

Sternberg, Ethan, Vancouver, Canada

PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)

PI US 5171749 19921215 <--

AI US 1991-718393 19910620 (7)

RLI Continuation-in-part of Ser. No. US 1989-414201, filed on 28 Sep 1989, now patented, Pat. No. US 5095030 which is a continuation-in-part of Ser. No. US 1988-221161, filed on 19 Jul 1988, now patented, Pat. No. US 4920143 which is a continuation-in-part of Ser. No. US 1987-41680, filed on 23 Apr 1987, now patented, Pat. No. US 4883790 which is a continuation-in-part of Ser. No. US 1987-5204, filed on 20 Jan 1987, now abandoned

DT Utility

FS Granted

LN.CNT 1795

INCL INCLM: 514/410.000

INCLS: 514/002.000; 514/006.000; 530/391.300; 530/391.700; 530/405.000; 530/409.000; 540/145.000

NCL NCLM: 514/410.000

NCLS: 514/002.000; 514/006.000; 530/391.300; 530/391.700; 530/405.000; 530/409.000; 540/145.000

IC [5]

ICM: A61K031-40

ICS: C07D487-22

EXF 514/410; 514/2; 514/6; 540/145; 530/389; 530/391; 530/405; 530/409

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 330 OF 362 USPATFULL on STN

AN 92:100910 USPATFULL

TI Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same

IN Siiman, Olavi, Davie, FL, United States

Burshteyn, Alexander, Miami Lakes, FL, United States

Gupta, Ravinder K., Pembroke Pines, FL, United States

PA Coulter Corporation, Hialeah, FL, United States (U.S. corporation)

PI US 5169754 19921208 <--

AI US 1990-607253 19901031 (7)

DT Utility

FS Granted

LN.CNT 1217

INCL INCLM: 435/005.000

INCLS: 436/524.000; 436/526.000; 436/531.000; 436/532.000; 428/403.000; 428/407.000; 427/131.000; 427/213.350; 427/216.000

NCL NCLM: 435/005.000

NCLS: 427/131.000; 427/213.350; 427/216.000; 428/403.000; 428/407.000; 436/524.000; 436/526.000; 436/531.000; 436/532.000

IC [5]

ICM: C12Q001-00

ICS: G01N033-544

EXF 435/5; 436/524; 436/526; 436/531; 436/532; 428/403; 428/407; 524/22; 427/127-132; 427/213.35; 427/216; 427/217

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 331 OF 362 USPATFULL on STN

AN 92:99030 USPATFULL

TI Mammalian expression of the bone morphogenetic protein-2B using BMP2A/BMP2B fusion

IN Hammonds, Jr., R. Glenn, Berkeley, CA, United States

Mason, Anthony J., Burlingame, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5168050 19921201 <--

AI US 1990-528300 19900524 (7)

DT Utility

FS Granted
LN.CNT 912
INCL INCLM: 435/069.100
INCLS: 536/027.000; 435/240.000; 435/326.100; 530/350.000
NCLM: 435/069.100
NCLS: 435/320.100; 435/360.000; 435/369.000; 530/350.000
IC [5]
ICM: C12P021-06
ICS: C12P019-34; C12N015-00; C12N007-00; C12N005-00; C12N001-22;
C12N001-16
EXF 536/27; 435/320.1; 435/69.4; 435/69.1; 435/252.33; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 332 OF 362 USPATFULL on STN
AN 92:97214 USPATFULL
TI Monoclonal antibodies to a new antigenic marker in epithelial prostatic
cells and serum of prostatic cancer patients
IN Horoszewicz, Julius S., Williamsville, NY, United States
PA Cytogen Corporation, NJ, United States (U.S. corporation)
PI US 5162504 19921110 <--
AI US 1988-202869 19880603 (7)
DT Utility
FS Granted
LN.CNT 1308
INCL INCLM: 530/388.200
INCLS: 435/240.270; 435/070.210; 435/007.230; 530/388.800
NCLM: 530/388.200
NCLS: 435/007.230; 435/070.210; 435/344.000; 530/388.800
IC [5]
ICM: C07K015-28
ICS: C12N005-20; C12P021-08
EXF 530/387; 435/70.21; 435/240.27; 435/7; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 333 OF 362 USPATFULL on STN
AN 92:92536 USPATFULL
TI Methods and compositions for the treatment of Hodgkin's disease
IN Thorpe, Philip, Ruislip, United Kingdom
Engert, Andreas, London, United Kingdom
PA Imperial Cancer Research Technology, London, United Kingdom (non-U.S.
corporation)
PI US 5165923 19921124 <--
AI US 1989-440050 19891120 (7)
DT Utility
FS Granted
LN.CNT 2191
INCL INCLM: 424/085.910
INCLS: 530/391.900; 530/388.700; 530/388.730; 530/388.750
NCLM: 424/179.100
NCLS: 424/153.100; 424/154.100; 424/178.100; 530/388.700; 530/388.730;
530/388.750; 530/391.900
IC [5]
ICM: A61K039-44
ICS: C07K017-02; C07K015-28
EXF 530/390; 530/391; 530/388; 424/85.91
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 334 OF 362 USPATFULL on STN
AN 92:42878 USPATFULL
TI Protein active in humoral hypercalcemia of malignancy-PTHRP
IN Martin, Thomas J., Kew, Australia
Moseley, Jane M., North Balwyn, Australia
Kemp, Bruce E., Kew, Australia
Wettenhall, Richard E. H., Camberwell, Australia
PA The University of Melbourne, Victoria, Australia (non-U.S. corporation)
PI US 5116952 19920526 <--
WO 8800596 19880128 <--
AI US 1988-199235 19880509 (7)
WO 1987-AU165 19870604
19880509 PCT 371 date
19880509 PCT 102(e) date
PRAI AU 1986-7027 19860718
AU 1987-349 19870213
DT Utility
FS Granted
LN.CNT 869

INCL INCL: 530/399.000
 INCL: 530/395.000; 530/412.000; 530/416.000; 530/417.000
 NCL NCLM: 530/399.000
 NCL: 530/395.000; 530/412.000; 530/416.000; 530/417.000
 IC [5]
 ICM: C07K015-14
 ICS: C07K003-28; C07K003-22; C07K003-18
 EXF 530/399; 530/395; 530/350; 530/412; 530/416; 530/417
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 335 OF 362 USPATFULL on STN
 AN 92:40437 USPATFULL
 TI Covalently linked polypeptide cell modulators such as
 interferon-lymphotoxin conjugates
 IN Bell, Leslie D., Thame, United Kingdom
 McCullagh, Keith G., Princes Risborough, United Kingdom
 Porter, Alan G., High Wycombe, United Kingdom
 PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
 PI US 5114711 19920519 <--
 AI US 1989-379509 19890713 (7)
 RLI Continuation of Ser. No. US 1985-803748, filed on 2 Dec 1985, now
 patented, Pat. No. US 4935233
 DT Utility
 FS Granted
 LN.CNT 1067
 INCL INCL: 424/085.100
 INCL: 424/085.200; 424/085.400; 424/085.500; 424/085.600; 424/085.700;
 424/085.800; 530/351.000; 530/395.000; 530/405.000; 530/409.000;
 530/391.100; 530/391.700; 530/391.900; 530/388.230; 530/389.200;
 514/002.000; 514/008.000; 514/012.000; 514/021.000; 930/142.000;
 930/143.000
 NCL NCLM: 424/085.100
 NCL: 424/085.200; 424/085.400; 424/085.500; 424/085.600; 424/085.700;
 424/178.100; 424/179.100; 424/181.100; 514/002.000; 514/008.000;
 514/012.000; 514/021.000; 530/351.000; 530/388.230; 530/389.200;
 530/391.100; 530/391.700; 530/391.900; 530/395.000; 530/405.000;
 530/409.000; 930/142.000; 930/143.000
 IC [5]
 ICM: A61K037-66
 ICS: A61K039-44; C07K015-26; C07K017-02
 EXF 530/351; 530/388; 530/405; 530/409; 530/395; 424/85.1; 424/85.2;
 424/85.4; 424/85.5; 424/85.6; 424/85.7; 424/85.8; 930/142; 930/143;
 514/2; 514/8; 514/12; 514/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 336 OF 362 USPATFULL on STN
 AN 92:26477 USPATFULL
 TI Lymphographic and organ imaging method and kit
 IN Goldenberg, Milton D., Short Hills, NJ, United States
 PA Immunomedics, Inc., Warren, NJ, United States (U.S. corporation)
 PI US 5101827 19920407 <--
 AI US 1988-167077 19880311 (7)
 RLI Continuation of Ser. No. US 1985-751877, filed on 5 Jul 1985, now
 patented, Pat. No. US 4735210
 DT Utility
 FS Granted
 LN.CNT 1097
 INCL INCL: 128/653.400
 INCL: 424/009.000; 128/654.000
 NCL NCLM: 424/001.490
 NCL: 424/009.340; 600/420.000; 600/431.000
 IC [5]
 ICM: A61B005-05
 EXF 128/653; 128/654; 424/4; 424/9; 424/1.1; 436/806; 358/111; 324/309;
 324/31
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 337 OF 362 USPATFULL on STN
 AN 92:25251 USPATFULL
 TI Method of producing and isolating IGG-binding protein a fusion peptides
 and a vector therefor
 IN Lofdahl, Sven, Uppsala, Sweden
 Uhlen, Mathias, Uppsala, Sweden
 Lindberg, Martin, Uppsala, Sweden
 Sjoquist, John, Uppsala, Sweden
 PA Pharmacia LKB Biotechnology AB, Uppsala, Sweden (non-U.S. corporation)

PI US 5100788 19920331 <--
AI US 1988-196846 19880509 (7)
RLI Continuation of Ser. No. US 1984-667492, filed on 9 Oct 1984, now
abandoned
PRAI SE 1983-693 19830209
DT Utility
FS Granted
LN.CNT 2485
INCL INCLM: 435/069.700
INCLS: 435/071.200; 435/091.000; 435/172.300; 435/252.300; 435/252.310;
435/252.330; 435/320.100
NCL NCLM: 435/069.700
NCLS: 435/071.200; 435/091.410; 435/252.300; 435/252.310; 435/252.330;
435/320.100; 435/488.000
IC [5]
ICM: C12P021-02
ICS: C12N015-09; C12N015-11; C12N001-20
EXF 435/91; 435/172.3; 435/69.1; 435/79.1; 530/300; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 338 OF 362 USPATFULL on STN
AN 92:24837 USPATFULL
TI Techniques for controlling osteoporosis using non-invasive magnetic
fields
IN Liboff, Abraham R., Birmingham, MI, United States
McLeod, Bruce R., Bozeman, MT, United States
Smith, Stephen D., Lexington, KY, United States
PA Life Resonances, Inc., Bozeman, MT, United States (U.S. corporation)
PI US 5100373 19920331 <--
AI US 1989-295164 19890109 (7)
DT Utility
FS Granted
LN.CNT 1298
INCL INCLM: 600/013.000
INCLS: 600/015.000; 128/419.000F; 602/002.000
NCL NCLM: 600/013.000
NCLS: 600/018.000; 602/002.000
IC [5]
ICM: A61N001-40
EXF 128/419R; 128/419F; 128/421; 128/422; 128/424; 128/799; 128/82.1;
600/13-15

L3 ANSWER 339 OF 362 USPATFULL on STN
AN 92:18975 USPATFULL
TI Wavelength-specific cytotoxic agents
IN Levy, Julia G., Vancouver, Canada
Dolphin, David, Vancouver, Canada
Chow, Jack K., Vancouver, Canada
Sternberg, Ethan, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 5095030 19920310 <--
AI US 1989-414201 19890928 (7)
RLI Continuation-in-part of Ser. No. US 1988-221161, filed on 19 Jul 1988,
now patented, Pat. No. US 4920143 which is a continuation-in-part of
Ser. No. US 1987-41680, filed on 23 Apr 1987, now patented, Pat. No. US
4883790 which is a continuation-in-part of Ser. No. US 1987-5204, filed
on 20 Jan 1987, now abandoned
PRAI CA 1988-556875 19880119
EP 1988-300409 19880119
JP 1988-11847 19880120
JP 1988-181442 19880719
DT Utility
FS Granted
LN.CNT 1234
INCL INCLM: 514/410.000
INCLS: 540/145.000
NCL NCLM: 514/410.000
NCLS: 540/145.000
IC [5]
ICM: A61K031-40
ICS: C07D487-22
EXF 514/410; 540/145
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 340 OF 362 USPATFULL on STN
AN 91:96331 USPATFULL

TI Cyclodextrins as carriers
 IN Weinshenker, Ned M., Palo Alto, CA, United States
 PA Cyclex, Inc., New Brunswick, NJ, United States (U.S. corporation)
 PI US 5068227 19911126 <--
 AI US 1989-298634 19890118 (7)
 DT Utility
 FS Granted
 LN.CNT 929
 INCL INCLM: 514/058.000
 INCLS: 436/544.000; 436/056.000; 436/057.000; 436/086.000; 514/777.000;
 514/778.000; 514/002.000; 424/001.100; 424/085.800; 424/088.000;
 424/094.100
 NCL NCLM: 424/178.100
 NCLS: 424/001.370; 424/094.100; 436/056.000; 436/057.000; 436/086.000;
 436/544.000; 514/002.000; 514/058.000; 514/777.000; 514/778.000
 IC [5]
 ICM: A61K031-70
 ICS: C08B037-16; G01N033-533
 EXF 536/103; 514/58; 514/777; 514/778; 436/56; 436/57; 436/86; 436/544;
 424/1.1; 424/85.8; 424/88; 424/94.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 341 OF 362 USPATFULL on STN
 AN 91:79975 USPATFULL
 TI Compositions for photodynamic therapy
 IN Liu, Daniel, Vancouver, Canada
 PA Quadra Logic Technologies Inc., Vancouver, Canada (non-U.S. corporation)
 PI US 5053423 19911001 <--
 AI US 1990-498042 19900322 (7)
 DT Utility
 FS Granted
 LN.CNT 968
 INCL INCLM: 514/410.000
 INCLS: 514/002.000; 540/145.000
 NCL NCLM: 514/410.000
 NCLS: 514/002.000; 540/145.000
 IC [5]
 ICM: A61K031-40
 ICS: C07D487-22
 EXF 514/2; 514/410; 540/145
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 342 OF 362 USPATFULL on STN
 AN 91:60645 USPATFULL
 TI Bone inducing agent from a human osteosarcoma cell line
 IN Anderson, H. Clarke, Shawnee Mission, KS, United States
 Sugamoto, Kazuomi, Oyodoku Osaka, Japan
 PA University of Kansas, Kansas City, KS, United States (U.S. corporation)
 PI US 5035901 19910730 <--
 AI US 1987-107299 19871009 (7)
 DT Utility
 FS Granted
 LN.CNT 280
 INCL INCLM: 424/573.000
 INCLS: 435/240.200
 NCL NCLM: 424/573.000
 IC [5]
 ICM: A61K035-12
 ICS: C12N005-08
 EXF 435/259; 435/68; 435/240.2; 424/195.1; 424/95; 424/573; 530/828; 530/422

L3 ANSWER 343 OF 362 USPATFULL on STN
 AN 91:44860 USPATFULL
 TI Anti-human adenocarcinoma antigen specific monoclonal antibody
 IN Tahara, Eiichi, Hiroshima, Japan
 Ochiai, Atsushi, Hiroshima, Japan
 Yokozaki, Hiroshi, Hiroshima, Japan
 Hozumi, Toyoharu, Hiroshima, Japan
 Kyo, Eikai, Hiroshima, Japan
 PA Wakunaga Seiyaka Kabushiki Kaisha, Osaka, Japan (non-U.S. corporation)
 PI US 5021553 19910604 <--
 AI US 1989-377764 19890710 (7)
 RLI Continuation of Ser. No. US 1985-790400, filed on 23 Oct 1985, now
 abandoned
 PRAI JP 1984-223830 19841026
 JP 1985-198592 19850910

DT Utility
FS Granted
LN.CNT 560
INCL INCLM: 530/387.000
INCLS: 530/388.000; 530/395.000; 530/808.000; 530/828.000; 435/070.210;
435/240.270; 435/172.200
NCL NCLM: 530/388.800
NCLS: 435/070.210; 435/344.000; 530/395.000; 530/808.000; 530/828.000;
530/864.000
IC [5]
ICM: A61K039-395
ICS: C07K015-28; C12N005-02
EXF 530/387; 530/388; 530/389; 530/395; 530/808; 530/828; 530/806; 424/85.8;
435/7; 435/240.27; 435/240.26; 435/70.21; 435/172.2

L3 ANSWER 344 OF 362 USPATFULL on STN
AN 90:78226 USPATFULL
TI Controlled release of macromolecular polypeptides
IN Eppstein, Deborah A., Palo Alto, CA, United States
Schryver, Brian B., Redwood City, CA, United States
PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 4962091 19901009 <--
AI US 1986-866625 19860523 (6)
DT Utility
FS Granted
LN.CNT 1235
INCL INCLM: 514/002.000
INCLS: 514/021.000; 514/964.000; 424/078.000; 424/089.000; 424/092.000;
424/085.100; 424/085.200; 424/085.600; 424/085.800; 424/085.400
NCL NCLM: 424/085.200
NCLS: 424/085.100; 424/085.400; 424/085.600; 424/130.100; 424/178.100;
424/184.100; 424/193.100; 424/499.000; 514/002.000; 514/021.000;
514/964.000
IC [5]
ICM: A61K031-12
ICS: A61K047-00
EXF 424/78; 424/89; 424/85; 424/46; 424/92; 424/DIG.7; 424/486; 514/773;
514/772; 514/774; 514/775-778; 514/782; 514/951; 514/3-20; 514/958;
514/213; 514/21; 514/12-19; 514/2; 514/964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 345 OF 362 USPATFULL on STN
AN 90:50737 USPATFULL
TI Method for the preparation of antibody-fragment conjugates
IN Ultee, Michiel E., Belle Mead, NJ, United States
Alvarez, Vernon L., Morrisville, PA, United States
PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
PI US 4937183 19900626 <--
AI US 1988-152209 19880203 (7)
DT Utility
FS Granted
LN.CNT 1050
INCL INCLM: 435/068.100
INCLS: 435/188.000; 435/272.000; 436/512.000; 436/547.000; 436/548.000;
935/107.000; 530/388.000; 530/389.000; 424/009.000
NCL NCLM: 424/001.530
NCLS: 424/009.340; 435/068.100; 435/188.000; 435/272.000; 436/512.000;
436/547.000; 436/548.000; 530/388.800; 530/391.500; 530/391.900;
530/866.000
IC [5]
ICM: C12P021-06
ICS: G01N033-563; C07K015-28; A61K049-00
EXF 435/7; 435/23; 435/68; 435/69; 435/188; 435/262; 435/272; 436/512;
436/547; 436/543; 436/544; 436/545; 436/548; 935/107; 530/388; 530/389;
424/85; 424/9; 424/1.1

L3 ANSWER 346 OF 362 USPATFULL on STN
AN 90:48618 USPATFULL
TI Covalently linked polypeptide cell modulators
IN Bell, Leslie D., Thame, United Kingdom
McCullagh, Keith G., Princes Risborough, United Kingdom
Porter, Alan G., High Wycombe, United Kingdom
PA G. D. Searle and Company, Chicago, IL, United States (U.S. corporation)
PI US 4935233 19900619 <--
AI US 1985-803748 19851202 (6)
DT Utility

FS Granted
LN.CNT 1014
INCL INCLM: 424/085.500
INCLS: 424/085.600; 424/085.700; 530/351.000; 435/069.510
NCL NCLM: 424/085.500
NCLS: 424/085.600; 424/085.700; 435/069.510; 530/351.000
IC [5]
ICM: A61K045-02
ICS: C07K015-26; C07K013-00; C12P021-00
EXF 530/351; 424/85; 424/85.5; 424/85.6; 424/85.7; 435/68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 347 OF 362 USPATFULL on STN
AN 90:32230 USPATFULL
TI Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
IN Levy, Julia G., Vancouver, Canada
Dolphin, David, Vancouver, Canada
Chow, Jack K., Burnaby, Canada
Sternberg, Ethan, Vancouver, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 4920143 19900424 <--
AI US 1988-221161 19880719 (7)
RLI Continuation-in-part of Ser. No. US 1987-41680, filed on 23 Apr 1987
which is a continuation-in-part of Ser. No. US 1987-5204, filed on 20
Jan 1987
DT Utility
FS Granted
LN.CNT 1057
INCL INCLM: 514/410.000
INCLS: 540/145.000
NCL NCLM: 514/410.000
NCLS: 540/145.000
IC [5]
ICM: A61K031-40
ICS: C07D437-22
EXF 540/145; 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 348 OF 362 USPATFULL on STN
AN 90:15369 USPATFULL
TI Method of conferring immuno-tolerance to a specific antigen
IN Fathman, C. Garrison, Menlo Park, CA, United States
PA The Board of Trustees of Leland Stanford University, Stanford, CA,
United States (U.S. corporation)
PI US 4904481 19900227 <--
AI US 1987-28682 19870320 (7)
RLI Continuation-in-part of Ser. No. US 1985-724063, filed on 17 Apr 1985,
now patented, Pat. No. US 4681760
PRAI EP 1986-302781 19860415
CA 1986-506846 19860416
JP 1986-89192 19860417
DT Utility
FS Granted
LN.CNT 771
INCL INCLM: 424/085.800
INCLS: 424/085.910; 424/086.000; 424/087.000; 424/088.000; 424/089.000;
424/090.000; 424/091.000; 424/092.000; 435/007.000; 435/810.000;
436/548.000; 436/547.000; 436/512.000; 436/506.000; 436/808.000;
514/885.000; 530/387.000; 530/391.000; 530/389.000; 530/388.000
NCL NCLM: 424/154.100
NCLS: 424/183.100; 424/184.100; 424/275.100; 435/810.000; 436/506.000;
436/512.000; 436/547.000; 436/548.000; 436/808.000; 514/885.000;
530/388.750; 530/391.700; 530/868.000
IC [4]
ICM: A61K039-00
ICS: A61K039-395
EXF 424/85-92; 424/85.8; 424/85.91; 435/7; 435/810; 436/548; 436/512;
436/506; 436/811; 436/547; 436/808; 514/885; 530/387; 530/391; 530/389;
530/388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 349 OF 362 USPATFULL on STN
AN 89:95735 USPATFULL
TI Wavelength-specific cytotoxic agents
IN Levy, Julia G., Vancouver, Canada
Dolphin, David, Vancouver, Canada

Chow, Jack K., Burnaby, Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 4883790 19891128 <--
AI US 1987-41680 19870423 (7)
RLI Continuation-in-part of Ser. No. US 1987-5204, filed on 20 Jan 1987
DT Utility
FS Granted
LN.CNT 644
INCL INCLM: 540/145.000
NCL NCLM: 540/145.000
IC [4]
ICM: A61K031-66
EXF 540/145; 514/410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 350 OF 362 USPATFULL on STN
AN 88:77432 USPATFULL
TI Method to achieve a linear standard curve in a sandwich immunoassay
IN Tung, Ker-Kong, Carlsbad, CA, United States
Cragle, Linda K., San Diego, CA, United States
Rood, Jr., Frederick W., Fallbrook, CA, United States
Lee, Shih-Yun, San Marcos, CA, United States
PA Beckman Instruments, Inc., Fullerton, CA, United States (U.S. corporation)
PI US 4788138 19881129 <--
AI US 1987-44099 19870430 (7)
DT Utility
FS Granted
LN.CNT 675
INCL INCLM: 435/007.000
INCLS: 436/513.000; 436/533.000; 436/534.000; 436/801.000; 436/803.000;
436/817.000; 436/820.000; 436/827.000
NCL NCLM: 435/005.000
NCLS: 435/007.230; 435/007.400; 435/007.500; 435/007.700; 435/007.940;
436/513.000; 436/533.000; 436/534.000; 436/801.000; 436/803.000;
436/817.000; 436/820.000; 436/827.000
IC [4]
ICM: G01N033-532
ICS: G01N033-546; G01N033-574; G01N033-576
EXF 435/7; 436/548; 436/533; 436/534; 436/513; 436/801; 436/803; 436/817;
436/820; 436/827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 351 OF 362 USPATFULL on STN
AN 88:43980 USPATFULL
TI Myeloma cell lines and uses thereof
IN Brown, Bruce L., Knoxville, MD, United States
PA Hazleton Biotechnologies, Inc., Vienna, VA, United States (U.S. corporation)
PI US 4757018 19880712 <--
AI US 1985-700199 19850211 (6)
DT Utility
FS Granted
LN.CNT 303
INCL INCLM: 435/240.200
INCLS: 435/172.200; 435/240.270; 435/240.250; 435/240.310; 935/104.000
NCL NCLM: 435/452.000
NCLS: 435/354.000
IC [4]
ICM: C12N005-00
ICS: C12N015-00
EXF 435/240; 435/241; 435/245; 435/948; 435/240.2; 435/240.21; 435/240.25;
435/240.26; 435/240.27; 435/240.3; 435/240.31; 435/172.1; 435/172.2;
935/89; 935/90; 935/92; 935/93; 935/95; 935/99; 935/100; 935/102-104;
935/108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 352 OF 362 USPATFULL on STN
AN 88:43979 USPATFULL
TI In vitro cell culture system
IN Cheung, Herman S., Waukesha, WI, United States
PA MCW Research Foundation, Inc., Milwaukee, WI, United States (U.S. corporation)
PI US 4757017 19880712 <--
AI US 1984-651392 19840914 (6)
DT Utility

FS Granted
LN.CNT 1200
INCL INCLM: 435/240.230
INCLS: 435/240.240
NCL NCLM: 435/384.000
NCLS: 435/403.000
IC [4]
ICM: C12N005-00
EXF 435/240; 435/241; 435/948; 435/240.1-240.31

L3 ANSWER 353 OF 362 USPATFULL on STN
AN 88:27604 USPATFULL
TI Antibody-metal ion complexes
IN Alvarez, Vernon L., Morrisville, PA, United States
Rodwell, John D., Yardley, PA, United States
Lee, Chyi, New Brunswick, NJ, United States
Goers, John W. F., Atascadero, CA, United States
Siegel, Richard C., Yorktown Heights, NY, United States
McKearn, Thomas J., New Hope, PA, United States
PA Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
PI US 4741900 19880503 <--
AI US 1984-646328 19840831 (6)
RLI Continuation-in-part of Ser. No. US 1982-442050, filed on 16 Nov 1982,
now abandoned which is a continuation-in-part of Ser. No. US
1982-356315, filed on 9 Mar 1982, now patented, Pat. No. US 4671958
DT Utility
FS Granted
LN.CNT 1687
INCL INCLM: 424/085.000
INCLS: 424/086.000; 424/087.000; 424/001.100; 530/389.000; 530/390.000;
530/391.000; 514/002.000; 514/006.000; 435/007.000; 435/029.000;
436/548.000
NCL NCLM: 424/001.530
NCLS: 424/009.340; 424/009.341; 424/179.100; 435/029.000; 435/972.000;
436/512.000; 436/536.000; 436/548.000; 514/002.000; 514/006.000;
530/388.400; 530/388.730; 530/391.500; 530/409.000
IC [4]
ICM: A61K043-00
ICS: A61K049-00; C12Q001-00; C07K013-00
EXF 260/112R; 260/112B; 424/85; 514/2; 514/6; 435/7; 435/29; 530/335;
530/387-391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 354 OF 362 USPATFULL on STN
AN 88:20405 USPATFULL
TI Lymphographic and organ imaging method and kit
IN Goldenberg, Melton D., Short Hills, NJ, United States
PA Immunomedics, Inc., Newark, NJ, United States (U.S. corporation)
PI US 4735210 19880405 <--
AI US 1985-751877 19850705 (6)
DT Utility
FS Granted
LN.CNT 1198
INCL INCLM: 128/654.000
INCLS: 424/001.100; 424/009.000
NCL NCLM: 424/001.290
NCLS: 424/001.490; 424/009.340
IC [4]
ICM: A61B006-00
EXF 424/4; 424/9; 424/1.1; 128/653; 128/654; 436/806; 260/429J; 358/111;
324/309; 324/310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 355 OF 362 USPATFULL on STN
AN 87:41600 USPATFULL
TI Magnetic particles for use in separations
IN Josephson, Lee, Arlington, MA, United States
PA Advanced Magnetix, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 4672040 19870609 <--
AI US 1985-749692 19850628 (6)
RLI Continuation-in-part of Ser. No. US 1983-493991, filed on 12 May 1983,
now patented, Pat. No. US 4554088 And Ser. No. US 1985-744351, filed on
13 Jun 1985, now patented, Pat. No. US 4628037 And Ser. No. US
1985-744435, filed on 13 Jun 1985 And Ser. No. US 1985-744434, filed on
13 Jun 1985 And Ser. No. US 1985-744457, filed on 13 Jun 1985

DT Utility
FS Granted
LN.CNT 1770
INCL INCLM: 436/526.000
INCLS: 435/006.000; 436/525.000; 436/527.000; 935/077.000; 935/078.000;
252/062.540; 252/062.510
NCL NCLM: 436/526.000
NCLS: 252/062.510R; 252/062.540; 435/006.000; 436/525.000; 436/527.000
IC [4]
ICM: G01N033-553
ICS: C12Q001-68
EXF 436/526; 436/525; 436/527; 436/806; 935/77; 935/78; 252/62.54;
252/62.51; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 356 OF 362 USPATFULL on STN
AN 87:11141 USPATFULL
TI Therapeutic apheresis
IN Marten, James F., Cohasset, MA, United States
PA Applied Immunesciences, Inc., Menlo Park, CA, United States (U.S.
corporation)
PI US 4643718 19870217 <--
AI US 1985-758065 19850723 (6)
RLI Continuation of Ser. No. US 1983-468158, filed on 22 Feb 1983, now
patented, Pat. No. US 4540401
DT Utility
FS Granted
LN.CNT 382
INCL INCLM: 604/028.000
NCL NCLM: 604/028.000
IC [4]
ICM: A61M003-00
EXF 604/4-6; 604/28; 436/829; 436/536; 436/538; 436/541

L3 ANSWER 357 OF 362 USPATFULL on STN
AN 85:53495 USPATFULL
TI In vivo therapeutic apheresis using lipid vesicles
IN Marten, James F., Cohasset, MA, United States
PA Applied Immune Sciences, Inc., Holmdel, NJ, United States (U.S.
corporation)
PI US 4540401 19850910 <--
AI US 1983-468158 19830222 (6)
DT Utility
FS Granted
LN.CNT 359
INCL INCLM: 604/028.000
NCL NCLM: 604/028.000
IC [3]
ICM: A61M031-00
EXF 604/4-6; 604/28; 436/829; 436/536; 436/538; 436/541

L3 ANSWER 358 OF 362 USPATFULL on STN
AN 84:64876 USPATFULL
TI Liposomes with glycolipid-linked antibodies
IN Szoka, Frank C., San Francisco, CA, United States
PA Liposome Technology Incorporated, Menlo Park, CA, United States (U.S.
corporation)
PI US 4483929 19841120 <--
AI US 1982-374031 19820503 (6)
DT Utility
FS Granted
LN.CNT 982
INCL INCLM: 436/533.000
INCLS: 435/007.000; 435/008.000; 436/512.000; 436/532.000; 436/534.000;
436/548.000; 436/800.000; 436/803.000; 436/819.000; 436/828.000;
436/829.000
NCL NCLM: 436/533.000
NCLS: 435/007.900; 435/008.000; 435/966.000; 436/512.000; 436/532.000;
436/534.000; 436/548.000; 436/800.000; 436/803.000; 436/819.000;
436/828.000; 436/829.000
IC [3]
ICM: G01N033-54
ICS: G01N033-58
EXF 436/512; 436/532; 436/533; 436/534; 436/808; 436/828; 436/829; 422/61;
435/7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 359 OF 362 USPATFULL on STN
 AN 82:25311 USPATFULL
 TI Tumor localization and therapy with labeled antibody fragments specific
 to tumor-associated markers
 IN Goldenberg, Milton D., 11837 Gainsborough Rd., Potomac, MD, United
 States 20854
 PI US 4331647 19820525 <--
 AI US 1980-126263 19800303 (6)
 DT Utility
 FS Granted
 LN.CNT 1064
 INCL INCLM: 424/001.000
 INCLS: 424/009.000
 NCL NCLM: 424/001.370
 NCLS: 424/001.490
 IC [3]
 ICM: A61K049-00
 ICS: A61K043-00
 EXF 424/119
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 360 OF 362 VETU COPYRIGHT 2003 THOMSON DERWENT on STN
 AN 1990-62754 VETU T E V
 TI Treatment of Hormonal Disorders with Cytoplasmatic, Homotoxicological and
 Potentiated Organ Preparations.
 (Die Behandlung hormoneller Störungen mit zytoplasmatischen,
 homotoxikologischen und potenzierten Organpräparaten.)
 AU Burgard H
 LO Saar, Ger.
 SO Prakt.Tierarzt (71, Suppl., 117-20, 1990)
 CODEN: PRTIAV
 AV Purrmannstrasse 4, 6670 St. Ingbert, Saar, West Germany.
 LA English
 DT Journal
 FA AB; LA; CT

L3 ANSWER 361 OF 362 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 AN 1996-107679 [12] WPIDS
 DNC C1996-034206
 TI Culture medium for endocrine cells e.g. ***parathyroid*** and mammary
 gland cells - contg. D-valine, foetal calf serum, growth factors and
 hormones, the cells may be used to treat innate or acquired endocrine
 insufficiency.
 DC B04 D16
 IN ZABOT, M T; ZABOT, J M
 PA (DLEO-I) DE LEOBARDY F; (DUGA-I) DUGAST H; (ZABO-I) ZABOT J M; (ZABO-I)
 ZABOT M T
 CYC 20
 PI FR 2722797 A1 19960126 (199612)* 15p C12N005-02 <--
 WO 9603496 A1 19960208 (199612) FR 20p C12N005-06 <--
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 W: AU CA JP US
 AU 9530799 A 19960222 (199621) C12N005-06 <--
 ADT FR 2722797 A1 FR 1994-9330 19940722; WO 9603496 A1 WO 1995-FR961 19950718;
 AU 9530799 A AU 1995-30799 19950718
 FDT AU 9530799 A Based on WO 9603496
 PRAI FR 1994-9330 19940722
 IC ICM C12N005-02; C12N005-06
 ICS C12N005-08

L3 ANSWER 362 OF 362 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN
 AN 1994-097031 [12] WPIDS
 DNC C1994-044224
 TI Monoclonal antibody recognising osteoclast - used for evaluation of new
 drugs for inhibition of bone absorptions.
 DC B04 D16
 PA (FARH) HOECHST JAPAN LTD
 CYC 1
 PI JP 06046877 A 19940222 (199412)* 4p C12P021-08 <--
 ADT JP 06046877 A JP 1992-201380 19920728
 PRAI JP 1992-201380 19920728
 IC ICM C12P021-08
 ICS G01N033-53; G01N033-577
 ICA A61K037-395; C12N015-08
 ICI C12P021-08, C12R001:91

STN INTERNATIONAL LOGOFF AT 17:12:12 ON 08 DEC 2003